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RESULTS FRCM THE SALFORD HOME BLOOD GLUCOSE MONITORING PROJECT
In a study of this scale seme data is inevitably missing or 
unreported. In seme cases this is an aspect of assessment in the 
study, e.g. in assessing ccmpliance by the number of 
appropriately collected blood spot filter paper cards returned 
during the study. Consequently for each of the results sections I 
will state at the beginning whether or not subgroup analysis was 
performed deliberately or whether data was incomplete.
1:1 PATIENT RECRUITMENT AND DROP OUT RATES
450 - 500 insulin-treated diabetics could initially have 
been considered for the study, of whom roughly 300 would have 
fulfilled most of the entry criteria. During the 18 month 
recruitment period over 200 patients were approached of whom 153 
agreed to participate in the study. Their progress and the drop 
outs are recorded in Table 19.
Over 50% of insulin-dependent diabetics who were 
subsequently identified as suitable for the study were recruited 
initially. This pick up rate is high enough to minimise any 
selection bias. Of 153 patients, 124 completed 1 year of the 
study. The 19% drop out rate is roughly that expected in such 
studies, and is low enough to allow sequential analysis by 
groups. In the second year of the study the drop out rate was 
even lower so that of 124 patients 123 completed the study. 
The 2 deaths in the run in period were due to myocardial 
infarction and of the two who died following randomisation, one 
developed bowel cancer to which he succumbed, and the other died
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Table 19. PATIENT RECRUITMENT AND DROP-OUT RATE IN THE HOME
BLOOD GLUCOSE MONITORING STUDY.
No. OF INSULIN-TREATED DIABETICS IN SALFORD 
IDENTIFIED FOR U100 CHANGEOVER Approx.500
No. AVAILABLE AND SUITABLE FOR THE HOME
BLOOD GLUCOSE MONITORING STUDY Approx.300
No. INTERVIEWED REGARDING PARTICIPATION
IN THE STUDY 200
No. WHO ENTERED INITIAL RUN-IN
(INTENSIVE) PHASE I OF STUDY
WITHDRAWAL DURING RUN-IN PHASE OF STUDY ^6
DEATHS DURING RUN-IN PHASE 2
NON-COMPLIANCE WITH STUDY 
PROTOCOL (NON-ATTENDANCE) 4
No. SUITABLE FOR RANDOMISATION (PHASE 2)
WITHDRAWAL AT POINT OF RANDOMISATION -18
REFUSAL TO GIVE UP BLOOD GLUCOSE 
METER WHEN RANDOMISED TO URINE 
TESTING 2
"INSUFFICIENT TIME FOR STUDY" 5
"ANXIETY" 1
INABILITY TO COMPREHEND 2
FAILURE TO ATTEND 3
DEATH 2
"SOCIAL PROBLEMS" 2
LEFT AREA 1
153
147
No. WHO COMMENCED PHASE 2 (BLOOD vs URINE 
TESTING) OF STUDY 129
DROP-OUTS DURING 1st YEAR OF STUDY 
DEATHS
AMPUTATION OF LIMB 
NON ATTENDANCE 
LEFT AREA
No. WHO COMPLETED 1st YEAR OF STUDY
No. WHO COMMENCED PHASE 3 (YEAR 2) OF 
STUDY
DROP-OUTS DURING 2nd YEAR OF STUDY 
No. WHO COMPLETED 2nd YEAR OF STUDY
-5
124
124
123
4
frcm cardiac failure secondary to myocardial infarction. 60% of 
the patients had no relevant past medical history. Coronary 
heart disease was previously documented in 3 (2%) patients,
hypertension in 4 (3%), peripheral vascular disease in 3 (2%), 
chronic obstructive airways disease or asthma in 22 (14%),
associated endocrine disease (predominantly thyroid disease) in 9 
(6%), articular disease in 10 (7%), early renal disease in 3 
(2%), pancreatic disease in 3 (2%) and hyperlipidaemia in 1 
(0.7%).
40% of patient were on regular medication at entry to the 
trial, primarily analgesics (10%), hypnotics (8%), non-steroidal 
anti-inflammatories (5%), thyroxine (4%), antibiotics (4%), 
bronchodilators (3%), peripheral vasodilators (3%), p Blockers 
(3%), antidepresants (3%), diuretics (2%), haematinics (2%), 
antacids/H2 antagonists (2%) and lipid lowering agents (0.7%). 6
wcmen were on the oral contraceptive at entry to the study. No 
patients were on anticoagulants, digoxin, antiplatelet agents, 
calcium antagonists or ACE inhibitors. Of the original 153 
patients, 98 were working at entry to the study. Of these, 72 
(73%) had not missed any time frcm work in the preceding year. 
In the remaining 26 patients, the duration of time off work 
ranged frcm 1 - 2 5  days, with a mean of 7.5 days.
1:2. RANDOMISATION TO BLOOD OR URINE GLUCOSE TESTING
Of the 147 individuals suitable for randomisation to either 
blood or urine glucose testing, 68 were allocated blood glucose 
testing and 79 were allocated to urine glucose testing. This 
inequality of numbers reflects the 20 block randomisation
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schedule. In the event, of the 124 patients who completed 1 year 
in the study, roughly equal numbers were performing either blood 
(61) or urine (63) testing. The characteristics of the 153 
patients who started the study are compared with these randomised 
to blood or urine testing and the control clinic population in 
Tables 20-24.
With regard to these characteristics the groups were 
reasonably well matched for demographic and initial clinical and 
biochemical variables. Using analysis of variance, GSA was higher 
in those randomised to urine testing (p=0.04), although
fructosamine levels were lower (p<0.01), whilst the group
randomised to blood glucose testing were younger than the urine 
testing and control groups (p<0.05), and the latter had a higher 
body mass index (p=0.004) and a longer duration of diabetes
(p<0.001) than the study groups. The control group also had
higher levels of serum urea (p = 0.04) and creatinine (p<0.01), 
lower levels of creatinine clearance (p<0.01) and fasting blood 
glucose (p = 0.04), and were more frequently negative for C- 
peptide (p<0.01), in comparison to the study groups, whilst the 
LDL cholesterol / apo B-ratio was higher and the HDL/LDL and 
HDL/total cholesterol ratio lower in those who were randomised to 
urine testing (p<0.05). Finally, the levels of blood pressure 
and the prevalence of ischaemic heart disease and proliferative 
retinopathy were greater in the control population.
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Table 20
DEMOGRAPHIC CHARACTERISTICS OF STUDY AND CONTROL GROUPS AT ENTRY
TO STUDY.
INITIAL RANDOMISATION AT 6-8 WEEKS 
RECRUIT BLOOD GLUCOSE URINE STICKS 
TESTING WITH TESTING FOR 
METER GLUCOSE
CLINIC
CONTROL
GROUP
TOTAL NO OF 
PATIENTS 153 68 79 52
MALE SEX
(NO. (%)) 99 (64.7) 41 (60.2) 54 (68.4) 29 (55.8)
AGE (YEARS) 40 (1) 38 (2) * 43 (2) 44 (2) *
BODY MASS INDEX
(Kg/ m2) 23.6(0.3) 23.0 (0.4) ~ 24.1 (0.4) 26.1 (0.5)**
AGE AT DIAGNOSIS 
OF DIABETES
(YEARS) 27 (1) 26 (2) 29 (2) 27 (2)
DURATION OF
DIABETES (YEARS) 13 (1) 12 (1) 14 (1) 17 (1) +
PREVIOUS ORAL 
HYPOGLYCAEMIC 50 (32.6) 
TREATMENT (NO. (%))
22 (32.3) 28 (35.4) 16 (30.8)
DAILY INSULIN DOSE 
(UNITS) 51 (1) 52 (2) 50 (2) 49 (2)
DAILY INSULIN 
INJECTIONS (No.) 1.6 (0.1) 1.6 (0.1) 1.6 (0.1) 1.5 (0.1)
PATIENTS USING 
SOLUBLE INSULIN 
(No. (%)) 70 (46) 32 (47) 35 (44) 20 (38)
TYPE OF INSULIN 
No (%)
BEEF 80 (52%) 
HUMAN 52 (34%) 
PORCINE 21 (14%)
34 (50%) 
24 (35%) 
10 (15%)
42 (53%) 
27 (34%) 
10 (13%)
25 (48%) 
20 (39%) 
7 (13%)
* P<0.05 **P = 0.004 + P<0.001 Blood testing different
frcm urine testing, study group different frcm control group.
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Table 21
CHARACTERISTICS OF STUDY AND CONTROL GROUPS AT ENTRY TO STUDY.
INTITAL
RECRUIT
RANDOMISATION AT 6-8 WEEKS 
BLOOD TESTING URINE TESTING
CONTROL
GROUP
TOTAL NO 
OF PATIENTS 153 68 79 52
SMOKERS (%) 47% 51% 46% 45%
ALCOHOL
(U/WEEK) 3.0 (0-60) 3.6 (0-40) 3.,8 (0-60) ■3.5 (0-50)
REGULAR 
EXERCISE (%) 45 46 44 40
EMPLOYMENT 
STATUS No (%)
EMPLOYED
HOUSEWIFE
98 (64%) 
27 (18%)
39 (57%) 
*16 (24%)
58 (73%) 
8 (10%)
35 (67%) 
4 (7%)
UNEMPLOYED 
SEEKING WORK 
RETIRED
18 (12%) 
9 (6%)
9 (13%) 
3 (4%)
7 (9%) 
6 (8%)
6 (12%) 
5 (10%)
SICK NOT 
SEEKING WORK 1 ( 1%) 1 (1%) 0 (0%) 2 (4%)
PATIENTS' SOCIAL 
CLASS (No (%))
I 9 (6%) 
II 15 (10%) 
III 29 (19%)
3 (4%)
6 (9%) 
12 (18%)
6 (8%)
7 (9%) 
17 (22%)
3 (6%)
3 (6%) 
15 (29%)
IV 
V a 
b
45 (29%) 
29 (19%) 
26 (17%)
21 (31%) 
16 (24%) 
10 (15%)
22 (28%)
13 (16%)
14 (17%)
23 (44%) 
4 (8%)
4 (8%)
MARITAL STATUS 
(NO (%))
MARRIED 102 (67%) 
SINGLE 32 (21%)
46 (68%) 
14 (21%)
53 (67%) 
16 (20%)
32 (62%) 
8 (15%)
DIVORCED
WIDOWED
7 (5%) 
10 (7%)
2 (2.5%) 
4 (6%)
4 (5%) 
6 (8%)
6 (12%) 
5 (10%)
COHABITING 2 (1%) 2 (2.5%) 0 (0%) 1 (2%)
*p<0.05 Blood group different frcm the urine
testing group.
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Table 22 PREVALENCE OF COMPLICATIONS IN STUDY AND CONTROL
GROUPS AT ENTRY TO THE STUDY
INITIAL RANDOMISATION AT 6-8 WEEKS CONTROL 
RECRUIT BLOOD TESTING URINE TESTING GROUP
TOTAL No.
OF PATIENTS 153 68 79 52
ISCHAEMIC HEART 
DISEASE
NUMBER (%) 16 (10%) 6 (9%) 10 (13%) ***12 (23%)
PERIPHERAL 
VASCULAR 
DISEASE 
NUMBER (%) 15 (10%) 7 (10%) 8 (10%) 7 (13%)
BACKGROUND 
RETINOPATHY 
NUMBER (%) 63 (41%) 30 (44%) _ 33 (42%) ***10 (19%)
PROLIFERATIVE 
RETINOPATHY 
NUMBER (%) 33 (22%) 15 (22%) 18 (23%) ***20 (38%)
PREVIOUS LASER 
PHOTOCOAGULATION 
NUMBER (%) 13 (8%) 7 (10%) 6 (8%) 5 (10%)
CLINICAL 
NEPHROPATHY 
NUMBER (%) 45 (29%) 20 (29%) 25 (32%) 22 (42%)
PERIPHERAL
NEUROPATHY 13.4 (0.3) 
SCORE *(1-16)
13.9 (0.4) 12.8 (0.4) 12.9 (0.3)
AUTONOMIC
NEUROPATHY 2.1 (0.2) 
SCORE (1-10)
IMPOTENCE 
(% MEN) 41 
SYSTOLIC PRESSURE 
(mrriHg) 133 (2) 
DIASTOLIC PRESSURE 
(mrriHg) 76 (1)
1.9 (0.3) 
38
131 (2)
74 (1)
2.3 (0.3)
44 
134 (3)
77 (2)
2.0 (0.3) 
40
147 (4)* 
83 (2)+
PREVALENCE OF 
HYPERTENSION
NUMBER (%) 24 (16%) 9 (13%) 14 (18%) 14 (27%)
** P<= 0.005 *** P=0.001 Control group different frcm
study groups. Figures are mean (SEM) or as stated.
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Table 23
BIOCHEMICAL FEATURES OF STUDY AND CONTROL GROUPS AT ENTRY TO STUDY.
INITIAL RANDOMISATION AT 6-8 WEEKS CONTROL
RECRUIT BLOOD URINE GROUP
TESTING TESTING
RENAL
RENAL THRESHOLD
FOR GLUCOSE
(NUMBER (%))
HIGH
(> 12 mmol/L) 12 (8%) 7 (10%) 4 (5%) 5 (10%)
MEDIUM
(8-11 mmol/L) 70 (46%) 34 (50%) 34 (43%) 25 (48%)
LOW
(< 8 mmol/L) 71 (46%) 27 (40%) 41 (52%) 22 (42%)
SERUM UREA
(mmol/L) 5.3 (0.2) 5.3 (0.2) 5.3 (0.1) 5.9 (0.3)*
SERUM
CREATININE
(pmol/L) 81 (2) 79 (2) ' 82 (2) 94 (4)**
CREATININE
CLEARANCE 132 (5) 133 (5) 132 (4) 93 (4)**
(ml/min/1.73m2)
URINARY PROTEIN
EXCRETION 0.22 0.22 0.22 0.26
(g/24 hrs) (0.05-5.30) (0.05-6.00) (0.05-5.30) (0.05-4.20)
GLYCAEMIA
FASTING BLOOD
GLUCOSE 11.0 (0.7) 10.4 (0.7) 11.8 (0.7) *9.5 (0.6)
(mmol/L)
MEAN BLOOD
GLUCOSE 12.5 (0.3) 12.1 (0.5) 13.0 (0.4) 11.7 (0.4)
(mmol/L)
M VALUE
(units) 119 (9) 113 (9) 127 (9) 120 (10)
HhAx (%) 9.2 (0.2) 9.2 (0.2) 9.3 (0.2) 9.5 (0.2)
GSA (%) 9.8 (0.4) 9.0 (0.5) 10.5 (10.5)* -
FRUCTOSAMINE
mmol/L (No) 4.13 (0.08) 4.30 (0.09) 4.00 (0.08)**
C- PEPTIDE STATUS 
C PEPTIDE
NEGATIVE 67 (44%) 37 (54%) 24 (30%) 43 (83%)**
(NO (%))
C-PEPTIDE
VALUE 0.005 0.001 0.03 0.001
(pnol/ml) (0.00-2.50) (0.00-1.25) (0.00-2.50) (0.00-0.60)
* p = 0.04 ** p<0.01 Control v Study Groups, Blood v Urine
testing group. Figures are mean (SEM), median (range).
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Table 24 LIPIDS AND LIPOPROTEINS IN STUDY AND CONTROL GROUPS
AT TRIAL ENTRY.
INITIAL
RECRUIT
RANDOMISATION AT 6-8
BLOOD TESTING URINE TESTING
WEEKS CONTROL
GROUP
TOTAL SERUM 
TRIGLYCERIDES 1.29 1.10
(mmol/L) (0.36-23.29) (0.36-23.29)
TOTAL SERUM 
CHOLESTEROL 
(mmol/L)
LDL
CHOLESTEROL
(mmol/L)
HDLUC
CHOLESTEROL
(mmol/L)
hdl2uc
CHOLESTEROL
(mmol/L)
'3 u cHDL 
CHOLESTEROL 
(mmol/L)
5.66
(0.18)
3.78
(0.12)
1.45
(0.03)
0.73
(0.031)
0.72
(0.02)
APOLIPOPROTEIN B 
(mg/dL) 101 (2)
5.58
(0.18)
3.59
(0.17)
1.50
(0.04)
0.77
(0.04)
0.73
(0.03)
104 (3)
LDL
CHOLESTEROL 1.50 1.41
APO B (0.05) (0.07)
HDL 
LDL
HDL
0.44 0.49
(0.02) (0.03)
TOTAL
CHOLESTEROL
0.27 0.29
(0.81) (0.01)
1.29
(0.39-8,
5.70
(0.17)
3.92
(0.16)
1.42
(0.04)
0.69
(0.04)
0.72
(0.03)
99 (3)
1.57*
(0.06)
0.41*
(0.02)
0.26*
(0.01)
15)
1.35
(0.39-5.40)
5.93
(0.20)
3.48
(0.19)
1.44
(0.05)
0.68
(0.04)
0.76
(0.03)
109 (4)
1.33*
(0.04)
0.47
(0.03)
0.25*
(0.01)
* p<0.05 Study v Control Group, Blood v Urine testing group. 
Figures are mean (SEM), median (range).
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1:3. ASSESSMENT OF PATIENTS1 SELF MANAGEMENT SKILLS, KNOWLEDGE
ABOUT DIABETES AND ATTITUDES REGARDING DIABETES
The questionnaire designed to evaluate diabetic practice and 
knowledge and attitudes amongst those 153 insulin-treated 
diabetics originally recruited is contained in the initial trial 
entry document. (Appendix 1). The clinical characteristics of 
the group can be seen in figures (A-E).
GENERAL KNOWLEDGE: 1) (88%) felt that regular clinic
attendance was important. Of these, 95 (70%) felt that
attendance allowed glycaemic control.to be checked, 18 (13%) 
suggested that clinics provided the opportunity to screen for 
diabetic complications, and 9 (7%) that clinics served to allow 
management of active problems. Only 13 (10%) felt that diabetic 
clinics operated on all these levels.
2) An adequate definition of diabetes 
(with mention of key words pancreas, insulin and blood glucose) 
was forthcoming in only 99 (65%) of cases.
3) 41 (27%) of the subjects did not
think normal blood glucose levels were important provided that
they felt alright.
INSULIN INJECTION 1) 130 (85%) were on highly purified
insulin initially, and as many as 55 (41%) administered insulin 
once daily. 39 (25%) still used glass syringes, but the majority 
(75%) had used disposable syringes for sane time.
2) The most popular injection sites
were the legs (84% of cases), and thereafter the abdomen (48%),
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arms (39%) and buttocks (10%). Only 89 (58%) were in the 
practice of regularly rotating injection sites. 48 (31%) had 
experienced lumps or pitting at injection sites.
3) Although only 3 of the 153 
volunteered any difficulty drawing up their insulin, 28 (18%) 
were found to have problems with mixing insulins or with their 
injection technique. The canmonest problems encountered were 
failing to break the vacuum in the vials by injection of air, or 
swabbing the skin with alcohol. In addition many doses were 
drawn up with isophane added to the vial prior to soluble when 
mixing insulins.
URINANALYSIS 1) 22% of patients did NOT monitor
their urine for glycosuria. Of the 119 who did, 71 (60%) 
performed double voiding to improve the accuracy of recording and 
only 49 (41%) of than tested for ketonuria at any time. 55 (46%) 
tested their urine before meals, 10 (8%) after meals and the 
majority (45%) at either time.
2) Clinitest tablets, which give a 
qualitative measure of glycosuria, were used by 50 (42%) 
patients. Of the quantitative measures of glycosuria, Diastix 
was used more frequently (39%) than Clinistix (12%).
3) The majority (61%) monitored their 
urine daily, but 21% of patients only assessed glycosuria weekly, 
3% performed monthly tests and testing was even less frequent in 
the remaining 15% of cases.
4) Urinanalysis was said to be most 
canmonly negative for glycosuria in 32% of cases. 0.1% glycosuria
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was reported as the most canmon result in 9 (7%), 0.25% in 5 (4%) 
of cases, 0.5% in 8 (7%), 1.0% in 22 (18%) and 2.0% in 18 (15%). 
19 (16%) of the patients said glycosuria was too variable to
declare which degree of glycosuria was most cannon.
5) The technique for urinanalysis was 
examined in all 153 patients, and found to be inadequate in 27 
(17%) cases. The canmonest sources of error were failure to 
record the time or result accurately or a simple inability to 
read the result accurately. In addition the concept of the
'percentage' of glycosuria was often not understood by patients.
HYPOGLYCAEMIA 1) 8 (5%) of the patients claimed never
to have experienced episodes of hypoglycaemia. Of the 145 who 
did, 15 (10%) experienced symptans daily, 22 (14%) weekly, 12 
(8%) monthly, and the majority (96 (63%)) less frequently.
2) 59 (41%) usually experienced
nocturnal hypoglycaemia, 18 (12%) usually had symptans during the 
day, and in 10 (7%) cases hypoglycaemia was most cannon in the 
evening. For the remaining 40% the timing of hypoglycaemic 
episodes was unpredictable.
3) On enquiry as to the number of
symptans of hypoglycaemia each patient knew, 6 (4%) of the total 
group of 153 could not recollect any symptans of hypoglycaemia. 
50 (33%) knew at least 5 symptans of hypoglycaemia and the mean 
number of symptans recalled was 3.5. The canmonest reported 
symptans of hypoglycaemia were sweating (64%), shivering (32%), 
faintness (32%), blurred vision (20%), hunger (15%) and perioral 
paraesthesiae (15%). The full list of symptans is seen in Table 
25.
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4) Reactions were attributed to 
excessive exercise (42%), missed or delayed meals (27%) or 
excessive insulin (11%). 21% had unexplained reactions. 74%
always experienced premonitory symptans, whilst in 4% of cases 
hypoglycaemia was unheralded.
5) All but 2 patients knew to take 
carbohydrate when symptans devloped. However as many as 20% (31) 
did not always carry a carbohydrate source with them, and 24 
(13%) did not routinely carry diabetic identification with them.
HYPERGLYCAEMIA / KETOACIDOSIS 1) 107 (70%) of the 153 had
experienced at least 1 previous episode of ketoacidosis, but only 
52% of the total group recognised specific symptans or signs of 
ketoacidosis. 26 of the 49 patients who tested for ketonuria 
reported detection of ketones at sane stage.
2) All but four patients were able to 
volunteer symptans of hyperglycaemia. The symptans reported are 
in Table 26.
3) In the context of hyperglycaemia 
associated with illness, only 37% (57 cases) would have taken 
extra insulin, 23 (15%) would have contacted their General 
Practitioner, and 3 (2%) would have contacted the hospital for 
advice. More importantly, 42% of patients would have taken the 
wrong action or were uncertain what to do.
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Table 25. REPORTED SYMPTOMS OF HYPOGLYCAEMIA AND THEIR PREVALENCE
IN 147 INSULIN-TREATED DIABETICS
SYMPTOM PREVALENCE (%)
SWEATING 64
SHIVERING 32
FAINTNESS 32
BLURRED VISION 20
HUNGER 15
PERIORAL PARAESTHESIAE 15
LETHARGY 10
CONFUSION 9
LIMB PARAESTHESIAE 7
'MOODINESS' 7
HEADACHE 7
SLURRED SPEECH 5
INABILITY TO CONCENTRATE 4
AMNESIA 4
'CLUMSINESS1 3
STAGGERING 1
'NERVOUSNESS' 1
COLD FEET 1
HEAVY LIMBS 1
ABDOMINAL PAIN 1
NAUSEA 0.7
AGGRESSIVE 0.7
PALPITATIONS 0.3
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Table 26. REPORTED SYMPTOMS OF HYPERGLYCAEMIA AND THEIR
PREVALENCE IN 149 INSULIN-TREATED DIABETICS
SYMPTCM PREVALENCE (%)
POLYDYPSIA 43
POLYURIA 25
FATIGUE 19
WEIGHT LOSS 13
NAUSEA - VOMITING 6
'BAD TEMPER1 5
DRY MOUTH 3
SWEET TASTE IN MOUTH 3
HEADACHE 3
BLURRED VISION 2
PRURITUS 1
ANOREXIA 0.7
ABDOMINAL PAIN 0.7
COLD DRY SKIN 0.7
LABOURED RESPIRATION 0.7
MYALGIA 0.7
INFECTIONS 0.7
DEPRESSION 0.7
'BLOATED FEELING' 0.7
UNWELL 0.7
SWEATING 0.7
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EDUCATIONAL ASSESSMENT A series of questions on various
aspects of self-management was asked and each patient reponse was 
graded frcm 1 (excellent) to 5 (terrible).
1. INSULIN INJECTION / DOSAGE - Subjects were asked to adjust 
their current insulin regime on the basis of various 
hyperglycaemic and hypoglycaemic situations and reported on the 
simple kinetics of soluble and isophane insulin (time of onset 
and peak action and duration of action). They were asked whether 
they were in the practice of self-adjustment of their insulin 
regime. The mean score for the 144 patients interviewed was 3.0; 
17% of cases were graded as poor or terrible.
2. HYPOGLYCAEMIA - I ascertained knowledge regarding the effects
of altering insulin, diet or energy expenditure in inducing 
hypoglycaemia, and hypoglycaemic symptans and how to deal with
them. Regular carriage of sugar and diabetic identification was 
scored favourably. The mean score for 144 patients was 3.1, and 
31% of cases were graded as poor or terrible.
3. GLUCAGON - We asked trial patients what glucagon was, when and 
how to use it, how it worked, whether it had been previously 
used, or whether a family member or friend had been trained to 
use it. The mean score was 4.7, which highlighted the fact that 
86% of the study group were graded as terrible through no fault 
of their own as they had never been previously exposed to 
glucagon..
4. DIET - Patients were asked about the fibre and fat content of
18
their diets and the relative importance of these canponents. We 
asked them to identify frcm lists, those foods with predominant 
carbohydrate, fat or protein content. The mean score was 3.3, and 
poor dietary practice and knowledge (score 4 or 5) was observed 
in 39% of cases.
5. EXERCISE - Exercise was graded as strenuous, regular or 
sporadic. Patients were asked what alterations in their insulin 
dose and diet preceded, accompanied or followed exercise, and 
what effect exercise would have on blood glucose levels. We 
inquired about appreciation of the phenomenon of delayed 
hypoglycaemic responses to exercise and the potential importance 
of exercise. Regular and/or strenuous exercise was assessed. 
The mean score was 3.7, and 57% of cases led a sedentary 
existence without insight into the role of exercise in diabetes 
care.
6. ILLNESS - We enquired about the effect of illness on blood 
glucose levels; the mechanism of ketone body production, symptoms 
of impending ketoacidosis; dietary management; the use of extra 
insulin and the role of medical assistance in dealing with 
certain types of illness. No patient scored excellent in this 
area, and the mean score was 4.1, with 70% of subjects scoring 
poor or terrible.
ATTITUDES TO DIABETES 1. 94% of patients stated that they had
accepted diabetes as part of their daily life, although 22% 
admitted to feeling depressed about having diabetes. (V.I.). 3%
admitted to feeling hostile and 9% felt angry about being 
diabetic, although 5% felt fearful of their diabetes.
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2. Patients were asked if they had any 
specific concern about diabetes canplications. Gangrene/ foot 
amputations (26%) and blindness (24%) were the canmonest 
concerns. (Table 27). Only 4% of patients expressed concern 
about renal failure, 3% about macrovascular disease, and no one 
volunteered awareness or anxiety about neuropathy, hypertension 
or cerebrovascular disease.
3. Foot care was felt to be important in 
88% of cases, but 35% of patients did not examine their feet 
regularly. Foot problems were canmonly recognised as being more 
cctnmon due to circulatory disease (20%). or infection (16%), less 
ccrrmonly to neuropathy (2%), or more usually a combination of 
these factors (48%).
4. A family history of diabetes was present 
in 45% of 153 cases, and roughly 21% of the 153 patients had a 
1st degree relative with diabetes mellitus. 60% of the total 
group knew at least 1 other person with diabetes.
Comment
A disappointing but not unexpected lack of knowledge was 
apparent frcm the educational assessment. Patients were deficient 
in virtually all important basic aspects of diabetes self care: 
insulin injection, urinanalysis and awareness regarding 
management of hypoglycaemia and hyperglycaemia. Of most concern 
was lack of knowledge regarding self-care during incidental 
illness and a lack of exposure to glucagon in the vast majority 
of cases. In addition, diet patterns were found to be 
suboptimal. The dominant concern amongst patients regarding
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amputation and blindness was expected. However there appeared to 
be a lack of awareness about renal failure and neuropathy and 
perhaps more importantly, cardiovascular disease.
Following these assessments, patients were instructed in 
modification of insulin and diet during illness, and glucagon was 
given to all patients where a responsible friend or relative was 
available who could be instructed on hone blood glucose 
monitoring and subcutaneous glucagon administration. A marked 
improvement in virtually all aspects of diabetes knowledge and 
self-management was apparent at the end of the run-in period, 
which was maintained after 1 year (Table 28).
21
Table 27 CONCERN ABOUT DIABETIC COMPLICATIONS IN 147 DIABETICS
AT INITIAL TRIAL ENTRY.
COMPLICATION REPORTED CONCERN (% PREVALENCE)
GANGRENE/AMPUTATION 26
BLINDNESS 24
KIDNEY FAILURE 4
HYPOGLYCAEMIC COMA 2
PERIPHERAL VASCULAR DISEASE 2
DIABETIC KETOACIDOSIS 1
SEVERE INFECTIONS 1
SUDDEN DEATH/REDUCED 
LIFE EXPECTANCY 1
IMPOTENCE 0.7
HEART DISEASE 0.7
PREGNANCY IN DIABETES 0.7
CHANGE IN APPEARANCE 0.7
CONTRACEPTION DIFFICULTY 0.7
LIFE INSURANCE DIFFICULTY 0.7
HYPERTENSION 0
CORONARY HEART DISEASE 0
NEUROPATHY 0
22
Table 28
EDUCATIONAL ASPECTS IN TOTAL STUDY GROUP AFTER INITIAL INTENSIVE 
MANAGEMENT PERIOD AND AFTER 1 YEAR
INITIAL POINT OF 1 YEAR
RANDOMISATION
No. OF PATIENTS 153 147 124
PATIENT KNOWLEDGE
GENERAL 3.5 (0.1) 2.2 (0.1)**** 2.6 (0.1)****
INSULIN INJECTION 2.9 (0.1) 2.2 (0.1)**** 2.2 (0.1)****
HYPOGLYCAEMIA 3.2 (0.1) 3.3 (0.1) 2.0 (0.1)****
GLUCAGON 4.7 (0.1) 2.7 (0.1)**** 3.0 (0.1)****
DIET 3.3 (0.1) 2.6 (0.1)**** 2.6 (0.1)***
EXERCISE 3.7 (0.2) 3.1 (0.1)**** 2.2 (0.1)****
ILLNESS 4.1 (0.1) 2.1 (0.1)**** 3.1 (0.1)****
INSULIN INJECTION 
TECHNIQUE 2.9 (0.1) 2.1 (0.1)**** 2.2 (0.1)****
BLOOD GLUCOSE
MONITORING
TECHNIQUE
3.0 (0.1) 2.0 (0.1)**** 2.3 (0.1)****
URINE GLUCOSE
MONITORING
TECHNIQUE
2.9 (0.1) 2.6 (0.1)*** 2.4 (0.1)***
*** p = 0.001 ****: P = 0.0001 Figures are mean (SEM)
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1:4 EFFECTS OF INITIAL INTENSIFICATION OF MANAGEMENT ON
METABOLIC CONTROL 
Significant reductions in all aspects of glycaemic control 
were apparent after 6 weeks at the point of randomisation (Table 
29). In addition after only 2 weeks, there were obvious 
reductions not only in direct measures of glycaemia, but also in 
levels of GSA and fructosamine (Table 29). A more detailed 
examination of the relationships between direct measures of 
glycaemia and the different glycated blood proteins is discussed 
in Chapter 5.
Lipid and lipoprotein values also showed major differences 
after 6 weeks. Significant reduction were observed in total 
serum levels of cholesterol and triglycerides, as well as levels 
of LDL cholesterol, HDL3 cholesterol and the mass ratio of 
cholesterol to apolipoprotein B within LDL (Table 30). Levels of 
apolipoprotein B and the total HDL and HDL2 cholesterol did not 
alter appreciably over this period. A more detailed breakdcwn of 
these changes is discussed in Chapter 4. * -
Measures of glycaemic control and lipid metabolism inproved 
markedly in those who were hyperlipidaemic at entry to the study 
(Table 31).
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Table 29
CHANGES IN GLYCAEMIC CONTROL DURING INTENSIVE MANAGEMENT PERIOD
RECRUITMENT WEEK 2 WEEK 4 RANDOMISATION 
(BASAL) (WEEK 6)
No OF
PATIENTS 153 147 147 147
HhAi (%) 9.3 (0.2) - - *** 8.2 (0.1)
GSA 9.8 *** 8.5 *** 7.5 *** 7.3
(%) (0.4) (0.3) (0.3) (0.3)
FRUCTOSAMINE 
(mmol/L) 4.13 
(0.08)
*** 3.84 
(0.07)
*** 3.80 
(0.07)
*** 3.58 
(0.07)
SERUM
ALBUMIN
(g/L)
44.3
(0.3)
43.7
(0.3)
43.8
(0.3)
43.7
(0.3)
CORRECTED 3.75 
FRUCTOSAMINE (0.07)
*** 3.54 
(0.07)
*** 3.49 
(0.08)
*** 3.28 
(0.07)
FASTING
BLOOD
GLUCOSE
11.0
(0.05)
(mmol/L)
*** 7.4 
(0.03)
*** 7 0
(2:53)
*** 7.4 
(0.02)
MEAN
BLOOD
GLUCOSE
12.5
(0.3)
(mmol/L)
*** 9.6 
(0.2)
*** 9.1 
(0*2)
*** 8.7 
(0^ 2)
M Value 
(UNITS)
119
(6)
59
***(5)
47 42
24 HR 203 
URINE (18) 
GLUCOSE 
EXCRETION 
(mmol/24hrs)
- - -
FASTING
URINE
GLUCOSE
(SCORE)
0.80
(0.14)
***0.67
(0.14)
***0.50
(0.10)
***0.40
(0.08)
MEAN
URINE
GLUCOSE
SCORE
0.97
(0.13)
**0.91
(0.12)
**0.68
(0.09)
***0.54
(0.07)
Figures are mean (SEM) , median (range) ** p<0.01 ***
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Table 30
CHANGES IN LIPIDS AND LIPOPROTEINS DURING INTENSIVE MANAGEMENT
PERIOD
AT RECRUITMENT O AT RANDOMISATION +
TRIGLYCERIDES
mmol/1
CHOLESTEROL
romol/1
LDL CHOLESTEROL 
rrcnol/1
1.29(0.36-23.29) **** 1.14 (0.24-19.36)
1.76 (0.17)
5.64 (0.12) 
3.78 (0.12)
APOLIFOPROTEIN B 101 (2)
mg/dl
HDLUC CHOLESTEROL 1.46 (0.03) 
irrnol/1
HDL2uc CHOLESTEROL 0.73 (0.03) 
mmol/1
HDL3uc CHOLESTEROL 0.73 (0.02) 
rnnol/1
**
HDL CHOLESTEROL 0.44 (0.02)
LDL
HDL CHOLESTEROL 0.27 (0.01)
TOTAL
LDL CHOLESTEROL 1.50 (0.05)
APO B
o number = 147 
+ number = 137
Figures are mean (SEM) or median (range)
** p<0.01 *** p<0.005 **** p<= 0.0001
1.52 (0.17) 
**** 5.26 (0.12)
*** 3.46 (0.12)
101 (2)
1.40 (0.03)
0.76 (0.03)
*** 0.64 (0.02)
0.46 (0.02)
0.29 (0.02)
1.37 (0.04)
26
Table 31.
CHANGES IN GLYCAEMIC CONTROL AND LIPID METABOLISM IN 57 
HYPERLIPIDAEMIC SUBJECTS DURING THE INTENSIVE MANAGEMENT PERIOD.
After Intensive 
Initial Management
Number of subjects 57 26
HbAi (%) 9.6 (0.6) 8.3 (0.5) ***
Total Cholesterol (mmol/1) 7.00 (0.22) 5.89 (0.34) ***
Total Triglycerides (mmol/1) 3.00
(0.36 - 23.29)
1.65
(0.34
***
- 19.39)
LDL Cholesterol (mmol/1) 5.00 (0.24) 4.02 (0.28) ***
HDL Cholesterol (mmol/1) 1.34 (0.07) 1.27 (0.08)
HDL2 Cholesterol (mmol/1) 0.66 (0.05) 0.69 (0.07)
HDL3 Cholesterol (mmol/1) 0.68 (0.06) 0.58 (0.06)**
Apolipoprotein B (mg%) 113 (7) 108 (6)
Figures are mean (SEM) or median (range). 
*** p<0.001 ** p<0.05
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1.5 COMPARISON OF BLOOD AND URINE GLUCOSE MONITORING GROUPS IN
THE FIRST YEAR OF THE STUDY 
Following the period of intensive management and 
optimisation of control, 68 individuals were randomised to blood 
glucose testing, of whcm 61 (90%) completed the first year of the 
study, whilst 79 commenced urine glucose monitoring of whcm 63 
(80%) completed the first year of the study. The higher drop-out 
rate in the urine testing group (p<0.05), was mainly due to 
withdrawal at the point of randomisation when most refused to 
stop blood glucose monitoring. The fall off in patient numbers 
in blood and urine glucose testing groups is seen in Table 32.
Table 32 RATE OF DROP-OUT IN BLOOD AND URINE GLUCOSE MONITORING 
GROUPS DURING 1ST YEAR OF THE STUDY
Point of 
Randomisation
Mth
3
Mth
6
Mth
9
1 yr
Blood Glucose Testing 
Group
68 65 62 61 61
Urine Glucose Testing 79 * 71 68 67 63
Group
Figures refer to numbers of patients still in study (*p<0.05)
The clinical and biochemical characteristics at entry to the 
study of those ultimately randomised to either blood or urine 
testing are shown in Tables 20-24. The two groups were 
comparable in all respects apart from levels of GSA and the age 
of patients which were significantly higher at study entry in 
those randomised to urine testing (p = 0.04) although GSA levels 
closely approximated in the two groups at the point of
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randcmisation.
Metabolic Control 
GLYCAEMIC CONTROL
Levels of glycosylated haemoglobin (Hh^) were equivalent in 
both groups at entry to the study and at point of randcmisation 
when a significant fall (p<0.001) frcm baseline level was 
apparent in both groups. Thereafter HhAx levels remained more 
stable in the urine glucose monitoring group whilst a non­
significant trend towards further reduction in Hh^ was observed 
in the blood glucose monitoring group, and the difference was 
significant (p<0.02) after 6 months (Figure 14).
Fasting and mean blood glucose levels and the M-values were 
assessed frcm monthly filter card blood glucose profiles. The 
degree of compliance was variable between the two groups. The 
number of completed returned patient profiles per month is shown 
in Table 33. The response rate varied between 69% and 85% in the 
blood testing group (mean response rate 78%) which was 
significantly higher than the urine glucose monitoring group, 
where the response rate varied between 63 and 86% (mean response 
rate 68%) (p<0.05). Notwithstanding the poorer response in the 
urine testing group, fasting filter paper blood glucose levels 
were significantly higher in the urine glucose monitoring group 
at months 5, 6 and 8 (p< 0.05), (Figure 15) whilst mean filter 
paper blood glucose levels were higher in the urine monitoring 
group at months 3,4,5,6,8,11 and 12 (p<0.04 - 0.001) (Figure 16).
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FIG. 14 Comparison of changes in HbAj in urine and blood glucose testing 
groups during the 1st year of the study.
Figures represent Mean ± SEM
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FIG. 15 Comparison of changes in filter paper fasting blood glucose levels 
in urine and blood glucose testing groups during the 1st year of the 
study.
Figures represent Mean ± SEM
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Comparison of changes in filter paper mean blood glucose levels in 
urine and blood glucose testing groups during the 1st year of the 
study.
Figures represent Mean ± SEM
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A similar pattern also emerged with regard to filter paper 
M- values, which remained higher in the urine glucose monitoring 
group at months 3,4,5,6,8,10,11 and 12 (p<0.03-0.01) (Figure 17).
TABLE 33. NUMBER OF COMPLETED PROFILES (% RESPONSE RATE OF 
PATIENTS) SUITABLE FOR ANALYSIS IN BLOOD AND URINE GLUCOSE
MONITORING GROUPS.
MONTH BLOOD GLUCOSE MONITORING URINE GLUCOSE MONITORING
1 51 (78%) 47 (66%)
2 52 (80%) 48 (68%)
3 46 (71%) 48 (68%)
4 50 (81%) 44 (65%)
5 46 (74%) 45 (66%)
6 49 (79%) 43 (63%)
7 42 (69%) 44 (66%)
8 51 (84%) 44 (66%)
9 51 (84%) 45 (67%)
10 49 (80%) 41 (65%)
11 45 (74%) 46 (73%)
12 52 (85%) 54 (86%)
A significant difference in GSA levels was seen during the 
year in both blood and urine glucose monitoring groups. The 
lowest levels were seen at the point of randcmisation when they 
were comparable in the two groups. Those randomised to urine 
testing had significantly higher levels at recruitment to the 
study and also after 3 months (p<0.05), and GSA levels tended to 
be higher throughout the study in the urine testing group (Figure 
18). As with GSA levels, levels of fructosamine varied 
significantly during the study in both blood and urine glucose 
monitoring groups. In comparison to the blood testing group, the
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FIG. 17 Comparison of changes in filter paper M values in urine and blood 
glucose testing groups during the 1st year of the study.
Figures represent Median
34
Significance between groups *  p <  0.05
Significance within groups * *  p <  0.01
*** p <  0.001
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FIG. 18 Comparison of changes in GSA in urine and blood monitoring groups 
during the 1st year of the 1st year of the study.
Figures represent Mean ± SEM
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Urine4 . 0 -
Blood
FIG. 19 Comparison of changes in fructosamine in urine and blood glucose 
monitoring groups during the 1st year of the study.
Figures represent Mean ± SEM
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urine testing group had significantly higher fructosamine levels 
at the outset of the study (p<0.01) and also after 9 months (p<
0.05), but levels were indistinguishable after 1 year (Figure 19).
The number of episodes of hospital admissions in the 1st 
year with diabetic ketoacidosis was similar in both groups (blood 
testing 4, urine testing 5). The frequency of syrrptomatic 
hypoglycaemia and number of patients who had experienced at least 
one episode was assessed every 3 months, and did not differ 
appreciably between the two groups. No assessment of the 
severity of hypoglycaemia was made (Table 34).
Likewise there was no apparent difference in patient 
satisfaction with the respective methods of monitoring and degree 
of control between the blood and urine testing groups. (Table 
34).
LIPIDS AND LIPOPROTEINS (Table 35)
Apart frcm higher triglyceride levels initially in those 
randomised to urine testing (p<0.05), there were no differences 
throughout the first year of the study between the blood and 
urine glucose monitoring groups with regard to levels of 
triglycerides or total cholesterol, LDL and HDL cholesterol, the 
HDL2 and HDL3 cholesterol subfractions, or levels of 
apolipoprotein B. Likewise the ratios of LDL cholesterol/apo B, 
HDL/LDL cholesterol and HDL/total cholesterol remained similar in 
both groups during the 1st year of the year, although the LDL 
cholesterol/apo B ratio was higher initially in those randomised 
to urine testing (Table 35).
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CARBOHYDRATE INTAKE / WEIGHT (Table 36)
Body mass index (EMI) and weight was higher at initiation to 
the study in those randomised to urine testing although 
thereafter they were comparable. However a graded increase in 
EMI and weight was apparent after 6 months which rose further 
after 9 months and 1 year, irrespective of the means of 
monitoring metabolic control, and despite no apparent change in 
the alleged carbohydrate intake.
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Table 34 INCIDENCE OF HYPOGLYCAEMIC AND KETQACIDOTIC EPISODES
AND SATISFACTION WITH DEGREE/METHOD OF CONTROL IN
GLUCOSE MONITORING GROUPS 
BLOOD TESTING
EPISODES OF 
DIABETIC KETOACIDOSIS 
DURING THE 1ST YEAR 4
MONTHLY RATE OF 
SYMPTOMATIC 
HYPOGLYCAEMIA.
1. RANDOMISATION 
- MONTH 3
No. OF PATIENTS WITH 
AT LEAST ONE EPISODE
(%)
FREQUENCY
2. MONTH 3 -
MONTH 6 
No. OF PATIENTS WITH 
AT LEAST ONE EPISODE
(%)
FREQUENCY
3. MONTH 6 -
MONTH 9 
No. OF PATIENTS WITH 
AT LEAST ONE EPISODE
(%)
FREQUENCY
4. MONTH 9 -
MONTH 12 
No. OF PATIENTS WITH 
AT LEAST ONE EPISODE
(%) 32 (52%)
FREQUENCY 0.6 (0-10)
PATIENT SATISFACTION WITH 
METHOD/DEGREE OF CONTROL 
NUMBER (%) 49 (80%)
35 (57%) 
1.1 (0-29)
33 (53%) 
0.7 (0-28)
40 (62%) 
1.1 (0-20)
BLOOD AND URINE
URINE TESTING
5
42 (59%) 
1.0 (0-10)
41 (60%) 
1.1 (0-30)
45 (67%) 
1.3 (0-28)
37 (59%) 
0.8 (0-5)
56 (84%)
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TABLE 35
Serum lipid and lipoproteins in blood and urine glucose monitoring 
groups during the study
TYPE (F 
GROUP INITIAL
POINT OF 
RANDCMSATICN 6 MONTHS 1 YEAR
TRIGLYCERIDES 
(rrmol/1)
BLOCD 1.10 (0.36- 3.29)
1.14
(0.24-19-39)
1.04
(0.19-58.90)
1.09
(0.29-11.89)
URINE 1.29(0.39-8.15)
1.09
(0.34-9.38)
1.34
(0.24-6.44)
1.23
(0.44-8.90)
CHOLESTEROL
BLOCD 5.58 (0.18) 5.29 (0.18) 5.63 (0.35) 5.48 (0.15)
(mnol/1) URINE 5.70 (0.17) 5.24 (0.16) 5.57 (0.19) 5.51 (0.17)
LDL CHOLESTEROL
BLOCD 3.59 (0.17) 3.41 (0.15) 3.52 (0.17) 3.49 (0.14)
(mnol/1) URINE 3.92 (0.16) 3.50 (0.15) 3.76 (0.20) 3.32 (0.16)
AFOLLFOPROIEIN B BLOCD 104 (3) 103 (3) 100 (3) 102 (3)
(iqg/dL) URINE 99 (3) 99 (3) 105 (3) 104 (3)
LDL CHOLESTEROL BLOCD 1.41 (0.07) 1.32 (0.06) 1.35 (0.06) 1.37 (0.05)
Apo B URINE 1.57 (0.06)* 1.48 (0.06) 1.46 (0.07) 1.27 (0.07)
HDL CHOLESTEROL BLOCD 1.50 (0.04) 1.40 (0.05) 1.40 (0.04) 1.46 (0.04)
(nmol/I)
URINE 1.42 (0.04) 1.40 (0.05) 1.37 (0.04) 1.42 (0.04)
HDL, CHOLESTEROL 
(mnol/1)
BLOCD 0.73 (0.03) 0.77 (0.05) 0.74 (0.05) 0.72 (0.04)
URINE 0.69 (0.04) 0.75 (0.04) 0.69 (0.04) 0.68 (0.04)
HDL. CHOLESTEROL 
(rnnol/L)
BLOCD 0.77 (0.04) 0.63 (0.03) 0.66 (0.02) 0.75 (0.03)
URINE 0.72 (0.03) 0.65 (0.03) 0.68 (0.03) 0.75 (0.03)
HDL CHOLESTEROL BLOCD 0.49 (0.03) 0.46 (0.03) 0.47 (0.03) 0.46 (0.02)
LDL
URINE 0.41 (0.02) 0.47 (0.03) 0.43 (0.03) 0.51 (0.04)
HDL CHOLESTEROL BLOCD 0.29 (0.01) 0.25 (0.01) 0.28 (0.01) 0.28 (0.01)
TOTAL
URINE 0.26 (0.01) 0.28 (0.03) 0.26 (0.01) 0.28 (0.1)
*p < 0.05
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Table 36 CARBOHYDRATE INTAKE, WEIGHT AND BODY MASS INDEX (EMI)
IN BLOOD AND URINE GLUCOSE TESTING GROUPS DURING THE FIRST YEAR
OF THE STUDY
WEIGHT (kg)
BLOOD GLUCOSE 
TESTING
URINE GLUCOSE 
TESTING
INITIAL 65.6 (1.5) (*) 70.2 (1.2)
RANDCMISATION 66.1 (1.5) 69.9 (1.3)
MONTH 3 66.8 (1.4) 70.2 (1.3)
MONTH 6 67.4 (1.3) *** (*) 71.2 (1.3) **
MONTH 9 68.0 (1.3) *** 71.9 (1.4) ***
YEAR 1 68.7 (1.4) ick-k 72.8 (1.4) ***
EMI
INITIAL 23.0 (0.4) (*) 24.1 (0.4)
RANDCMISATION 23.2 (0.4) 24.1 (0.4)
MONTH 6 23.6 (0.3) *** 24.4 (0.4) **
YEAR 1 24.1 (0.4) *** 24.9 (0.4) ***
CARBOHYDRATE INTAKE (g/DAY) 
INITIAL 192 (9)
POINT OF 
RANDCMISATION
YEAR 1
185 (6) 
184 (6)
Significance within groups ** p = 0.004 *** p
Significance between groups (*) p = 0.04
184 (6)
185 (5) 
185 (6) 
0.0001
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Table 37 INDICES OF MICROVASCULAR AND MACROVASCULAR DISEASE IN
BLOOD AND URINE GLUCOSE MONITORING GROUPS DURING THE STUDY
Blood Testing Group Urine Testing Group
Initial 1 year Initial 1 year
NEPHROPATHY
SERUM UREA
(mmol/1) 5.3 (0.2) 5.1 (0.2) 5.3 (0.1) 5.2 (0.2)
SERUM CREATININE 
(pmol/1) 79 (2) 81 (2) 82 (2) 83 (2)
CREATININE CLEARANCE 
(ml/min) 133 (5) 125 (5) 132 (4) 112 (4)
AER (TOTAL) 6.9 
(pg/min) (1.0-355.0)
5.4
(1.1-1000.0)
5.5
(0.3-625.0)
6.4
(1.5-1000.0)
AER (DAY) 6.5 
pg/min) (0.9-398.0)
5.0
(0.5-884.4)
6.1
(0.1-690.0)
7.6
(0.9-1000.0)
AER (NIGHT) 5.3 
(pg/min) (1.0-355.0)
3.7
(1.0-1000.0)
4.7
(0.2-999.8)
4.6
(0.7-1000.0)
% ALBUSTIX 
>0.3 g/L 9 3 11 8.
PERIPHERAL
NEUROPATHY**
SCORE 13.9 (0.4) 13.6 (0.5) 12.8 (0.4)
*** * 
12.2 (0.4)
AUTONOMIC
NEUROPATHY
SCORE 1.9 (0.3) 1.9 (0.3) 2.3 (0.3) 2.3 (0.3)
RETINOPATHY 
% NIL 34 43 35 32
% BACKGROUND 44 34 42 40
%
PROLIFERATIVE 22 23 23 28
% ISCHAEMIC HEART 
DISEASE 9% 11% 13% 13%
% PERIPHERAL VASCULAR 
DISEASE 10%
* p<0.05 within group
9%
** p<0.02/
10% 13%
*** p<0.002 between group
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MICROVASCULAR AND MACROVASCULAR DISEASE (Table 37)
Various measures of renal and autoncmic function were
similar in both groups initially and after 1 year. Likewise the 
prevalence of ischaemic heart disease, peripheral vascular 
disease and retinopathy was no different in the blood or urine 
testing groups during the study. However the peripheral
neuropathy score was initially higher in those who were 
randanised to blood testing (p<0.02) and fell in those doing 
urine testing (p<0.05) so that a highly significant difference 
was apparent between the 2 groups after 1 year (p<0.002).
INSULIN SPECIES, DOSAGE AND FORMULATION (Table 38)
The daily insulin dosage, soluble component or species did 
not differ between the 2 groups although a significant increase 
(p<0.001) in the number of patients in both groups using soluble 
insulin was apparent at the point of randcmisation which 
continued during the 1st year of the study.
CONTACT WITH HEALTH PROFESSIONALS (Table 39)
More urine testing patients contacted their GP after 3-6 
months (p<0.05), and they also lost more time off work after 3
and 6 months. However the blood testing group had made
significantly more hospital contact after 6 months (p<0.05), and 
contacted me more often after the first 3 months (p<0.05).
EDUCATIONAL ASPECTS (Table 40)
Although educational scores were still improved in both 
groups after 1 year, knowledge about the role of exercise and 
management during illness appeared better in the blood testing 
groups after 1 year (p<0.01).
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Table 38 INSULIN SPECIES, DOSAGE AND FORMULATION IN BLOOD (B) AND
URINE (U) GLUCOSE MONITORING GROUPS DURING THE STUDY
INITIAL POINT OF MONTH 
RANDOMISATION 3
MONTH
6
MONTH
9
MONTI
12
DAILY B 
DOSE
52(2) 52(2) 52(3) 52(3) 52(3) 54(3)
INSULIN U 
(U)
50(2) 49(2) 51(2) 51(2) 52(2) 52(2)
% ON B 
MORNING
47 51 49 60 64 67
SOLUBLE U 44 44 54 57 57 60
MORNING B 12.9 4.1 4.1 5.5 5.4 5.7
SOLUBLE (1.9) (0.7) (0.7) (0.9) (0.9) (0.9)
DOSE U 10.4 3.4 3.9 4.8 4.7 4.7
(1.6) (0.5) (0.6) (0.7) (0.7) (0.7)
% ON B 46 93*** 94*** 92*** 90*** 90***
MORNING U 
ISOPHANE
46 90*** 92*** 91*** 91*** 91***
MORNING B 13.5 30.8 31.2 30.3 29.6 30.1
ISOPHANE (2.2) (1.9) (1.8) (2.0) (2.0) (2.0)
DOSE U 14.3 28.8 29.4 28.9 29.0 29.5
(2.0) (1.7) (1.7) (1.7) (1.8) (1.9)
% ON B 
EVENING
26 19 28 37 43 51
SOLUBLE U 24 24 27 32 28 30
EVENING B 5.3 1.4 1.6 2.3 2.6 3.1
SOLUBLE (1.3) (0.5) (0.5) (0.6) (0.6) (0.6)
DOSE U 4.9 1.3 1.4 2.3 2.1 2.0
(1.1) (0.3) (0.3) (0.5) (0.5) (0.5)
% ON B 44 88** 86** 89** 85** 85**
EVENING U 
ISOPHANE
39 83** 83** 79** 81** 81**
EVENING B 6.4 12.6 12.3 12.6 11.6 11.7
ISOPHANE (1.0) (1.1) (1.1) (1.3) (1.1) (1.2)
DOSE U 6.3 12.3 12.3 11.9 12.3 12.5
(1.0) (1.1) (1.1) (1.2) (1.2) (1.3)
INSULIN B 56% B 49% B 51% B 52% B 52% B 51% B
38% H 33% H 34% H 32% H 32% H 34% H
SPECIES 6% P 18% P 17% P 15% P 16% P 15% P
U 54% B 47% B 49% B 50% B 50% B 51% B
41% H 39% H 37% H 35% H 35% H 37% H
5% P 14% P 14% P 15% P 15% P 12% P
**p<0.01, ***p<0.001 different frcm initial. Mean (SEM).
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Table 39 CONTACTS WITH HEALTH PROFESSIONALS AND WORK PATTERNS
FOLLOWING RANDOMISATION IN BLOOD AND URINE GLUCOSE MONITORING
GROUP
MONTH 3 MONTH 6 MONTH 9 1 YEAR
BLOOD URINE BLOOD URINE BLOOD URINE BLOOD URINE
CONTACTS WITH 
DIABETIC NURSE
TOTAL 14 12 2 7 3 0 1 2
PATIENTS WHO
MADE CONTACT 6(9%) 4(6%) 2(3%) 5(7%) 3(3%) 0(0%) 1(2%) 2(3%)
CONTACTS WITH 
G.P.
TOTAL 7 31* 14 30* 20 19 15 15
PATIENTS WHO 
MADE CONTACT 5 16 9 18 11 11 8 9
(8%) (23%) (15%) (26%) (18%) (16%) (13%) (14%)
CONTACTS WITH 
CASUALTY
TOTAL 4 6 8* 3 3 2 2 1
PATIENTS WHO 
MADE CONTACT 3(5%) 5(7%) 5(8%) 3(4%) 2(3%) 2(3%) 2(3%) 1(2%)
CONTACTS WITH 
TRIAL DOCTOR 
TOTAL 12* 6 15 8 17 16 1 1
PATIENTS WHO 
MADE CONTACT 10 5 8 8 10 8 1 1
(15%)(7%) (13%)(12%) (16%) (12%) (2%) (2%)
INPATIENT
ADMISSIONS
TOTAL 1 1 1 1  2 3 1 1
No OF PATIENTS 1 1 1 1  2 3 1 1
DAYS OFF WORK
DUE TO DIABETES
No. WORKING 35 *55 35 46 34 44 34 44
TOTAL DAYS OFF 5 *15 0 *70 10 16 10 18
(AV.PER PATIENT)0 .14 *3.7 0 *1.5 0.3 0.4 0.3 0.4
No OF PATIENTS
OFF WORK 1 3 0 4 1 1 2 2
* p<0.05
Figures are number + (%).
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Table 40 EDUCATIONAL ASPECTS IN BLOOD AND URINE GLUCOSE
MONITORING GROUPS
INITIAL Randcmisation to 1 YEAR
BLOOD URINE BLOOD URINE BLOOD URINE
PATIENT KNOWLEDGE
**** k k k k k k k k  k k k k
GENERAL 3.5(0.1 3.5(0.1) 2.2(0.1) 2.2(0.1) 2.5(0.1) 2.7(0.1)
k k k k **** ****
INSULIN
INJECTION 2.9(0.1 2.9(0.1) 2.1(0.1) 2.2(0.1) 2.1(0.1) 2.3(0.1)
HYPOGLYCAEMIA **** k k k k
3.1(0.1 3.2(0.1) 3.3(0.1) 3.3(0.1) 1.9(0.1) 2.1(0.1)
**** k k k k k k k k  k k k k
GLUCAGON 4.7(0.1 4.7(0.1) 2.7(0.1) 2.7(0.1) 3.1(0.2) 2.8(0.1)
k k k k **** k k k k  k k k k
DIET 3.4(0.1 3.3(0.1) 2.6(0.1) 2.6(0.1) 2.5(0.1) 2.7(0.1)
*** k k k k  ^k^ k k k k
EXERCISE 3.6(0.1 3.7(0.1) 3.1(0.1) 3.0(0.1) 2.0(0.1) 2.4(0.1)
****(*)
ILLNESS 4.1(0.1 4.1(0.1) 2.0(0.1) 2.2(0.1) 2.8(0.1) 3.3(0.1)
INSULIN INJECTION **** **** k k k k  k k k k
TECHNIQUE 2.9(0.1 2.8(0.1) 2.1(0.1) 2.0(0.1) 2.2(0.1) 2.3(0.1)
BLOOD GLUCOSE k k k k k k k k **
MONITORING 3.1(0.1 2.9(0.1) 2.0(0.1) 2.1(0.1) 2.3(0.1) —
TECHNIQUE
URINE GLUCOSE k k k k k k k k k k
MONITORING 3.0(0.1 2.8(0.1) 2.5(0.1) 2.4(0.1) 2.4(0.1)
TECHNIQUE
(*) p<0.01 between groups
**p <0.01 *** p = 0.001 **** p = 0.0001 within groups
Figures are mean (SEM).
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1:6 QUALITY CONTROL ASSESSMENT OF THE REFLOLUX METER AND PATIENT
GENERATED HOME BLOOD GLUCOSE MONITORING RESULTS 
Evaluation of the Reflolux blood glucose meter
Fasting blood values were measured by the biochemistry 
laboratory (Yellow Springs Analyser) and compared with the results 
that I obtained myself frcm the same samples using the Reflolux 
meter. Both measures use glucose oxidase to produce an enzymatic 
colorimetric reaction. This was repeated on 3 different 
occassions duing the study (at 6 weeks, 6 months and 1 year). The 
correlation between the 2 measures was highly significant over the 
range of blood glucose values for 63-106 measures (r ranging from 
0.95-0.98, p<0.0001) (1 year data shown in figure 20(a)).
However if only paired measures were compared when laboratory 
glucose values were reported as less than 3 mmol/1, no such 
relationship emerged (r = 0.09, p n/s) (figure 20(b).
Furthermore there was a general tendency for Reflolux blood 
glucose values to be greater than that measured in the 
biochemistry laboratory (figure 20). The implication frcm these 
observations was that significant biochemical hypoglycaemia may 
not have been detected by patients with hypoglycaemic unawareness 
who were carrying out blood testing using the Reflolux machine. 
This impression was confirmed by comparing the laboratory based 
filter card glucose measurements with Reflolux readings 
subsequently carried out by patients during the study (v.i.). 
Evaluation of patient generated blood glucose results
68 patients were randomised to self blood glucose monitoring
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Reflolux 
Fasting Blood
26-r
24-
22- r = 0.95, p <  0.0001
20-
18-
16-
14-
12-
10-
8-
6-
4 -
2-
0 2 4 6 8 10 12 14 16 18 20 22
Laboratory Fasting Blood Glucose mmol/l
FIG. 20a Correlation between Reflolux and Yellow Springs fasting blood 
glucose levels; all levels.
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Reflolux 
Fasting Blood 
Glucose mmol/l
r = 0.09
(y = b x + a : 3.0 = 0.12 (2.3) + 2.7)
1 2 30
Laboratory Fasting Blood Glucose mmol/l
FIG. 20b Correlation between Reflolux and Yellow Springs fasting blood 
glucose levels, levels within the hypoglycaemic range.
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TABLE 41
Differences in patient and laboratory glycaemic measures derived 
frcm monthly blood glucose filter paper card data in patients 
randomised to blood glucose testing.
MONTH AFTER NUMBER OF FASTING BLOOD MEAN BLOOD M VALUE
RANDOMISATION PATIENT GLUCOSE GLUCOSE (UNITS)
SAMPLES (mmol/1) (irmol/1)
LAB PATIENT LAB PATIENT LAB PATIE1
1 51 6.8
(0.6)
7.4
(0.5)
7.6
(0.3)
8.4
(0.2)
30 
( 5)
39 
( 4)
2 53 6.5
(0.5)
7.1
(0.4)
7.9
(0.4)
8.9
(0.4)
33 
( 6)
51 
( 6)
3 46 6.9
(0.5)
8.2
(0.5)
7.4
(0.4)
8.8
(0.4)
29 
( 6)
44 
( 6)
4 50 6.5
(0.5)
7.9
(0.5)
7.3
(0.4)
9.0
(0.3)
28 
( 6)
48 
( 6)
5 46 6.0
(0.5)
7.2
(0.5)
7.0
(0.4)
8.6
(0.3)
23 
( 5)
44 
( 5)
6 48 6.2
(0.5)
7.3
(0.4)
7.0
(0.3)
8.4
(0.3)
23 
( 4)
38 
( 5)
7 42 6.7
(0.7)
7.1
(0.4)
6.6
(0.3)
8.7
(0.3)
14 
( 5)
42 
( 5)
8 51 6.5
(0.6)
7.8
(0.5)
6.7
(0.4)
8.6
(0.3)
20 
( 6)
41 
( 5)
9 51 6.4
(0.5)
7.5
(0.3)
7.1
(0.4)
8.8
(0.3)
24 
( 5)
45 
( 5)
10 49 5.9
(0.4)
7.5
(0.5)
6.9
(0.4)
9.0
(0.4)
15 
( 4)
47 
( 5)
11 45 5.8
(0.4)
7.8
(0.4)
6.2
(0.3)
8.2
(0.3)
8
( 5)
34 
( 6)
12 52 6.1
(0.4)
7.8
(0.4)
6.4
(0.2)
8.2
(0.3)
13 
( 3)
33 
( 4)
Figures are mean (SEM). All comparisons lab. v. patient p<0.01.
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during the first year of the study and were asked to complete a 
monthly 10 point filter card spot blood glucose profile and 
record their own blood glucose values recorded simultaneously on 
the Reflolux meter.
55 individuals provided information during the first year. 
Of a maximum of 120 paired blood spots and patient results, the 
average number (mean (SEM)) suitable for analysis over the year 
was 94 (4) per person. Only 10 patients provided 120 spots for 
analysis. Patient recorded results were generally higher then 
laboratory measured filter card blood glucose values. On average
62.2 (2.8)% mean (SEM) of patients blood glucose recordings 
deviated by at least 20% more then the laboratory values. The 
month by month differences in patient and laboratory glycaemic 
measures are shown in table 41. In addition to clear differences 
throughout the year, there was no suggestion of a trend towards 
an improved correlation with time between patient and laboratory 
results, with patient mean blood glucose results roughly 1 nmol/1 
higher.
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CHAPTER 4
ASPECTS OF LIPID METABOLISM
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1:1 FASTING LIPIDS AND LIPOPROTEINS IN INSULIN-DEPENDENT DIABETIC
MEN WITHOUT CLINICAL NEPHROPATHY 
Subjects: Of the 99 males recruited to the study, 57 with insulin 
dependent diabetes mellitus (IDEM) (previous ketoacidosis in 80% of 
cases) were matched with a group of 81 healthy male factory 
workers with no history of diabetes mellitus, who had been 
studied on a separate occassion by Dr. Paul Durrington at the 
Manchester Royal Infirmary. All subjects were aged between 35 
and 70 years. The two groups were of similar social backgrounds 
and came frcm the adjacent districts of Old Trafford and Salford 
within Greater Manchester. None of the subjects were taking 
drugs known to affect levels of serum lipids and lipoproteins 
other than insulin or had any other disease which might affect 
lipid and lipoprotein metabolism.
In the group of men with IDEM, renal function was well 
preserved (serum creatinine less than 140 pmol/L and proteinuria 
less than 0.3 g/L). Glycaemic control in the diabetic men 
was suboptimal but was not poor (¥QoA1 9.1 + 1.7% (mean + SD); 
fasting blood glucose 11.1 + 6.4 mmol/L, mean blood glucose
12.6 + 3.7 mmol/L).
Results : Clinical and lipid and lipoprotein data on the two 
groups are shown in Tables 42 and 43. Total serum and LDL 
cholesterol levels tended to be lower in the diabetic men than 
the healthy controls, but the differences were not significant. 
However the serum concentration of apolipoprotein B, the major 
protein component of LDL, was significantly lower in the 
diabetic men than in the controls.
Serum triglyceride and HDL and HDL2 cholesterol levels were
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slightly bat not significantly higher in the diabetic men. 
Levels of HDL3 cholesterol, and the ratios of HDL to LDL 
cholesterol and of HDL to total serum cholesterol, were 
significantly higher in the diabetic population.
Table 42 CLINICAL DATA FOR HEALTHY MALE CONTROLS AND MALE
IDEM PATIENTS
HEALTHY CONTROLS IDDM PATIENTS
NUMBER 81 57
AGE (YEARS) 49.6(6.6) 49.8(9.5)
QUETELET'S INDEX 25.6 (2.9) " 24.0 (2.9)
(B.M.I.)
ALCOHOL DRINKERS (%) 88 75
ALCOHOL CONSUMPTION
c(g/WEEK) 98 (0 - 810) 102 (0 - 700)
SMOKERS (%) * 22 30
STRENUOUS EXERCISE (%) 25 28
SYSTOLIC BLOOD PRESSURE
(mmHg) 133 (19) 142 (20)
DIASTOLIC BLOOD PRESSURE
(mmHg) 82 (12) 80 (12)
Figure are mean (SD), median (range) or as stated.
* greater than 10 cigarettes a day.
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Table 43 SERUM LIPIDS AND LIPOPROTEINS IN HEALTHY MALE 
CONTROLS AND MALE IDDM PATIENTS
HEALTHY CONTROLS IDDM PATIENTS
SERUM TRIGLYCERIDES 1.30 1.52
(mmol/L) (1.15-1.49) (1.31-1.78)
TOTAL SERUM CHOLESTEROL 6.34 (1.14) 5.88 (1.53)
(mmol/L)
LDL CHOLESTEROL 
(mmol/L)
AFOLIPOPROTEIN B 
(mg/dl) ***
HDL CHOLESTEROL 
(irmol/L)
HDL2 CHOLESTEROL 
(innol/L)
HDL3 CHOLESTEROL 
(rrmol/L) ***
LDL CHOLESTEROL +
APO B ***
HDL CHOLESTEROL 
TOTAL **
HDL CHOLESTEROL 
LDL *
Figures are mean (SD) or geometric mean (95% confidence limits) 
+ MASS RATIO (1 mmol/L LDL CHOLESTEROL = 39 mg/dl)
* p<0.05
** p<0.002
*** p<0.001
4.31 (1.21) 
137 (29) 
1.36 (0.32) 
0.73 (0.32) 
0.63 (0.20) 
1.18 (0.40) 
0.21 (0.07) 
0.33 (0.15)
4.06 (1.14) 
103 (32) 
1.45 (0.36) 
0.67 (0.31) 
0.78 (0.24) 
1.61 (0.59) 
0.26 (0.08) 
0.41 (0.22)
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1:2. FASTING LIPIDS AND LIPOPROTEINS AND VASCULAR DISEASE IN IDDM
WITH AND WITHOUT EARLY CLINICAL NEPHROPATHY 
Subjects : 205 insulin-dependent diabetics (the 153 recruited to
the trial and the 52 controls) were evaluated, frcm whom I 
identified 22 individuals (20 men) with early clinical 
nephropathy (persistent proteinuria >0.5g/day) in whan 
creatinine clearance was well preserved (>40 ml/min/1.73m2). 
These 22 patients were matched in order of importance for sex, 
age, duration of diabetes (to within 5 years except in 3 cases), 
and HbAi (to within 1% except in 1 case) with 22 insulin- 
dependent diabetics out of 140 with normal albumin excretion 
rates. The urinary protein output and albumin excretion rates 
of those with clinical nephropathy were 1.35 (0.4-4.5) g/24 hours 
(geometric mean (range)) and 452.5 (213.0-961.4) pg/min,
respectively, whereas the corresponding values for those with 
normal albumin excretion rates were 0.1 (0.05-0.3)g/24 hours and 
5.3 (2.9-9.6) pg/min. All patients with clinical diabetic
nephropathy had been diabetic for at least 7 years, with 
persisent proteinuria for a minimum of 6 months, and none had any 
history or findings suggestive of non-diabetic renal disease. 
All the subjects in the study were considered to be insulin- 
dependent and 84% had experienced at least one previous 
documented episode of ketoacidosis. None of the subjects was 
taking drugs other than insulin at the time of assessment 
which might affect lipoprotein metabolism or renal function. No 
specific advice regarding the dietary content of fat, fibre or 
protein had been given at the time of assessment.
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Table 44 CHARACTERISTICS OF INSULIN DEPENDENT DIABETICS
WITH NORMAL ALBUMIN EXCRETION RATE OR PROTEINURIA.
NORMAL ALBUMIN EXCRETION 
RATE IDEM
PROTEINURIA
IDEM
NUMBER (SEX)
OF PATIENTS
AGE (YEARS)
AGE AT ONSET OF 
DIABETES (YEARS)
DURATION OF 
DIABETES (YEARS)
BODY MASS 
(QUETELET’S) INDEX
INSULIN DOSE 
(UNITS/DAY)
NO. OF SMOKERS
WEEKLY ALCOHOL 
CONSUMPTION (g)
FASTING BLOOD 
GLUCOSE (mmol/L)
HhAx (%)
SERUM UREA (mmol/L)
SERUM CREATININE 
(pmol/L)
CREATININE CLEARANCE 
(ml/min/1.73 m2)
SERUM ALBUMIN (g/1)
22 (20M,2F)
44.2 (13.6)
25.2 (13.6)
19.1 (8.4)
24.1 (3.3)
51 (14)
6.
48 (0-240)
11.4 (3.0-26.7)
8.9 (1.5)
5.6 (1.5)
91 (12)
105 (29)
43 (2)
Figures are mean (SD), median (range) or as stated 
* p<0.05 ** p<0.02
22 (2QM,2F)
43.7 (13.7)
23.8 (14.4)
20.0 (8.5)
25.1 (3.7)
56 (18)
8.
64 (0-640)
9.6 (1.3-24.5)
8.7 (1.0)
7.2 (2.5) ** 
112 (30) *
92 (34)
42 (3)
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Table 45.
CLINICAL FEATURES OF INSULIN-DEPENDENT DIABETICS WITH NORMAL
ALBUMIN EXCRETION OR WITH PROTEINURIA
NORMAL ALBUMIN 
EXCRETION RATE
PROTEINURIA
MACROVASCULAR DISEASE 3
(EITHER ISCHAEMIC HEART)
(DISEASE AND/OR PERIPHERAL)
(VASCULAR DISEASE)
ISCHAEMIC HEART DISEASE 2
PERIPHERAL VASCULAR DISEASE 2
BACKGROUND RETINOPATHY 11
PROLIFERATIVE RETINOPATHY 4
SYSTOLIC BLOOD PRESSURE 135 (19)
(inrriHg) $
DIASTOLIC BLOOD PRESSURE 79 (15)
(mmHg) £
Figures are NUMBER, OR MEAN (SD)
10
8 *
8 *
4 *
11 *
161 (18)***
90 (12)**
$ 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN MEANS 15 TO
38 mmHg.
£ 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN MEANS 3 TO
19 mmHg
* p<0.05 ** p<0.02 *** p<0.0001
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Results: The groups with proteinuria and normal albumin
excretion rates were similar with regard to age, age at onset 
and duration of diabetes, body mass (Quetelet's) index, and 
daily insulin dosage. There was no excess of smokers or 
difference in alcohol consumption in those with proteinuria, and 
glycaemic control and serum albumin concentrations were 
comparable in both groups. Patients with proteinuria had on 
average moderately increased serum urea (p<0.02) and creatinine 
(p<0.05) concentrations, although their corrected creatinine 
clearance was not reduced significantly. (Table 44). 
Macrovascular disease (ischaemic heart disease, peripheral 
vascular disease, or both) was significantly more prevalent in 
diabetics with proteinuria (p<0.05). Although retinopathy was 
present in 15 patients in each group, proliferative features were 
more frequent in those with proteinuria (p<0.05). Systolic and 
diastolic blood pressures were higher in the patients with 
proteinuria (p<0.0001 and p<0.02 respectively). (Table 45).
Concentrations of serum cholesterol, triglycerides, LDL 
cholesterol, apolipoprotein B, and the mass ratio of LDL 
cholesterol to apolipoprotein B tended to be higher in patients 
with proteinuria, but without reaching levels of significance, 
though the increased total serum cholesterol was close (p<0.1; 
95% confidence interval - 0.39 to 1.20 nmol/1). Total HDL 
cholesterol concentrations did not differ significantly when 
isolated by ultracentrifugation, but the value was decreased in 
patients with proteinuria when precipitation was used (p = 0.03). 
There was also a significant reduction in the concentration of 
cholesterol in the HDL2 subfraction determined by
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ultracentrifugation (p = 0.03), with a suggestively higher
concentration of cholesterol within the HDL3 subfraction (p = 
0.08; 95% confidence interval - 0.01 to 0.23 mmol/1) in patients 
with proteinuria. (Table 46).
60
Table 46
LIPIDS AND LIPOPROTEINS IN INSULIN-DEPENDENT DIABETICS WITH
NORMAL ALBUMIN EXCRETION RATE OR WITH PROTEINURIA
NORMAL ALBUMIN PROTEINURIA
EXCRETION RATE
TRIGLYCERIDES (irmol/1) 1.27 0.68-2.39) 1.42 0.81-2.70)
CHOLESTEROL (mmol/1)$ 5.51 1.25) 6.13 1.44)
LDL CHOLESTEROL (mmol/1) 3.39 1.17) 3.84 1.52)
APOLIPOPROTEIN B (mg/dl) 107.1 (36.1) 111.1 (31.6)
LDL CHOLESTEROL (*) 
APOLIPOPROTEIN B
1.31 0.49) 1.42 0.62)
HDL uc CHOLESTEROL 
(mmol/1)
1.49 0.39) 1.38 0.26)
HDL pt CHOLESTEROL £ 
(mmol/1)
1.46 0.37) 1.24 0.25) **
HDL3 uc cholesterol 
(mmol/1) @
0.69 0.21) 0.79 0.22)
HDL2 uc cholesterol 
(nmol/1) +
0.80 0.35) 0.59 0.27) **
HDL uc CHOLESTEROL 0.50 0.23) 0.42 0.20)
LDL uc
Figures are geanetric mean (range) or mean (SD) ** p = 0.03
uc Refers to ultracentrifugation data 
pt Refers to precipitation data
(*) LDL CHOLESTEROL CONVERTED TO mg/dl (x39) FOR CALCULATION 
OF RATIO
$ 95% CONFIDENCE INTERVAL - 0.39 TO 1.20 mmol/1
£ 95% CONFIDENCE INTERVAL 0.02 TO 0.41 mmol/1
@ 95% CONFIDENCE INTERVAL - 0.01 TO 0.23 mmol/1
+ 95% CONFIDENCE INTERVAL 0.02 TO 0.40 nmol/1
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1:3. PREVALENCE OF HYPERLIPIDAEMIA AND RELATED CLINICAL FEATURES
Subjects: 205 insulin-dependent diabetic aged 16-70 (126M, 79F) 
were studied. All had well preserved renal function with normal 
serum creatinine levels except in 3 cases (153,154 and 156 
pmol/1). I also compared the prevalence of hyperlipidaemia in 
the 81 healthy male factory workers with no history of diabetes 
mellitus with 81 insulin-dependent diabetic men of similar age 
range (35-70 years old).
Results: 55 (27%) of cases had fasting hypercholesterolaemia
(>6.5 mmol/1), whilst 44 (21%) had fasting hypertriglyceridaemia 
(>2.25 irmol/1). Altogether, 40% (82) of the subjects with IDEM 
had hyperlipidaemia.
When 81 healthy control males matched for age were compared 
with 81 men with IDDM, body mass index, frequency of exercise and 
consumption of tobacco and alcohol did not differ between the two 
groups. Hypertriglyceridaemia was more prevalent in IDEM 
(p<0.05) and combined hyperlipidaemia marginally more common, 
whilst hypercholesterolaemia was if anything less common (Table 
47).
The 205 individuals with IDEM were grouped according to 
whether they had normolipidaemia, combined hyperlipidaemia or 
hypercholesterolaemia or hypertriglyceridaemia alone. No 
differences were noted between the groups regarding sex ratio, 
body mass index or patterns of alcohol and tobacco consumption. 
Normolipidaemic patients were younger at the time of the study (p 
= 0.03) and at the age when diabetes was diagnosed (p = 0.012), 
and had lower levels of systolic (p = 0.01) and diastolic blood 
pressure (p<0.05), in comparison to the hypertriglyceridaemic
62
Table 47
PREVALENCE OF HYPERLIPIDAEMIA AND RELATED CLINICAL FEATURES IN 
81 INSULIN-DEPENDENT DIABETIC AND 81 HEALTHY CONTROL MALES
INSULIN DEPENDENT HEALTHY
DIABETIC MEN CONTROLS
NUMBER 81 81
AGE (YEARS) 49.4 (6.0) 49.6 (6.6)
BODY MASS INDEX 25.1 (2.1) 25.6 (2.9)
SMOKERS (%) 28 22
STRENUOUS EXERCISE
(%) 29 25
ALCOHOL CONSUMPTION
(g/WEEK) 100 (0-750) 98 (0-810)
PREVALENCE OF 
HYPERCHOLESTEROLAEMIA
(NUMBER(%)) 25 (30.9%) 36 (44%)
PREVALENCE OF 
HYPERTRIGLYCERIDAEMIA
(NUMBER (%)) 23 (28.4 %) 11 (13.6 %) *
PREVALENCE OF COMBINED
HYPERTRIGLYCERIDAEMIA & 10 (12.3 %) 5 (6.1 %)
HYPERCHOLESTEROLAEMIA
(NUMBER (%))
Figures are as stated, median (range) or mean (SD)
* p<0.05
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group. The daily insulin dose was greater in the canbined 
hyperlipidaemic group in canparison to normolipidaemic and 
hypercholesterolaemic patients (p<0.05) (Table 48).
Levels of HhZ^ did not differ significantly, although 
fasting blood glucose levels in the group with canbined 
hyperlipidaemia were greater than the other groups (p<0.002). 
Serum urea levels were conparable, but serum creatinine levels 
were lowest in normolipidaemic patients (p = 0.03), and total 
urinary protein excretion tended to be higher in patients with 
canbined hyperlipidaemia (p<0.06) (Table 49).
Total triglyceride and cholesterol levels were highest in 
the group with canbined hyperlipidaemia, indicating that when 
marked hypercholesterolaemia does occur in IDEM, it is almost 
invariably accompanied by hypertriglyceridaemia. Levels of LDL 
cholesterol, apolipoprotein B and the ratio of LDL cholesterol to 
apo B were significantly less in patients with normal lipid 
levels and hypertriglyceridaemia compared to the other groups (p< 
0.001). HDL and HDL2 cholesterol levels were least in the 
hypertriglyceridaemic group (p = 0.05 and p = 0.02 respectively), 
but levels of HDL3 cholesterol did not differ between groups. 
The ratios of HDL/LDL and HDL/total cholesterol were greatest in 
the normolipidaemic patients and least in those with combined 
hyperlipidaemia (p<0.0001) (Table 50).
The cumulative frequency distributions of triglyceride and 
cholesterol levels are shown in Figures 21a and 21b. 
Multivariate analysis including insulin dosage, age at diagnosis 
of diabetes, age, body mass index, H h ^ , fasting blood glucose,
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FIG. 21a Cumulative frequency of triglyceride data for 205 subjects with IDDM
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FIG. 21b Cumulative frequency of cholesterol data for 205 subjects with IDDM
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alcohol and smoking habits and urinary protein excretion as co­
variables showed that the most significant predictors of levels 
of triglycerides in IDDM were insulin dosage, age at diagnosis, 
HbA.! and body mass index, whilst cholesterol levels were 
predicted by the age at the time of study, body mass index, 
urinary protein excretion, fasting blood glucose and HbAx levels 
(Table 51). Of these the most substantial contribution (partial 
regression coefficient) was provided by HbAx in the case of 
serum triglycerides, and proteinuria in the case of cholesterol.
Discussion: Although I was able to demonstrate hyperlipidaemia
in 40% of cases, only hypertriglyceridaemia appeared to be 
commoner than in the non-diabetic population. Hyperlipidaemia in 
IDEM was independently associated with ageing, early renal 
dysfunction, higher daily insulin requirements, obesity and 
poorer glycaemic control.
The cut off levels for fasting hyperlipidaemia are 
arbitrary but the levels beyond which a benefit frcm treatment of 
hyperlipidaemia is considered probable in non-diabetics (737- 
739).
In support of the previous observation of increased 
cholesterol levels in early diabetic nephropathy, serum 
cholesterol was independently associated not only with protein 
excretion, but also with serum creatinine levels in patients with 
stable glomerular filtration function, confirming the importance 
of the kidney in lipid metabolism in IDEM.
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Triglyceride levels appeared more conspicuously associated 
with diabetic glycaemic control than cholesterol levels, and the 
latter tended to be elevated in conjunction with 
hypertriglyceridaemia. The higher daily insulin requirements in 
such cases of canbined hyperlipidaemia might suggest a greater 
degree of insulin resistance in addition to less stable metabolic 
control in these patients. It was also of interest to find an 
association with renal dysfunction and canbined hyperlipidaemia 
since this subpopulation with IDEM are at great risk for vascular 
disease (560), and appear similar in both these respects to 
individuals with type III hyperlipoproteinaemia.
Finally, HDL2 cholesterol levels were reduced in these 
patients with hypertriglyceridaemia, although since the total HDL 
concentration in IDEM is often high, levels remained in the 
normal range for the non-diabetic population.
72
1:4. THE EFFECT OF APOLIPOPROTEIN E POLYMORPHISM ON LIPIDS AND
LIPOPROTEINS
Subjects: Of the 205 patients, apolipoprotein E phenotyping was
carried out on 120 (71M,49F), aged 15 - 72 years. Their duration 
of diabetes varied frcm 8 months to 42 years. 63% had no
detectable C-peptide response to a mixed meal, and more than 80% 
had experienced at least one episode of diabetic ketoacidosis. All 
had reasonable glycaemic control when assessed (HbAi 9.5 + 1.5% 
(mean + SD)).
None had evidence of hepatic disease or of advanced 
nephropathy (serum creatinine less than 140 pmol/1 except 2 cases 
(153 and 186 pmol/1). None were on medication which could affect 
lipid metabolism at the time of assessment other than insulin. 
The expected prevalences of the different apo E phenotypes based 
on gene frequency were determined according to Hardy-Weinberg 
equilibrium and compared with those observed. Absolute 
probabilities of the lowest three frequencies were compared using 
the t-test for the normal approximation to binomial distribution.
Results: Five of the six potential apo E phenotypes were
identified. Although gene frequencies were similar to non­
diabetic populations, a clear excess of the Apo E2/E2 phenotype 
(6.7%) was observed when compared to the prevalence of 0-2% 
described in non-diabetic populations. Prevalences of E2/E2 
homozygosity and E2/E3 heterozygosity were significantly 
different from those expected according to Hardy-We inberg 
equilibrium (p<0.0002 and p<0.005 respectively). The reported 
prevalences of the other phenotypes did not differ from those
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predicted (Table 52). No significant differences were found 
between the five groups with regard to age, body mass index, 
daily insulin dosage, glycaemic control, serum creatinine and 
urinary protein excretion. However in the apoE2/E2 group, 
duration of diabetes was less (p = 0.01) and C-peptide reserve 
was significantly greater (p = 0.025) than in the others (Table 
53).
Table 52
Apo E PHENOTYPE PREVALENCE AND GENE FREQUENCY IN 120 INSULIN
TREATED DIABETICS
Observed
Number
%
Expected
Number
%
E2/2 E2/3 E3/3 E3/4 E4/4 E2/4
8** 6* 79 23 4 0
6.7 5.0 65.8 19.2 3.3 0.0
1 17 73 24 2 3
0.8 14.2 60.8 20.2 1.7 2.3
Gene Frequency 
€2 0.091
63 0.780
64 0.129
*P<0.005 **P<0.0002 different from expected prevalence
according to Handy-Weinberg equilibrium
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Table 53
CLINICAL AND BIOCHEMICAL FEATURES OF 120 INSULIN-TREATED 
DIABETICS GROUPED ACCORDING TO Apo E PHENOTYPE
E2/2 E2/3 E3/3 E3/4 E4/4
SEX M:F 6:2 4:2 46:33 14:9 1:3
AGE (years) 43(3) 42(8) 42(2) 42(3) 41(9)
BODY MASS INDEX 28(2) 27(2) 24(1) 24(1) 24(2)
DURATION OF 
DIABETES (yrs)* 7(1) 12(1) 13(1) 19(2) 23(9)
INSULIN DOSAGE 
(U/day) 50(9) 43(8) 49(2) 52(2) 35(6)
FASTING BLOOD
GLUCOSE(mmol/L) 8.8(1.7) 14.9(2.3) 10.3(0.5) 12.3(1.3) 7.8(4.1) 
MEAN BLOOD
GLUCOSE 11.0(1.3) 14.6(2.4) 12.6(0.6) 12.9(0.8)12.5(6.3)
(mmol/L)
HhAi (%) 8.9(0.8) 8.6(0.9) 9.6(0.2) 9.7(0.4) 9.2(0.4)
C-PEPTIDE ** 0.370 0.025 0.002 0.004 0.127
(pnol/L) (0-2.50) (0-0.77) (0-1.90) (0-0.70) (0-0.760)
SERUM
CREATININE 77(4) 96(12) 80(2) 91(5) 92(12)
(umol/L)
URINARY 0.35 0.40 0.21 0.30 0.45
PROTEIN (0.05-0.90)(0.20-4.20)(0.05-5.30)(0.05-1.60)(0.05-2.20) 
(g/24 hrs)
Figures expressed are number, median (range) or mean (SEM) 
Ccmparisons not significant unless: *p = 0.01, **p = 0.025
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Results: Total serum cholesterol was lowest when the e2 allele 
was present (E2 hcmozygotes and heterogyzotes), intermediate in 
E3 hcmozygotes and highest in those possessing an 64 allele (E3/4 
or E4/4) (p=0.038). LDL cholesterol was similarly distributed, 
with lowest levels observed in those with an 62 allele and 
highest in those with an 64 allele (p = 0.042). A similar non­
significant (p= 0.1) trend was observed for apolipoprotein B. A 
tendency for HDL cholesterol levels to increase in parallel with 
LDL cholesterol was noted, due largely to HDL3, which meant that 
despite the higher LDL in the group possessing an 64 allele, 
their HDL to LDL and HDL to total cholesterol ratio tended to be 
lower (Table 54).
Of the 8 diabetics who were E2 hcmozygotes, only one was 
identified with classical type III hyperlipoproteinaemia with 
tuber-eruptive xanthcmata, arcus senilis formation and peripheral 
vascular disease. Another individual had fasting hyperlipidaemia 
(cholesterol 8.50 mmol/L; triglycerides 4.58 mmol/1) with 
dysbetalipoproteinaemia (pre-beta and broad beta band on 
electrophoresis), but without stigmata of type III 
hyperlipoproteinaemia. The remaining six were all normolipidaemic 
without detectable pre-p banding on electrophoresis and without 
clinical features of type III hyperlipoproteinaemia.
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Table 54
SERUM LIPIDS AND LIPOPROTEINS IN 120 INSULIN-TREATED DIABETICS 
GROUPED ACCORDING TO EXPRESSION OF €2,64 OR E373
62 E3/3 64
TRIGLYCERIDES 1.46 1.34 1.14
(mmol/L) (0.46-23.29) (0.36-5.40) (0.49-3.50)
CHOLESTEROL * 5.43(0.56) 5.61(0.16) 6.21(0.56)
(rmnol/L)
LDL CHOLESTEROL ** 3.07(0.41) 3.60(0.16) 4.02(0.52)
(irmol/L)
AFOLIPOPROTEIN B 97 (11) 106(3) 123(16)
(mg/DL)
LDL CHOLESTEROL 1.38(0.18) 1.36(0.06) 1.34(0.10)
APOLIPOPROTEIN B
HDL CHOLESTEROL 1.37(0.11) 1.46(0.04) 1.48(0.14)
(ircnol/L)
HDL2 CHOLESTEROL 0.69(0.12) 0.71(0.03) 0.72(0.14)
(mmol/L)
HDL3 CHOLESTEROL 0.68(0.12) 0.74(0.03) 0.77(0.13)
(mmol/L)
HDL/LDL 0.50(0.06) 0.47(0.02) 0.42(0.04)
CHOLESTEROL
HDL/TOTAL 0.27(0.03) 0.27(0.01) 0.25(0.02)
CHOLESTEROL
Figures expressed as median (range) or mean (SEM)
*p = 0.028, **p = 0.042
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1:5 THE EFFECTS OF SHORT TERM IMPROVEMENTS IN METABOLIC CONTROL
ON LIPIDS AND LIPOPROTEINS IN IDDM
In Chapter 3 I demonstrated that levels of total and LDL 
serum cholesterol and total triglycerides fell in response to 
intensification of management (Table 30). In view of the 
previous observations that hyperlipidaemia was present in 40% of 
all patients with IDEM that I examined (Chapter 4, 1:3), I
investigated whether the bulk of the overall response in serum 
lipids took place in those with hyperlipidaemia.
I therefore looked in detail at changes in lipid and 
lipoprotein levels in the initial 147 subjects on whom data was 
available, who were classified according to whether they were 
normolipidaemic (cholesterol less than 6.5 mnol/1, triglycerides 
less than 2.25 mmol/1), hypercholesterolaemic only (cholesterol 
greater than 6.5 mmol/1, triglycerides less than 2.25 mnol/1), 
hypertriglyceridaemic only (cholesterol less than 6.5 mmol/1, 
triglycerides greater than 2.25 mmol/1) or had combined 
hyperlipidaemia (cholesterol greater than 6.5 mmol/1, 
triglycerides greater than 2.25 mmol/1). 57 of the initial 147 
(39%) had hyperlipidaemia in one form or another, which is more 
or less the prevalence observed in the larger group of 205 which 
included diabetic controls who were not recruited to the heme 
glucose monitoring study. Of these 57, 24 had
hypercholesterolaemia, 19 had hypertriglyceridaemia and 14 had 
combined hyperlipidaemia. After the period of intensive 
management only 26 (19%) of the 137 subjects remained
hyperlipidaemic. 12 had hypercholesterolaemia, 4 had 
hypertriglyceridaemia and 10 had combined hyperlipidaemia
78
Intensive
Management
Baseline (Number = 147) 
Hyperlipidaemia in 39% (57)
6 Weeks (Number = 137) 
Hyperlipidaemia in 19% (26)
m Hypercholesterolaemia 
^  Combined Hyperlipidaemia 
H  Hypertriglyceridaemia
FIG. 22 The effect of intensification of management of the prevalence of 
hyperlipidaemia.
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(Figure 22). The actual changes in lipids and lipoproteins in 
the patients were grouped according to their initial lipid 
status and are shown in Tables 55 and 56. Triglyceride levels 
remained unaltered in the normolipidaemic group, but fell in the 
other groups, particularly in those patients with 
hypertriglyceridaemia. On the other hand total and LDL 
cholesterol levels only fell significantly in those who were 
hypercholesterolaemic initially.
Apolipoprotein B and total HDL cholesterol levels 
essentially remained unaltered although a marked fall in both was 
observed in the group with combined hyperlipidaemia. However the 
most obvious changes were with regard to HDL cholesterol 
subfractions. HDL2 cholesterol levels showed a definite rise in 
the hypercholesterolaemic group, whilst they fell in the combined 
hyperlipidaemic group and remained unaltered in the other 2 
groups. In distinction HDL3 cholesterol levels fell in all 4 
groups.
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1:6 THE EFFECTS OF LONG TEEM METABOLIC CONTROL ON LIPIDS AND
LIPOPROTEINS IN IDDM
Lipid and lipoprotein levels differed little according to 
whether patients were carrying out blood or urine glucose testing 
(Chapter 3, 1:5). However in both groups lipid levels seemed to 
rise a little after 6 months in relation to their levels at 6 
weeks, and thereafter fell. In order to assess this more closely 
I examined changes in lipids over this time with patients again 
categorized according to their initial lipid levels (Tables 57 
and 58). In addition lipids and lipoprotein levels were 
compared for the study group as a whole with the 52 diabetic 
clinic controls, initially, and after 6 and 12 months (Figure 
23).
In the normolipidaemic group mean levels of triglycerides 
and cholesterol remained unchanged throughout the year, despite 
the fact that hyperlipidaemia was observed in as many as 7 cases 
at 6 months and 1 year (Table 58). A sustained fall in total and 
LDL cholesterol was seen in both the hypercholesterolaemic and 
combined hyperlipidaemic groups at 6 months and 1 year; in 
addition triglyceride levels remained lower in the 
hypertriglyceridaemic and combined hyperlipidaemic levels 
throughout the year (Tables 57 & 58). The absolute number of 
subjects with hyperlipidaemia was roughly the same at 6 months 
and 1 year; and comparable although proportionately greater to
the number after 6 weeks of intensified management. Over the
.    '
whole year the maximum impact in reducing the number of 
hyperlipidaemic patients was seen in the hypertriglyceridaemic
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TOTAL CHOLESTEROL
Control Group6-
Study Group
5 -
mmol/L
LDL
Control Group
Study Group
3 -
*  P = 0.05
2 -1
1 YearBaseline 6 Months
FIG 23 Total and LDL cholesterol levels in control and study groups over 
1 year.
Figures represent Mean ± SEM
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group and to a lesser extent in the hypercholesterolaemic group. 
The number of patients with combined hyperlipidaemia remained 
fairly constant, and 8 cases had persistant combined 
hyperlipidaemia during the study. Levels of apolipoprotein B and 
HDL cholesterol remained fairly stable in the 4 groups throughout 
the year. Likewise HDL cholesterol subfractions remained 
unaltered, with the notable exception of the combined 
hyperlipidaemic group, in whom HDL2 cholesterol levels
continued to fall (Table 58).
Total and LDL cholesterol levels for the study group as a 
whole were comparable to the diabetic controls initially and at 6 
months, although LDL cholesterol levels tended to be lower after 
1 year in the study group (p = 0.05) (Figure 23). Triglyceride 
levels were also comparable in both groups basally but remained 
at the levels seen after 6 weeks intensive management in the 
study group at 6 months and 1 year (p<0.05 in comparison to 
baseline). On the other hand levels remained fairly stable in 
the control group, so consequently the levels were significantly 
greater in the control group at 6 months and 1 year (p<0.05).
HDL cholesterol levels tended to be higher (p = 0.05) in the 
control groups (1.48(0.35), mean (SEM), mmol/1) than in the study 
group (1.39 (0.04) mmol/1) after 6 months but after 1 year levels 
of HDL cholesterol had risen in the study group (1.44 (0.04) 
nmol/1) approximating to those in the control group. HDL2 
cholesterol levels were indistinguishable between control and 
study groups during the year, and therefore it was HDL3 
cholesterol levels which changed most, with higher levels in the 
control group (0.77 (0.03) mmol/1) at 6 months in comparison to
85
the study group (0.70 (0.04) mmol/1) (p< 0.05). Again levels had 
risen sanewhat by 1 year in the study group (0.75 (0.03) mmol/1) 
so the difference was no longer evident. Levels of 
apolipoprotein B remained stable in the control group throughout 
the year (119 (3) mg/dl at 6 months and 119 (3) mg/dl at 1 year), 
and consequently higher than the study population at these time 
points (p<0.05), although it should be pointed out that the 
control group also had higher apo B levels at the outset of the 
study.
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1:7 DISCUSSION
The series of investigations in this chapter demonstrated 
that conformational qualitative as well as quantitative 
abnormalities of lipoproteins are a feature of IDEM. I have been 
able to demonstrate that lipid metabolism in IDEM is altered not 
only by prevailing metabolic control, but also by early 
disturbances of renal function and genetic factors.
In the comparison of diabetic men without renal disease and 
healthy controls, the most striking features were the marked 
reductions in levels of apolipoprotein B, of which 90% is 
contained in low density lipoprotein (LDL). Although the LDL 
cholesterol level tended if anything to be lower in IDEM, a 
substantial increase in cholesterol relative to apolipoprotein B 
was apparent in 'LDL'. The consequent change in density means 
that the ’LDL1 would be more analagous in physical terms to 
intermediate density lipoprotein (IDL), which may be particularly 
atherogenic. This particular lipoprotein is characteristically 
present in large amounts in the serum of patients with type III 
hyperlipoproteinaemia, which also has clinical features in ccmmon 
with IDEM. A genetic basis for type III hyperlipoproteinaemia is 
described although co-existant diabetes is often required to 
allow clinical expression of this disorder (v.i.).
A further finding was the demonstration of higher HDL 
cholesterol levels in IDEM, which I found was due to an increase 
in the HDL3 cholesterol subfraction. Because HDL3 is normally 
catabolised to HDL2 the one logical explanation for the relative 
excess of HDL3 and deficiency of HDL2 would be an increased 
synthetic and catabolic rate of HDL in IDEM. HDL3 levels would
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then build up but early catabolism would reduce conversion to 
HDL2. Glycosylation of HDL may enhance its catabolism (181) 
which may in part explain the phenomenon.
In my case-control comparison of insulin diabetic patients 
with normal AER or proteinuria I found evidence that even a
minor degree of renal impairment may lead to further alterations
in lipid and lipoprotein levels.
Most notably early proteinuria is associated with
significant reductions in total HDL and HDL2 cholesterol levels. 
This observation raises the possibility that glomeruli in 
diabetic nephropathy are more porous to HDL3 and free 
apolipoprotein AI, thereby compounding the tendency for increased 
HDL3 synthesis and consequent urinary loss prior to acquiring 
sufficient cholesterol to become HDL2. I also found that HDL 
cholesterol levels were notably different when isolated by 
ultracentrifugation or precipitation in patients with
nephropathy. Lp(a) has a hydrated density and overlaps with 
HDL2. One possible explanation is that therefore Lp(a) is 
measured as HDL by ultracentrifugation. A higher level of Lp(a) 
is linked with coronary heart disease and could be ccmpatable 
with my observations in patients with diabetic nephropathy. Less 
marked elevations of total and LDL cholesterol, triglycerides and 
the mass ratio of cholesterol: apo B in LDL were observed. 
Therefore the lipid profile of patients with nephropathy was more 
akin to that recognised in general as at high risk for the 
development of premature atherosclerosis. The novel observation 
that this group already had an increased prevalence of 
hypertension and vascular disease may suggest that the
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development of quantitative abnormalities of lipids compounding 
the essential conformational changes in IDEM is implicated in the 
development of vascular disease. In addition of course, diabetic 
nephropathy is associated with alterations in platelet function 
(592), blood viscosity (591, 595) and vascular leakage (590), so 
it is clear that the abnormalities of lipid metabolism and blood 
pressure are not acting in isolation to encourage the progression 
of atherosclerosis and microvascular disease. I would speculate 
that a 'cascade' of pathological changes acting in synergy is one 
logical explanation for the association between early nephropathy 
and vascular disease in IDEM.
In section 1:4 I found that apolipoprotein E polymorphism 
exerted an effect on lipid and lipoprotein levels in IDEM, just 
as in the normal population. What was unexpected however, was 
the marked increase in the prevalence of E2 hcmozygosity in IDDM. 
Despite this, only one of the 8 patients who were E2 hcmozygous 
had type III hyperlipoproteinaemia, perhaps reflecting in part 
the fact that the E2 hcmogygous group had greater C-peptide 
levels and a lesser duration of diabetes. Residual endogenous 
insulin secretion may therefore have conferred seme protection 
against the expression of type III hyperlipoproteinaemia.
My conclusion fran these studies is that IDEM has several 
biochemical, genetic and clinical features in caimon with type 
III hyperlipoproteinaemia. This is not to say that the 
conditions are the same, but simply to point out that only a 
percentage of patients with IDEM develop an excess of vascular 
disease. The majority of these have diabetic nephropathy which 
is associated with the abnormalities of lipoproteins. It is
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conceivable that associated genetic traits in sctne cases of 
diabetic nephropathy modify the metabolism of triglyceride rich 
lipoproteins such as IDL, where the eventual outcane is similar 
to that seen in type III hyperlipoproteinaemia. Of course these 
factors do not operate in isolation to cause hyperlipidaemia in 
IDEM. Dietary indiscretion is recognised to lead to the 
hyperlipidaemia in both diabetics and non-diabetics, but was not 
the subject of intensive scrutiny in my studies.
In the assessment of the prevalence of hyperlipidaemia in 
IDDM (1:3), I found that hypertriglyceridaemia and combined 
hyperlipidaemia was commoner in diabetic compared to non-diabetic 
men, but that hypercholesterolaemia was less common in IDEM 
without advanced nephropathy. In addition to the previous 
observations on renal function, hyperlipidaemia in IDEM also 
appeared to be independently associated with higher daily insulin 
requirements, obesity, and in the case of hypertriglyceridaemia, 
with poorer control. This last feature was particularly apparent 
in the longitudinal studies, when hypertriglyceridaemia was found 
to be the most amenable to correction following improved 
glycaemic control. On the other hand those patients with 
combined hyperlipidaemia tended to remain hyperlipidaemic. The 
higher daily insulin dose and poorer glycaemic control in the 
patients with combined hyperlipidaemia may be related, and 
suggest that insulin resistance may be the common link in this 
group.
Despite the suggestion that combined hyperlipidaemia is 
relatively more resistant to correction, the short term and long
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term longitudinal studies revealed that considerable changes in 
lipid metabolism accompany inproved glycaemic control and 
diabetic management. I found that the prevalence of 
hyperlipidaemia halved during the initial 6 week period of 
intensified management, predominantly due to a reduction in 
hypertriglyceridaemia, although the number of subjects with 
hypercholesterolaemia also halved.
Levels of apoliprotein B were essentially unaltered during 
this period with the exception of the combined hyperlipidaemic 
group, where a marked reduction was noted. As most of the fall 
in cholesterol took place within the LDL fraction, it would 
appear that intensive therapy is capable of altering the 
conformational changes in LDL to seme extent, particularly in 
patients with hypercholesterolaemia.
Although HDL cholesterol levels did not fall during the 
first 6 weeks in the total group (Table 30), a substantial fall 
was recorded in those patients with combined hyperlipidaemia, in 
whom levels of both HDL2 and HDL3 cholesterol fell. I found that 
HDL3 cholesterol levels fell significantly in all the sub-groups 
over this period, which may reflect a general decrease in 
synthesis. HDL2 levels otherwise remained unaltered (or 
increased in those with hypercholesterolaemia) so it would appear 
that intensified therapy does not lead to any undesirable changes 
in the cardioprotective component of HDL.
Although metabolic control was less tight following the 6 
week period intensive management, lipid levels tended to run 
slightly lower in the study group than the controls, so it would 
appear that improvements in lipid metabolism were maintained for
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at least 1 year, at least in seme cases. This appears to have 
been due mainly to sustained reductions in LDL cholesterol and 
triglycerides, since HDL cholesterol levels remained fairly 
constant, with the exception of the combined hyperlipidaemic 
group where HDL2 cholesterol levels showed a continued fall over 
the year.
In addition to demonstrating that lipid levels may been 
lowered in patients who were initially hyperlipidaemic, I found 
that 10 patients who were originally normolipidaemic became 
hyperlipidaemic. It appears therefore that the development of 
hyperlipidaemia in IDEM is not 'preconditioned*, and may arise 
for a multitude of reasons. Improved diabetic management can 
make a considerable sustained impact on hyperlipidaemia, although 
it is perhaps less effective in cases of combined hyperlipidaemia 
associated with early diabetic nephropathy and/or insulin 
resistance.
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CHAPTER 5
ASSESSMENTS OF CLINICAL VALUE OF EKUCTOSAMINE AND GLYCOSYLATED 
SERUM ALBUMIN IN THE MEASUREMENT OF GLYCAEMIC CONTROL IN IDEM
95
1:1 CROSS-SECTIONAL STUD* OF DIRECT MEASURES OF GLYCAEMIA AND 
GLYCOSYLATED BLOOD PROTEINS IN NORMQLEPIDAEMIC AND 
HYPEREJPIDAEMIC HEM.
I examined associations between direct measures of glycaemia 
and the various glycosylated blood proteins basally in 113 
subjects (68 males, 45 females) in whan data was complete, and 
examined whether or not the ' fructosaminef assay was affected by 
varying serum concentrations of lipids, albumin or C- 
peptide. The patients were aged 40.3 (1.1) years (mean (SEM)), 
(range 15-69 years), and had been diabetic for 13.1 (0.8) years 
(range 4 months - 57 years). They were of average body mass 
index (EMI 23.6 (0.8), range 15-35), and had preserved renal 
function (urea 5.3 (0.1) mmol/1) and normoalbuminaemia (range 
37-51g/l). 54 (49%) of the subjects had no detectable C-peptide
response following a standard meal. The glycaemic variables were 
measured on admission to the hone blood glucose monitoring study 
during the initial 24 hour stay in hospital. The M value of
Schlichtkrull (97) was calculated, using an arbitrary normal
blood glucose level of 4.4mmol/l, by the equation:
M-value = (10 log10x) 3/
( 4 . 4  ") / n + y
where x is the blood glucose value, y the difference between the
maximum and minimum value and n the number of blood glucose
measurements made (in this case 10). Fructosamine levels were
assessed directly and after correction to a standard albumin
concentration of 40g/l.
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Results Fructosamine levels were 3.92 (0.08) mmol/1,
corrected to 3.57 (0.08) mmol/1 after standardisation to an
albumin concentration of 40g/l, glycosylated serum albumin (GSA) 
9.8 (0.4) %, MbAi 9.1 (0.2) %, serum albumin 44.2 (0.3) g/1, 
cholesterol 5.69 (0.14) mmol/1 and triglycerides 1.80 (0.22) 
mmol/1 (range 0.39-23.29mmol/l). Neither fructosamine or GSA 
values were significantly altered by correction for prevailing 
albumin concentrations. Fasting blood glucose levels were 11.1 
(0.6) mmol/1, mean blood glucose 12.5 (0.3) mmol/1 and the M 
value 117 (7) units.
29 (26%) had fasting hypercholesterolaemia (greater than 
6.5mmol/l) and 24 (21%) were hypertriglyceridaemic (greater than 
2.25 mmol/1). C-peptide levels ranged frcm 0-2.5pmol/ml (median 
0.027 pmol/ml).
Serum fructosamine levels correlated closely with corrected 
fructosamine levels (r=0.95, p=0.001), but less so with GSA 
(r=0.48, p=0.001) (Figure 24), HbAi (r=0.44; p=0.001) (Figure 25) 
or levels of fasting blood glucose (r=0.35, p=0.001), mean blood 
glucose (r=0.30, p=0.001) and the M value (r=0.33, p=0.001) 
(Table 58a). Fructosamine levels did not correlate with serum 
levels of albumin, cholesterol or triglycerides. After 
fructosamine was corrected to a standard albumin concentration of 
40g/l,correlations were essentially the same, except that the 
corrected levels inversely correlated with serum albumin (r=- 
0.32, p=0.001).
GSA correlated more closely with HhAx (r=0.68, p<0.001) 
(Figure 26), the M value (r=0.42, p=0.001), and fasting
(r=0.37,p=0.001) and mean blood glucose levels (r=0.39, p=0.001)
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TABLE 58a
Correlation between direct measures of glycaemia and glycosylated 
blood proteins in 113 subjects with insulin dependent diabetes
mellitus (IDEM)
HhA-L Fructosamine GSA
Fasting Blood Glucose r=0.34 r=0.35 r = 0.37
(r = 0.37)*
Mean Blood Glucose r = 0.35 r = 0.30 r = 0.39
(r = 0.31)*
M Value r = 0.35 r = 0.33 r = 0.42
(r = 0.34)*
* Fructosamine values corrected to serum albumin 
concentration of 40g/l.
p for all correlations = 0.001
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TABLE 58b
MEASURES OF GUYCAEMIC CONTROL IN 29 HYPERCHXESTEROLAEMIC AND 84 
N08EMXH3LESEEEOjAEMIC IDEM SUBJECTS Figures are mean (SEM)
Hypercholesterolaemic Normocholesterolaemic 
IDEM IDEM
HE&! (%) 9.3 (0.4) 9.0 (0.2)
Fasting blood 12.5 (1.1) 10.6 (0.2)
Glucose (mmol/1)
Mean blood 12.6 (0.6) 12.5 (0.4)
Glucose (mmol/1)
M Value (units) 116 (12) 119 (9)
GSA (%) 10.0 (0.7) 9.7 (0.4)
Fructosamine 3.87 (0.17) 3.93 (0.09)
(mmol/1)
Serum Albumin (g/1) 43.4 (0.6) 44.5 (0.3)
Collected
Fructosamine 3.59 (0.18) 3.56 (0.09)
(mol/1)
Figures are mean (SEM).
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in comparison to fructosamine (Table 58a). There was no 
correlation between GSA and cholesterol (r=0.03) or with serum 
albumin (r=-0.01) but a weak relationship with triglyceride 
levels (r=0.26, p=0.003) was recorded.
When the 29 hypercholesterolaemic subjects were compared to 
those 84 with normocholesterolaemia, no difference was recorded 
for any measure of glycaemic control including fructosamine 
levels (3.87 (0.17) V 3.93 (0.09) mmol/1, respectively). (Table 
58b). However, whilst levels of fasting blood glucose and GSA 
were significantly greater (p<0.03) in the 24 
hypertriglyceridaemic patients than in those with 
normotriglyceridaemia, levels of fructosamine tended to be lower 
(Table 58c). Furthermore, after correction for the difference in 
fasting blood glucose, fructosamine levels were significantly 
reduced (p<0.05) in patients with hypertriglyeridaemia (Table 
58c). No such effect was observed for GSA levels.
C-peptide levels correlated inversely with fasting blood 
glucose (r=-0.30, p=0.001), fructosamine (r= -0.26, p=0.008) and 
corrected fructosamine (r=-0.24, p=0.002), and to a lesser extent 
with the M values (r= -0.25,p=0.005), GSA (r= -0.22, p=0.01), the 
mean blood glucose value (r= -0.18, p n/s) and HbAx (r= -0.16, p 
n/s). In the 59 patients with detectable C-peptide, closer 
inverse correlations were recorded with mean blood glucose levels 
(r= -0.32, p=0.007), M values (r= -0.36, p=0.003), and the HbAx 
(r= -0.24,p=0.03) than when all patients were included in the 
analysis, although this was not the case for either GSA (r= -
0.15, pn/s) or fructosamine (r=0.05, pn/s).
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TABTJC 58c
Measures of glycaenic control in 24 hypertriglyceridaemic and 89 
nonrotriglyceridaemic patients with IDEM
Hypertriglyceridaemic Normotriglyceridaemic
IDEM IDEM
Triglyerides (mmol/1) 3.04 1.05
(2.29-23.29) (0.39-2.24)
Fasting Blood Gluose 13.6 (1.3) 10.4 (0.6)*
(mmol/1)
Mean Blood Glucose 13.8 (0.8) 12.1 (0.4)
(mmol/1)
M Value (units) 144 (18) 111 (7)
HhAi (%) 9.9 (0.5) 8.9 (0.2)
GSA (%) 11.8 (0.9) 9.3 (0.4)*
Fructosamine (mmol/1) 3.79 (0.16)+ 3.95 (0.09)
Serum Albumin (g/1) 44.2 (0.3) 43.9 (0.4)
Corrected Fructosamine 3.50 (0.16) 3.59 (0.09)
(mmol/1)
Figures are median (range) or mean (SEM)
*p <0.03
+p< 0.05 significantly lower than normotriglyceridaemic group 
after correction for fasting blood glucose levels.
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1:2 EROSPECTEVE EVALUATION OF THE RELATIVE CLINICAL UTILITY OF GSA 
AND FRUCTOSAMINE DURING SHORT TERM IMPROVEMENTS IN GLYCAEMIC 
GCNTO3L
I assessed changes in GSA, fructosamine, HhAi and direct 
measures of glycaemia during the initial 6 week period when 
attempts were made to improve glycaemic control. Of the 113 
subjects who were analysed initially, comprehensive data was 
available in 100 cases. Direct measures of glycaemia were based 
on patient-generated data verified by measuring stored blood 
sticks in a hospital blood glucose reflectance meter and by 
validation with filter card blood glucose measurements.
Cross sectional analysis of the data collected after 2, 4 and 
6 weeks was carried out, and in addition levels of GSA, 
fructosamine and HhAi were compared with the direct measures of 
glycaemia made 2, 4 and 6 weeks previously. Finally, a comparison 
was made of the relative ability of GSA, HbAx and fructosamine to 
reflect improvements in glycaemia over periods of 2 weeks (A 2 
weeks, 4 weeks (A 4 weeks) and 6 weeks (A  6 weeks).
RESULTS
1. Patterns of Glycaemia During 6 weeks improved glycaemic 
control (Figures 27 and 28).
Marked improvements were recorded in all direct measures of 
glycaemia after the initial 2 week period (p=0.001) Figure 27). 
These were paralleled by significant reductions in GSA, 
fructosamine (p=0.001), and corrected fructosamine (p<0.01) to a 
lesser degree (v.i.) (Figure 28). By 4 and 6 weeks, further 
falls in all measures of glycaemic control had taken place in
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FIG. 27 Serial changes over 6 weeks in direct measures of glycaemia in 100 
subjects with IDDM.
Figures represent Mean ± SEM
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comparison to initial values (p<0.001) (Figures 27 and 28).
2. Cross Sectional Correlations between direct measures of 
glyaemia and glycated blood proteins (Table 59)
Fasting blood glucose correlated to a greater or lesser 
extent at the initial, 2, 4 and 6 week time points with levels of 
GSA (rs range 0.22 to 0.44) and with fructosamine levels (rs range
0.21 to 0.39) although corrected fructosamine levels were not 
always correlated. Mean blood glucose levels were more closely 
related at the same time points to levels of GSA (rs range 0.30 
to 0.50) and both corrected and direct fructosamine levels (rs 
range 0.30 to 0.50). Likewise M values reflected measures of GSA 
(rs range 0.31 to 0.52) and of direct and corrected fructosamine 
(rs range 0.33 to 0.49).
GSA levels correlated with fructosamine (corrected and 
direct) at all time points (rs range 0.46 to 0.66), but there was 
no suggestion that the measurements closely paralleled one 
another.
HbA.! was more highly correlated with GSA than fructosamine 
both initially (rs=0.68 Vs 0.42 to 0.44) and after 6 weeks 
(rs=0.47 Vs 0.22 to 0.23).
3. Cross sectional comparisons of direct measure of glycaemia and 
subsequent GSA and fructosamine levels (Table 60)
Poor correlation was observed when initial fasting blood 
glucose levels were compared with GSA and fructosamine values at 2 
and 6 weeks. 2 and 4 weeks fasting blood glucose concentrations 
showed improved correlations with 4 and 6 week GSA levels and with 
fructosamine levels at 6 weeks.
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On the other hand mean blood glucose levels initially and at 
2 and 4 weeks were correlated significantly with subsequent 
measures of GSA at all time points and to a lesser extent with 
fructosamine at most time points. A similar observation was made 
with M values and subsequent GSA or fructosamine levels.
Overall, direct measures of glycaemia were more highly 
correlated with GSA than with fructosamine.
4. Comparison of changes (A) in direct measures of glycaemia and 
glycated blood proteins (Tables 61-63)
The extent of the falls in all glycaemic measures frcm 
baseline are shown in Table 61. Direct glycaemic measures fell 
after 6 weeks by 30-56% frcm their original levels, whilst GSA 
fell by 26% and fructosamine and HbAi only fell by 11-13%.
A  HhAx, A  fructosamine and A  GSA significantly reflected 
the A  fasting, / \  mean blood glucose and the A  M value over 
6 weeks. However over 2 and 4 weeks A  GSA was more closely 
related to changes in direct measures of glycaemia than A  
fructosamine (Table 62).
Furthermore, although HhAx and A  fructosamine over 6 
weeks correlated with one another,changes in GSA and fructosamine 
over 2-6 weeks did not parallel one another (range 0.51 to 0.57) 
(Table 63).
1:3. A COMPARISON OF ICNG TERM CHANGES IN GSA, PHDCTOSAMTNE AND 
OTHER MEASURES OF G3GXCAEMIC CONTROL OVER A PERIOD OF 1 YEAR
I was able to analyse and compare the different measures of 
glycaemia in 98 subjects during the 1st year of the heme blood
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TABLE 6 2
COMPARISON OF CHANGES (A) IN DIRECT MEASURES OF GLYCAEMIA AND GLYCATED 
BLOOD PROTEINS OVER 2, 4 and 6 WEEK PERIODS IN 100 SUBJECTS WITH IDDM
AFASTING BLOOD 
GLUCOSE
A MEAN BLOOD 
GLUCOSE
AM VALUE
AHbA
over 6 weeks 0.161 0.22** 0.24**
AGS A
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.37***
0.28**
0.38***
0.28**
0.36***
0.36***
0.26**
0.32***
0.38***
AFRUCTOSAMINE 
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.18*
0.13
0.18*
0.00
0.19*
0.16*
0.01
0 .20*
0.18*
/CORRECTED FRUCTOSAMINE
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.28**
0 .20*
0 .20*
0.00
0.19*
0.17*
0.01
0 .20*
0.23**
Figures are correlation coefficients (r )
*p < 0.05 **p <: 0.01 ***p < 0.001
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TABLE 63
COMPARISON OF CHANGES (A) IN GLYCATED BLOOD PROTEINS OVER 2, 4 and 6 
WEEK PERIODS OF IMPROVED CONTROL IN 100 SUBJECTS WITH IDDM
AHbA
over 6 weeks
GSA
0.52***
FRUCTOSAMINE
0.42***
CORRECTED
FRUCTOSAMINE
0.43
HbA,
agsa
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.56***
0.53***
0.27**
0.57***
0.54***
0.25 0.52***
AFRUCTOSAMINE 
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.56*** 
0.53*** 
0.27**
0.89***
O g}***
0.92*** 0.42***
ACORRECTED FRUCTOSAMINE
. over 2 weeks 
. over 4 weeks 
. over 6 weeks
0.57***
0.54***
0.25**
0.89***
0.91***
0.92*** 0.43***
Figures are correlation coefficients (rs)
**p < 0.01 ***p < 0.001
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glucose monitoring study.
Firstly I examined potential associations between the various 
measures of control throughout the year. Glycated blood proteins 
were compared with various direct measures of glycaemia calculated 
frcm filter cards returned over the preceeding 3 month interval.
I also carried out Kappa Cohen analysis on the various 
measures of glycaemia at 3 monthly intervals to assess how 
frequently absolute discordance or concordance was observed 
between the various measures of glycaemic control. For this 
exercise I graded glycaemic control as excellent, fair or poor 
for each of the variables. Classification categories for the 
various measures are shown in Table 64.
Finally I compared other measures of control in a subgroup 
of subjects whose Hh^ levels were persistently less than or equal 
to 8.0% following the 6 week period of intensified management, 
at each 3 month interval during the first year of the study.
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TABLE 64
Glycaemic Control Categories
Excellent Fair
HhAx (%) < 8.0 8.0-10.0
GSA (%) < 6.0 5.0-8.0
Fructosamine (mmol/l) < 3.00 3.00-3.50
Filter Card Mean 
Fasting Blood
Glucose (mmol/l) <7.0 7.0-10.0
Filter Card Blood Glucose 
M Value (Units) < 15 15-50
Poor 
> 10.0 
> 8.0
> 3.50
> 10.0 
> 50
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RESULTS
The number of completed filter cards returned that were 
suitable for analysis in the 98 subjects was variable and ranged 
frcm 67-98 (mean 80) per month.
1. Serial changes in glycaemic measures over course of the study
(Figures 29-31)
Significant changes were observed in all measures of 
glycaemic control, mainly due to the improvement in glycaemic 
control during the 6 week period of intensified management. 
However in addition GSA and direct and correct fructosamine levels 
rose significantly thereafter, despite little further change in 
HhA-L or direct measures of glycaemia. Serum albumin levels 
remained stable throughout the study.
2. Correlations between different measures of glycaemic control 
over 1 year (Figures 32-35)
Because of the many comparisons, only p<0.001 is considered 
significant. Considerable variation was recorded in the 
correlation between fasting blood glucose and glycosylated blood 
protein levels. Fructosamine showed a significant correlation on 
only 3 of 14 occasions (rs range 0.35 to 0.39), GSA on only 2 out 
of the 14 occasions (rs range 0.37 to 0.44) as did HhAx (rs 
range 0.34 to 0.37) (Figure 32).
On the other hand, the relationship between mean blood 
glucose and glycosylated blood protein levels was more clearly 
defined (Fig. 33). Whilst fructosamine only correlated 
significantly on 4 of 14 occasions (rs 0.30 to 0.50), GSA was 
related on 6 occasions (rs range 0.36 to 0.54) as was HhA-L (rs 
range 0.36 to 0.48). Likewise M values were significantly
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FIG. 29 Changes in glycosylated blood proteins and serum albumin over 
1 year.
Figures represent Mean ± SEM
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FIG. 32 Correlations between fasting blood glucose and glycosylated blood 
proteins over the course of 1 year.
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related to HhAj on 7 occasions (rs range 0.34 to 0.45), but only
to fructosamine on 4 occasions (rs range 0.32 to 0.50) and GSA on
4 (rs range 0.42 to 0.58) (Fig. 34).
Correlations between various glycated blood proteins 
confirmed a continued significant association throughout the year 
between HhAi and GSA (rs range 0.47 to 0.68), and between GSA and 
fructosamine (rs range 0.48 to 0.76). The correlations between 
HhAx and fructosamine were less clear (rs range 0.38 to 0.44) and 
no significant correlation was apparent at the point of
randomisation or at 3 months (Fig. 35).
3.Comparison of different measures of glyaemic control categories 
(Tables 65 and 66)
The extent of agreement between the various glycaemic 
measures was studied throughout the year using the control 
categories frcm Table 64 to represent excellent, fair or poor 
control. Absolute concordance was present when both variables 
simultaneously were categorised in the same control group whilst 
absolute discordance referred to when 1 measure was categorised as 
'excellent' whilst the other was recorded as 'poor'.
Comparison of HhAx and fructosamine levels showed that 
absolute discordant values were recorded on between 16-29% of 
values during the year, and no significant agreement was recorded 
between these variables during the year. On the other hand a 
closer degree of association was observed between GSA and HhA!, 
where discordant data was recorded on between 11-19% of the 
values during the year, but where significant associations were 
recorded at baseline, the point of randomisation, 9 months and 1
123
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FIG. 34 Correlations between M values and glycosylated blood proteins over 
the course of 1 year.
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year (all p<0.01). Although the mean blood glucose values were 
discordant with HhA: levels on 4-19% of cases through the
year,the only time when a significant agreement was observed was 
at the point of randomisation (p<0.01) owing to the smaller 
number of filter mean blood glucose values suitable for 
comparison thereafter. Likewise M values showed discordance with 
HhAx ranging from 4-20%, but associations were only significant 
at the point of randomisation and after 1 year (p<0.01), when 
glycaemic control was relatively more stable.
As expected, a closer relationship was observed between GSA 
and fructosamine at all time points although absolute discordance 
was observed in 6-15% of cases during the study (Table 66). 
However, at each time point the association between the 2 measures 
was significant (p<0.01 to 0.001).
4. Levels of glycaemia in patients with persistently normal HfaAj
After the initial period of intensification of management, 57 
of the original cohort had attained normal levels of HbAi 
(<8.0%),of whcm 19 had levels within the normal range throughout 
the year. Using the same control criteria as in Table 64, I 
examined how frequently the other measures of glycaemia strayed 
into the fair or poor categories during the study. The pattern of 
the various measures of glycaemia is shown in Figures 36 and 37 
and confirm that whilst mean blood glucose and M values 
frequently remained within the range for 'excellent' control, the 
mean GSA and fructosamine levels were never in the normal range. 
The number of patients with elevated values (i.e. fair or poor) 
for each glycaemia measure at different time points is also shown 
in Figures 36 and 37 and confirms that patients' fructosamine
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FIG. 36 Fructosamine and GSA levels in Id subjects with IDDM who had 
normal HbA! levels throughout the year.
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values were most commonly outside the normal range, followed 
thereafter by GSA. With regard to the filter card mean blood 
glucose and M values, a distinct pattern was seen with less 
abnormal values recorded in the second half of the year.
3:4 HZFEESiniGLXCEEdDDAQflA AND II^UCIDSAMENE
One unexpected finding frcm the cross-sectional analysis of 
the baseline data was that fructosamine levels appeared 
artificially lower in hypertriglyceridaemic (greater than 
2.2mmol/l) subjects whereas if anything higher levels would have 
been anticipated since glycaemic control (assessed by GSA and 
fasting blood glucose) was not surprisingly somewhat poorer.
In the light of this finding and the subsequent observations 
on the limited role of fructosamine in reflecting short term 
improvements in glycaemia, I scrutinised the data more carefully 
at 6 weeks, 6 months and 1 year, when comprehensive measures of 
glycaemia and lipids were available. Of the 24 individual who 
were initially hypertriglyceridaemic, 9 were hyper- 
triglyceridaemic at least once during subsequent measurements, 
whilst 4 subjects remained persistently hypertriglyceridaemic 
throughout. In addition other patients developed
hypertriglyceridaemia at different time points. Therefore 
between 11 and 15 of the 113 cases had triglyceride levels 
greater than 2.2mmol/l during the study.
Measures of glycaemic control were compared at the different 
time points in the normotriglyceridaemic and hypertriglyceridaemic 
sub-groups by Mann Whitney tests. Furthermore levels of GSA and 
fructosamine in the 2 groups were compared after correcting for 
differences in fasting blood glucose levels by analysis of
131
variance.
RESULTS
As expected, the hypertriglyceridaemic subjects generally had 
poorer glycaemic control, although only HbAi levels were 
significantly greater after 6 weeks of intensified management in 
those with hypertriglyceridaemia. However after taking into 
account the difference in fasting blood glucose levels, GSA was 
also significantly higher at 6 weeks in the hypertriglyceridaemic 
group. The most striking anomaly was the observation of reduced 
fructosamine levels in hypertriglyceridaemic sera, most notably 
at 6 months and 1 year (Table 67), although they were also lower 
after 6 weeks of intensified management when the difference in 
fasting blood glucose levels was taken into account.
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1:5 DISCUSSION
The preceding series of studies demonstrates quite clearly 
that in IDDM, various measures of glycaemia give complementary 
rather than comparable information, particularly when metabolic 
control is less stable or changing. Support for this statement 
comes from the weak inverse correlation between C-peptide and 
measures of glycaemia. One explanation for the weak correlation 
is the relatively high percentage of patients who had no 
detectable endogenous insulin reserve, particularly since 
residual p cell function is thought to stabilise glycaemic 
control (v.i.) (551, 557).
In view of the recent introduction of the fructosamine assay 
into clinical practise, I was particularly interest to compare it 
with the established measures of glycaemia, as well as with the 
GSA assay that we had developed. I did not find that
fructosamine values were altered either by varying albumin 
concentrations or by hypercholesterolaemia. However a consistent 
artefactual reduction in fructosamine levels was apparent in the 
presence of hypertriglyceridaemia, despite generally poorer 
glycaemic control in this group. The reason for this anomaly is 
not explained by the current series of experiments, but it is 
possible that lipaemic sera leads to NBT reduction early in the 
time course of the reaction with consequently less substrate 
available for the glycated protein bonds to reduce thereafter.
Throughout the study I found that on occasion GSA and 
fructosamine conveyed different information regarding glycaemic 
control, despite suggestions that the fructosamine reaction is 
predominantly due to activity of the ketoamine bonds of GSA.
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Schleicher et al(23) found that 50% of the fructosamine value was 
derived frcm the measurement of unknown substance unrelated to 
glycated total serum proteins, and this important limitation may 
have been neglected in earlier studies.
In practice I found that only GSA was sensitive enough to 
detect improvements in glycaemic control after 2 weeks. 
Furthermore the relative magnitude of fall in GSA was much 
greater than that observed for either Hh^ or fructosamine after 
4 or 6 weeks. It was of interest to find that the cross- 
sectional relationship between measures of glycaemia varied quite 
considerably throughout the study. This explains the high 
discordance rate between HhAj and fructosamine and direct 
measures of glycaemia in particular. Perhaps the most damning 
evidence that fructosamine does not reflect predominantly GSA was 
the observation that absolute discordance (i.e. a normal level of 
one variable with an abnormal value for the other) was observed 
in up to 15% of conparisons.
Finally the observation of persistently normal ¥SoA1 levels 
despite elevated levels of GSA, fructosamine and direct measures 
of glycaemia confirms that HhAx is a relatively insensitive 
marker of hyperglycaemia in seme individuals.
It would therefore seem that GSA is the most important 
measure of glycaemia in IDEM because of its sensitivity to both 
hyperglycaemic and hypoglycaemic states and that its use 
alongside HbAi is to be recommended in further longitudinal 
studies. The significance of the fructosamine assay clearly 
requires further investigation, particularly into its mechanism.
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CHAPTER 6
ASPECTS AND DETERMINANTS OF CONTROL AND COMPLICATIONS
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1:1. AUTONOMIC NEUROPATHY AND URINARY SODIUM AND ALBUMIN
EXCRETION
Subjects: Fran the 205 insulin-dependent diabetic patients (153 
trial patients and 52 controls), I identified 30 with definite 
cardiovascular autonomic neuropathy according to the criteria of 
Ewing and Clarke (694). All 30 patients had Valsalva ratios 
<1.10, immediate heart rate response to standing (30:15) ratio 
<1.00, and heart rate variations during deep breathing of <10 
beats/minute. Of these, 20 (12M:8F) were matched in order of 
importance for sex, weight, age and duration of diabetes (to 
within 5 years), glycaemic control (to within 1% of HBAX) and 
supine systolic blood pressure (to within 4 mrriHg), with the same 
number of diabetics with normal cardiovascular autonanic tone 
(Valsalva ratio >1.21; 30:15 ratio >1.04, and heart rate
variation during deep breathing >15 beats/minute). In addition 
9 of the 20 diabetic patients with autoncmic neuropathy had a 
postural fall in systolic blood pressure of more than 30 mrriHg 
when adopting an erect frcm a supine posture, and a further 6 had 
a reduced diastolic blood pressure response (less than 10 mrriHg) 
to handgrip dynamcmetry. Of the 20 subjects in each group, 17 had 
no detectable C-peptide resonse to a mixed meal. All patients in 
both groups showed negative Albustix tests for urinary protein 
and had normal serum urea and creatinine levels.
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Table 68
CLINICAL AND BIOCHEMICAL FEATURES OF INSULIN-TREATED DIABETICS
WITH OR WITHOUT AUTONOMIC NEUROPATHY.
20 insulin-treated 
diabetics with 
Autoncmic Neuropathy
20 insulin-treated 
diabetics without 
Autoncmic Neuropathy
SEX RATIO M:F
AGE (YEARS)
AGE AT ONSET (YEARS)
DURATION OF DIABETES 
(YEARS)
BODY WEIGHT (Kg)
RETINOPATHY (NUMBER)
PERIPHERAL NEUROPATHY 
(NUMBER)
ISCHAEMIC HEART 
DISEASE (NUMBER)
PERIPHERAL VASCULAR 
DISEASE (NUMBER)
FASTING BLOOD GLUCOSE 
(mmol/L)
MEAN BLOOD GLUCOSE 
(mmol/L)
M VALUE (UNITS)
URINARY GLUCOSE 
(mmol/24h)
12:8
48.8 (11.2)
33.3 (13.3)
15.6 (10.3)
66.9 (20.8) 
18 (B13,P5)
16
10
12.3 (5.6)
12.6 (3.6) 
119 (27-272)
12:8
48.6 (10.8)
31.9 (10.6)
16.8 (10.0)
68.1 (14.1)
13 (B10,P3) *
13
110 (0.1-280.2) 206 
HhAi (%) 9.3 (1.5)
Figures are as stated, mean (SD) or mean (range) 
* p = 0.05
4 *
9.9 (7.2)
12.2 (2.9)
117 (32-203)
1 (0.4-1020.0) 
9.0 (1.6)
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Table 69
POSTURAL DIFFERENCES IN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
IN INSULIN-TREATED DIABETICS WITH OR WITHOUT AUTONCMIC NEUROPATHY
20 insulin-treated 20 insulin-treated 
diabetics with diabetics without
Autoncmic Neuropathy Autoncmic Neuropathy
SUPINE 143 (18) 145 (24)
83 (10) 77 (10)
SEATED 130 (26) 139 (23)
82 (8) 76 (12)
MEAN (SUPINE AND 136 (24) 143 (23)
SEATED) 82 (10) 76 (10)
STANDING 128 (17) 138 (27)
79 (7) 74 (11)
Figures refer to SYSTOLIC MEAN (SD) BLOOD PRESSURE 
DIASTOLIC
* p<0.05
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Results: Glycaemic control was comparable in the two groups.
Diastolic blood pressure was suggestively higher in the patients 
with autoncmic neuropathy irrespective of posture. Supine 
systolic blood pressures were comparable according to the study 
design, but both seating and standing systolic blood pressure 
values were lower in patients with autoncmic neurpathy in whom 
the prevalence of peripheral vascular disease and diabetic 
retinopathy tended to be greater (both p = 0.05) (Tables 68 and 
69). The daytime urine volume was significantly higher in the 
group without autoncmic neuropathy (p = 0.01), whilst the night­
time volume was higher in the group with autoncmic neuropathy 
(p<0.01). There was no difference observed in the daytime sodium 
excretion rate, although nocturnal sodium excretion was 
significantly enhanced in those diabetics with autoncmic 
neuropathy (P<0.05). The albumin excretion rates tended to be 
higher in those with autoncmic neuropathy in the pooled 24 hour 
and daytime urine samples, and the difference in the overnight 
samples between the groups was significant (p<0.02), as was the 
nocturnal urinary albumin/creatinine ratio (p<0.02). The latter 
values confirmed that the urine collections in all cases were 
sufficiently accurate for analysis (Table 70).
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Table 70
RENAL FUNCTION IN INSULIN-TREATED DIABETICS WITH AND WITHOUT
AUTONCMIC NEUROPATHY
20 insulin-treated 20 insulin-treated 
diabetics with diabetics without
Autoncmic Neuropathy Autoncmic Neuropathy
SERUM UREA
(mmol/L) 6.0 (1.7) 4.9 (1.1)
SERUM CREATININE
(pmol/1) 82 (23) 79 (12)
CREATININE CLEARANCE
(ml/min/1.73 sq.m) 129 (37) 129 (31)
DAYTIME URINE VOLUME
(ml) 1545 (620-3200) . 2106 (895-3000) *
NIGHT-TIME URINE VOLUME
(ml) 830 (250-1550) 554 (160-1140) **
DAYTIME SODIUM
EXCRETION (pmol/min) 153 (29-361) 171 (51-308)
NIGHT-TIME SODIUM
EXCRETION (pmol/min) 229 (54-288) 96 (36-207) +
24 HR. ALBUMIN
EXCRETION RATE 18.1(1.0-56.7) 9.9(2.3-38.0)
(pg/min)
DAYTIME ALBUMIN
EXCRETION RATE 20.5 (0.9-85.2) 11.3 (2.7-46.1)
(pg/min)
NIGHT-TIME ALBUMIN
EXCRETION RATE 13.2 (1.1-41.3) 5.8 (0.7-20.2) ++
(pg/min)
DAYTIME ALBUMIN/
CREATININE RATIO 25 (3-107) 13 (3-39)
NIGHT-TIME ALBUMIN/
CREATININE RATIO 20 (3-86) 6 (1-25) ++
Figures are mean (SD) or mean (range)
+ p <0.05 ++ p<0.02 * p = 0.01 ** p<0.01
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1:2 RESIDUAL C-PEPTIDE SECRETION AND METABOLIC CONTROL
CROSS-SECTIONAL OBSERVATIONS
I was able to examine the relationship between residual C- 
peptide secretion and measures of glycaemia and lipid metabolism 
in all 205 insulin-treated diabetic patients (153 frcm the trial 
and the 52 controls). C-peptide was measured in response to a 
standard meal and patients classified as non-responders if levels 
were less than 0.02 pmol/ml, as low responders if levels were 
between 0.02 and 0.60 pmol/ml, and as high responders if levels 
were greater then 0.60 pmol/ml. In particular I investigated how 
important residual p cell function was in determining levels of 
HDL cholesterol and its subfractions, using analysis of variance 
and co-variance, controlling simultaneously for the effects of 
gender and C-peptide levels. Age, duration of diabetes, log 
transformed triglycerides, HhAl and daily insulin dosage were 
included as co-variants.
RESULTS: The characteristics of the study population groups 
according to C-peptide status are shown in Table 71. The group 
with a high C-peptide response tended to be older (p<0.06) and 
contained relatively fewer men (N/S). Correction was made for the 
effects of age and gender in the analyses.
Although the high C-peptide response group had a shorter 
duration of diabetes and received less insulin in comparison to 
the non-responders (p<0.001), glycaemic control did not differ 
appreciably between the groups. Likewise body mass index, renal 
function, frequency of exercise and patterns of alcohol and 
tobacco consumption were similar in all groups.
The lipid and lipiprotein results are presented in Table 72.
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Serum triglycerides tended to be higher in those patients with 
high C-peptide levels (p<0.1), and levels of apolipoprotein B and 
the mass ratio of LDL cholesterol to apolipoprotein B were 
suggestively lower in those with low C-peptide levels (p<0.07), 
but no significant differences were observed with regard to HDL 
cholesterol distribution, regardless of the method of isolation.
I further examined the role of C-peptide in explaining the 
variation in HDL cholesterol levels by univariate analysis but 
found no correlation between HDL and its subfractions and the C- 
peptide response, although significant correlations with serum 
triglycerides were recorded (Table 73). The individual 
contributions of various potential determinants of the HDLU c 
cholesterol concentration, including the C-peptide response, were 
also tested by analysis of variance (Table 74). As expected, 
HhAi levels had a weak inverse relationship with C-peptide, and 
were positively associated with triglyceride levels. HDL 
cholesterol levels and its subfractions correlated closely with 
one another, regardless of the means of isolation. However, 
whilst serum triglyceride levels were negatively correlated with 
HDL cholesterol and its subfractions to a greater or lesser 
extent,no such association was demonstrated between HDL and 
either HbAl or C-peptide.
Total serum HDL cholesterol was not explained by C-peptide 
levels, although gender exerted a significant effect, with higher 
HDL levels observed in women. The log triglyceride value also 
made a substantial contribution, leading to lower levels of HDL 
cholesterol. Likewise gender and triglyceride values were 
important determinants of the variation in HDL2 cholesterol
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levels, but persistant C-peptide secretion also exerted an 
effect, resulting in lower HDL2 cholesterol levels. On the other 
hand, no significant predictors of HDL3 cholesterol levels were 
found.
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Table 71
CLINICAL CHARACTERISTICS OF PATIENTS GROUPED ACCORDING TO
C-PEPTIDE STATUS
NO C-PEPTIDE LOW C-PEPTIDE HIGH C-PEPTIDE 
RESPONSE RESPONSE RESPONSE
(<0.02ptnol/ml) (0.02-0.60pmol/ml) (>0.60pmol/ml)
No. of subjects 118 63 24
C-peptide 0.000*** 0.150 0.870
(pmol/ml) (0.000-0.017) (0.020-0.570) (0.680-1.430)
Age (years) 41.2 (1.3) 39.3 (1.7) 47.3 (3.2)
Sex Ratio (M:F) 75:43(1.7:1) 42:21(2.0:1) 11:13(0.8:1)
BMI (Weight/
Height21 ) 24.2 (0.3) 23.9 (0.5) 24.6 (1.0)
Duration of
Diabetes (years) 18 (1) *** 9 (1) 6 (1)
Daily insulin dose
(units/day) 54 (1) *** 51 (3) 34 (2)
HhAl (%) 9.4 (0.2) 9.4 (0.2) 8.8 (0.4)
Fasting blood
glucose (mmol/1) 11.3 (1.0) 10.4 (0.7) 8.3 (0.6)
Serum Creatinine
(umol/1) 82 (4) 84 (3) 85 (4)
Alcohol intake
+(units/week) 3.5 (0-30) 3.7 (0-60) 4.0 (0-24)
Regular exercise
(%) 27 50 25
Figures are mean (SEM), median (range) or as stated
*** p<0.001
+ 1 unit = lOg ALCOHOL
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Table 72
LIPIDS AND LIPOPROTEINS IN PATIENTS GROUPED ACCORDING TO
C-PEPTIDE STATUS
NO C-PEPTIDE LOW C-PEPTIDE HIGH C-PEPTIDE 
RESPONSE RESPONSE RESPONSE
Total cholesterol 
(mmol/1) 5.76 (0.14) 5.73 (0.20) 5.59 (0.27)
Total triglycerides 
(mmol/1)
1.29
(0.36-4.34)
1.29
(0.39-23.29)
1.55
(0.49-5.40)
LDL cholesterol 
(mmol/1) 3.70 (0.13) 3.73 (0.19) 3.64 (0.24)
Apolipoprotein B 
(mg/dl) 110 (3) 99 (3) 111 (5)
LDL cholesterolt 
apolipoprotein B 1.35 (0.05) 1.52 (0.08) 1.35 (0.11)
HDLUC cholesterol 1.43 (0.03) 1.48 (0.05) 1.47 (0.07)
HDLpt cholesterol 1.38 (0.05) 1.37 (0.07) 1.36 (0.10)
HDL2uc cholesterol 0.70 (0.03) 0.75 (0.07) 0.68 (0.05)
HDL2pt cholesterol 0.70 (0.05) 0.73 (0.07) 0.65 (0.11)
HDL3uc cholesterol 0.73 (0.02) 0.73 (0.03) 0.78 (0.07)
HDLUC/LDL
cholesterol 0.44 (0.02) 0.47 (0.03) 0.46 (0.04)
HDLUC/total 
cholesterol 0.26 (0.01) 0.27 (0.01) 0.27 (0.01)
Figures are mean (SEM) or median (range)
+LDL cholesterol converted to mg/dl for calculation of 
ratio
HDLUC refers to ultracentrifugation
HDLpt refers to precipitation data.
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Table 74
POTENTIAL DETERMINANTS OF HDL CHOLESTEROL AND ITS SUBFRACTIONS 
USING ANALYSIS OF VARIANCE
(a) HDL CHOLESTEROL LEVELS 
MAIN EFFECTS F
C -F E P T ID E 2.398
GENDER 12.467
Significance of F 
0.094 
0 . 0 0 1  ***
CO-VARIATES 
DURATION OF DIABETES 
AGE
Log. TRIGLYCERIDE 
DAILY INSULIN DOSAGE 
HhAi
1.305
0.099
9.458
0.158
0.351
0.255 
0.754 
0.002 *** 
0.692 
0.555
(b) HDL2 CHOLESTEROL LEVELS 
MAIN EFFECTS F
C-PEPTIDE 3.511
GENDER 25.481
Significance of F 
0.032 *
0.001 ***
CO-VARIATES
DURATION OF DIABETES 2.799
AGE 0.016
Log. TRIGLYCERIDE 10.906
DAILY INSULIN DOSAGE 1.415
HbAi 0.000
(c) HDL3CHOLESTEROL LEVELS 
MAIN EFFECTS F
C-PEPTIDE 07937
GENDER 0.858
0.096 
0.900 
0.001 *** 
0.236 
0.996
Significance of F 
0.394 
0.356
CO-VARIATES 
DURATION OF DIABETES 
AGE
Log. TRIGLYCERIDES 
DAILY INSULIN DOSAGE 
HhAi
0.133
0.127
0.177
0.631
0.559
0.716
0.722
0.675
0.428
0.456
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1:3 RESIDUAL C-PEPTIDE SECRETION AND METABOLIC CONTROL
LONGITUDINAL OBSERVATIONS 
Following the observations on all 205 subjects at initiation 
to the study, I then proceeded to examine prospectively whether 
residual post-prandial C-peptide secretion modified metabolic 
control during the 1st year of the hone blood glucose monitoring 
study. The same criteria for non-responders and low and high C- 
peptide responders (<0.020, 0.020-0.600, >0.600 pmol/ml,
respectively) were used to classify the 147 subjects who reached 
the point of randomisation. All subjects had serum creatinine 
levels less than 140 pmol/1.
Results: The characteristics of the patients classified
according to the C-peptide response at entry to the study are 
shown in Table 75. 70 (48%) of patients had undetectable C-
peptide following a standardised mixed meal, 57 (38%) had a low 
C-peptide response, and 20 (14%) a high C-peptide response. The 
three groups were similar to one another with regard to body mass 
index, frequency of exercise and patterns of alcohol and tobacco 
consumption. The daily insulin dose and duration of diabetes was 
least in the group with a high C-peptide response (P<0.001), but 
although they tended to be older and the group composed of 
relatively fewer men, gender distribution or the age difference 
between the groups did not differ significantly. Daily insulin 
dosage remained significantly lower in the group with a high C- 
peptide response throughout the study (P<0.001).
Glycaemic Control. HhAi fell significantly from initial levels 
during the study in all 3 groups to a greater or lesser degree.
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However whilst levels in the C-peptide negative and low C-peptide 
responsive groups remained virtually identical, the high C- 
peptide responder group had persistently lower levels throughout 
the year following the 6 week period of intensified management 
(Figure 38).
GSA levels fell significantly during the study in the low or 
negative C-peptide responsive groups, but appeared more variable 
in the high C-peptide responsive group. GSA levels remained 
least in the high C-peptide responders, intermediate in the lew 
C-peptide responders and highest in the C-peptide negative group 
at all times during the study with the exception of 6 months when 
mean levels were identical in the low and negative C-peptide 
responders (Figure 39).
Fructosamine levels varied much more than the other measured 
glycated blood proteins. Levels only altered appreciably with 
time in the C-peptide negative group and were similar in the lew 
and high C-peptide responder at most time points. Fructosamine 
levels generally remained highest in the C-peptide negative group 
with the exception of the 3 month time point, and were 
significantly higher at baseline and after 2 and 4 weeks and 9 
and 12 months (Figure 40).
Fasting blood glucose levels were higher in the C-peptide 
negative group initially, falling with time, and mean blood 
glucose fell significantly with time in all groups. Thereafter 
mean blood glucose levels remained slightly higher in the C- 
peptide negative group with a significant difference observed at 
12 months (Figure 41).
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FIG. 38 Changes in HbAi during home blood glucose monitoring study 
according to C-peptide status.
Figures represent Mean ± SEM
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FIG. 39 Changes in GSA during home blood glucose monitoring study accord­
ing to C-peptide status.
Figures represent Mean ± SEM
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FIG. 40 Changes in fructosamine during home blood glucose monitoring 
study according to C-peptide status.
Figures represent Mean ± SEM
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FIG. 41 Changes in fasting and mean blood glucose levels during home blood 
glucose monitoring study according to C-peptide status.
Figures represent Mean ± SEM
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Lipids and Lipoproteins. There were no differences in levels of 
triglycerides and total LDL and HDL cholesterol, in addition to 
the HDL2 and HDL3 cholesterol subfractions or apolipoprotein B 
between the groups at any point during the study (Figure 42, 
Table 76). However, the levels of HDL2 and HDL3 cholesterol 
fractions did change appreciably during the year within the 
groups (Table 76).
Table 75
INITIAL CLINICAL CHARACTERISTICS OF 147 PATIENTS WITH INSULIN-
INDEPENDENT DIABETES CLASSIFIED ACCORDING TO C-PEPTIDE RESPONSE
TO A MIXED MEAL
C-PEPTIDE LOW C-PEPTIDE HIGH C-PEPTIDE
NEGATIVE RESPONDERS RESPONDERS
(<0.020pmol/ml) (0.020-0.600pmol/ml) (>0.600pmol/ml)
No. of sujects 70 57 20
Sex Ratio (M:F) 45:25 40:17 10:10
(1.8:1.0) (2.0:1.0) (1.0:1.0)
Age (years) 40 (2) 40 (2) 47 (4)
EMI (Weight/
Height2 ) 23.6 (0.3) 23.5 (0.5) 23.9 (1.0)
Duration of
Diabetes (years) 18 (1)*** 9 (1) 6 (1)
Daily insulin dose
(units/day) 57 (2) 49 (3) 32 (2) ***
Alcohol intake
(units/week) 3.5 (0-30) 3.7 (0-60) 4.0 (0-24)
Smokers (%) 49 44 42
Regular exercise 43 54 25
*** p<0.001
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TOTAL CHOLESTEROL
Cholesterol
(mmol/L)
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FIG. 42 Changes in plasma total, HDL and LDL cholesterol levels during 
home blood glucose monitoring study according to C-peptide status.
Figures represent Mean ± SEM
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Table 76
LIPID M D  LIPOPROTEIN LEVELS OVER THE COURSE OF STUDY IN PATIENTS
WITH IDEM CLASSIFIED ACCORDING TO THE C-PEPTIDE RESPONSE TO A
MIXED MEAL
C-PEPTIDE LOW C-PEPTIDE HIGH C-PEPTIDE
NEGATIVE RESPONDERS RESPONDERS
(<0.02pmol/ml) (0.02-0.60pmol/ml)
? i—iI4oA
TRIGLYCERIDES
(mmol/1)
BASELINE 1.24 1.21 1.55
(0.36-4.24) (0.39-23.29) (0.49-4.40)
6 WEEKS INTENSIFIED 1.09 1.10 1.25
MANAGEMENT (0.24-2.94) (0.34-19.34) (0.29-3.24)
6 MONTHS 1.12 1.04 1.63
(0.19-3.14) (0.24-58.90) (0.29-3.74)
1 YEAR 1.09 1.19 1.24
(0.39-8.90) (0.29-11.89) (0.44-3.69)
APOLIPOPROTEIN B
(mg/dl)
BASELINE 102 (3) 97 (3) 110 (5)
6 WEEKS INTENSIFIED
MANAGEMENT 100 (3) 99 (3) 109 (5)
6 MONTHS 102 (3) 103 (4) 107 (5)
1 YEAR 104 (3) 103 (4) 102 (5)
HDLo CHOLESTEROL
(mmol/1)
BASELINE 0.73 (0.03) 0.76 (0.05) 0.64 (0.06)*
6 WEEKS
INTENSIFIED 0.73 (0.04) 0.76 (0.05) 0.85 (0.09)
MANAGEMENT
6 MONTHS 0.70 (0.04) 0.76 (0.05) 0.60 (0.06)
1  YEAR 0.73 (0.04) 0.67 (0.04) 0.76 (0.08)
HDL, CHOLESTEROL
(mmol/1)
BASELINE 0.72 (0.03)** 0.71 (0.03)** 0.79 (0.06)*
6 WEEKS
INTENSIFIED 0.65 (0.03) 0.63 (0.03) 0.63 (0.07)
MANAGEMENT
6 MONTHS 0.69 (0.03) 0.65 (0.05) 0.69 (0.03)
1  YEAR 0.73 (0.03) 0.75 (0.03) 0.69 (0.04)
*p<0.05 **p<0.01 Within group differences.
Figures are mean (SEM) or median (range).
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1:4 RESIDUAL C-PEPTIDE SECRETION IN LONGSTANDING .IDEM AND
COMPLICATIONS
I examined whether or not residual C-peptide secretion had 
any bearing on the prevalence and evolution of complications in 
IDEM. Because diabetic complications rarely present themselves 
early in the course of the disease, only subjects whose duration 
of diabetes exceeded 6 years were eligible for comparison. 
Furthermore, because of this factor and suggestions that the 
absolute age of the patient might be relevant, I selected 2 
groups of patients with and without C-peptide secretion who were 
matched in order of importance for age and duration of diabetes 
(to within 5 years in all cases), and body mass index (to within 
1 unit in all cases).
Of the 147 subjects randomised to take part in the 2 year 
study, 70 (48%) had no detectable C-peptide reponse to a mixed 
meal, of whom 31 (23 men) were suitably matched with 31 (20 men) 
with residual p cell function.
RESULTS: The clinical characteristics of the 31 subjects in
each group are shown in Table 77. The median stimulated C- 
peptide level in the C-peptide secretor group was 0.090 pmol/ml, 
of whom 20 had levels less than or equal to 0.200 pmol/ml. In 
addition to age, duration of diabetes and body mass index, the 
two groups did not differ with respect to daily insulin dosage or 
insulin species, patterns of tobacco or alcohol consumption, 
number of patients previously treated with oral hypoglycaemics or 
who had experienced diabetic ketoacidosis, or insulin antibody
158
titres. Furthermore patterns of urinary albumin and total 
protein excretion were similar, although serum creatinine levels 
were greater in the C-peptide secretory group (p<0.05) (Tables 77 
and 78).
Glycaemic Control and C-peptide Secretion. Following trial 
entry, an appreciable and sustained improvement in Hh^ and mean 
blood glucose was observed in both groups (p<0.01), with less 
impressive reductions in GSA. and fructosamine. HhA-L, 
fructosamine, GSA and to a lesser extent mean blood glucose 
values, generally remained higher in the C-peptide negative group 
throughout the year and the difference in GSA levels was 
significant at 3 and 6 months (p<0.05) (Figures 43 and 44).
No significant difference in insulin dose, insulin antibody 
titre or body mass index was apparent after 1 year (Table 79). 
However 2 individuals who were initially categorised as C-peptide 
negative (<0.020 pmol/ml) had detectable C-peptide levels (0.028 
and 0.038 pmol/ml) after 1 year. In contrast 7 individuals who 
secreted C-peptide initially had no detectable C-peptide response 
to a mixed meal after 1 year. The C-peptide level fell slightly 
overall frcm a median level of 0.090 to 0.068 pmol/ml. Of the 7 
subjects with residual C-peptide secretion initially but not 
after 1 year, 5 initially had levels less than 0.060 pmol/ml, 
whilst the levels of trial entry of the remaining two were 0.100 
and 0.360 pmol/ml. Glycaemic control in these 7 patients was 
persistently worse than the C-peptide secretor group as a whole, 
with mean levels of HbAj, GSA and fructosamine greater than the 
mean value plus 2 standard errors for all these parameters for
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the complete C-peptide responsive group throughout the year.
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FIG. 43 Glycaemic control over 1 year assessed by HbAj and GSA in 31 
insulin dependent diabetics with or without detectable C-peptide 
secretion at entry to the study.
Figures represent Mean ± SEM
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FIG. 44 Glycaemic control over 1 year assessed by fructosamine and monthly 
mean blood glucose values in 31 insulin dependent diabetics with 
or without detectable C-peptide secretion at entry to the study.
Figures represent Mean ± SEM
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Table 77
CHARACTERISTICS OF TWO GROUPS OF INSULIN-DEPENDENT DIABETIC 
PATIENTS WITH AND WITHOUT CIRCULATING C-PEPTIDE MATCHED FOR AGE, 
DURATION OF DIABETES AND BODY MASS INDEX AT ENTRY TO THE STUDY
C-PEPTIDE NEGATIVE C-PEPTIDE SECRETOR 
GROUP GROUP
Number (men)
C-peptide levels 
(pmol/ml)
Age (years)
Duration of 
Diabetes (years)
BMI (Weight/ 
Height2)
Daily insulin 
dosage (units)
Type of insulin 
(number) x
Previous diabetic 
Ketoacidosis (No.)
Previous oral 
hypoglycaemic 
therapy (No.)
Smokers (number)
Alcohol
(units/week)
Insulin Antibodies 
(binding units) 
BOVINE 
HUMAN
Serum creatinine 
(pmol/1)
31 (23)
0.000
(0-0.015)
41.7 (2.5) 
(18-64)
15.0 (1.4)
(6-32)
23.6 (0.6)
58 (3)
16B 15H
23
11
10
3 (0-30)
20.0 (5.2-104.0)
18.8 (4.4-97.0)
79 (3)
31 (20)
0.090
(0.020-1.200)
42.8 (2.5) 
(16-62)
15.4 (1.5)
(6-33)
24.0 (0.5)
53 (3)
17B 14H
18
11 
12 
6 (0-60)
16.5 (6.4-240.0)
17.0 (4.4-206.0)
87 (3)*
* p<0.05Figures are mean (SEM), median (range) 
x B = Beef H = Human
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Table 78
PREVALENCE OF SPECIFIC COMPLICATIONS AND RELATED BIOCHEMISTRY AT 
TRIAL ENTRY AND AFTER 1 YEAR IN TWO GROUPS OF INSULIN-DEPENDENT 
DIABETIC PATIENTS WITH AND WITHOUT CIRCULATING C-PEPTIDE AT
TRIAL ENTRY
C-PEPTIDE NEGATIVE C-PEPTIDE SECRETOR
GROUP GROUP
TRIAL ENTRY AFTER 1 YR. TRIAL ENTRY AFTER 1 YR.
No. of subjects 31 27 31 27
Retinopathy
(number) 10B IIP 8B 10P 18B 5P 10B 10P
Peripheral
neuropathy score 12.5 (0.7) 12.3 (0.7) 12.2 (0.5) 12.0 (0.7)
Autoncmic
neuropathy score 2.6 (0.4) 2.2 (0.5) 2.5 (0.5) 2.9 (0.4)
Albumin excretion 7.2 9.1 6.6 5.6
rate (pg/minute) (2.4-536.1) (1.4-1193.3) (0.3-229.9)(1.1-187.3)
Urinary protein 0.05 0.20 0.05 0.10
excretion (0.05-1.00) (0.05-2.00) (0.05-1.00)(0.50-1.90)
Microalbuminuria
(number) 6 6 5 3
Overt nephropathy
(number) 4 3 2 1
Serum creatinine
(pmol/1) 79 (3) 84 (3) 87 (3)* 87 (3)
Hypertension
(number) 6 7 5 5
Ischaemic heart
disease (number) 3 2 3 3
Peripheral vascular
disease (number) 1 1 6* 5
Figures are mean (SEM)f median (range)
* p< 0.05 between groups
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Glycaemic control was particularly poor for the two patients with 
initially high C-peptide levels (0.100 and 0.360 pmol/ml) and 
their mean GSA levels during the year averaged 10.0% and 13.6% 
respectively. Consequently, those subjects with persistant C- 
peptide secretion after 1 year achieved significantly better 
glycaemic control in comparison to the C-peptide negative group 
(data not shown).
Table 79
C-PEPTIDE LEVELS, BODY MASS INDEX, INSULIN DOSE, AND INSULIN 
ANTIBODY TITRES AFTER 1 YEAR IN 27 SUBJECTS WITH OR WITHOUT <> 
PEPTIDE SECRETION AT TRIAL ENTRY
C-PEPTIDE NEGATIVE C-PEPTIDE SECRETOR
GROUP
0.068 (0-1.190)
7
24.8(0.5)
55 (4)
17.3 (4.4-132.0)
15.5 (4.2-116.0)
Figures are Mean (SEM), Median (range).
GROUP
C-peptide
(pmol/ml) 0.000 (0-0.038)
Change in C-peptide 
status (number) 2
BMI (Weight/
Height2) 24.4(0.6)
Daily Insulin Dose
(units) 57 (3)
Insulin Antibody 
(binding units)
BOVINE 15.1 (3.1-200.0)
HUMAN 16.8 (2.8-86.0)
Canplications. The prevalence of canplications and related 
biochemistry in the two groups at trial entry and after 1 year is 
shown in Table 78.
Peripheral vascular disease and background retinopathy were 
more frequently detected in the C-peptide secretor group, whilst 
proliferative retinopathy was more prevalent in the C-peptide 
negative group (p<0.05) at entry to the trial. There was no 
difference in the prevalence of hypertension, nephropathy, 
microalbuminuria or ischaemic heart disease, nor in the 
peripheral or autoncmic neuropathy scores.
27 subjects fran each group completed the 1st year of the 
study. In the group with a detectable C-peptide response 
initially, one subject with peripheral vascular disease, 
nephropathy, hypertension, autoncmic neuropathy and background 
retinopathy underwent a below knee amputation and was withdrawn 
frcm the trial. Of the remaining three who all defaulted frcm 
follow up, one had definite peripheral neuropathy and 
proliferative retinopathy but 2 were free of complications.
In the group without C-peptide secretion one individual 
with hypertension, ischaemic heart disease, nephropathy, 
autoncmic neuropathy and proliferative retinopathy died following 
a myocardial infarction. One further drop out frcm this group 
had peripheral and autoncmic neuropathy and background 
retinopathy and the other two were free of canplications. 
Consequently whilst the prevalence of peripheral vascular disease 
after 1 year remained greater in the group with persistant C- 
peptide secretion, the difference was no longer significant.
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In addition, because of the progression of retinopathy, the 
prevalence of all other canplications (including retinopathy) was 
similar in both groups after 1 year, and peripheral and autoncmic 
neuropathy scores and urinary albumin and protein excretion was 
similar in both groups.
I also categorised subjects initially and after 1 year, on 
the basis of whether they had any significant microvascular 
disease (microalbuminuria, overt nephropathy or proliferative 
retinopathy), but the prevalence in the groups remained similar 
on both occasions. Furthermore when other individuals who only 
had autoncmic neuropathy and/or peripheral neuropathy and/or 
macrovascular disease were included in the comparison the 
prevalence of any complication in the 2 groups remained 
remarkably similar (Table 80).
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Table 80
PREVALENCE OF ANY MICROVASCULAR { + NEUROPATHIC) (+MACROVASCULAR) 
COMPLICATIONS AT TRIAL ENTRY AND AFTER 1 YEAR IN TWO GROUPS OF
PATIENTS WITH IDEM WITH AND WITHOUT CIRCULATING C-PEPTIDE AT
TRIAL ENTRY
TRIAL ENTRY AFTER 1 YEAR
C-PEPTIDE C-PEPTIDE C-PEPTIDE C-PEPTIDE
NEG. GROUP SEC. GROUP NEG. GROUP SEC. GROUP
MICROVASCULAR
COMPLICATIONS 14 13 13 12
(microalbuminuria
(and/or persistant
(proteinuria and/or
(proliferative
(retinopathy
MICROVASCULAR 
COMPLICATIONS AND
NEUROPATHY 26 22 19 20
(peripheral and/or
(autoncmic
MICROVASCULAR, 26 23 19 21
MACROVASCULAR AND
NEUROPATHIC
COMPLICATIONS
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1:5 INSULIN SPECIES, ANTIBODIES, CONTROL AND COMPLICATIONS
The effect of insulin species on metabolic control and 
canplications was investigated at entry to the study and during 
the 1st year.
Of the 147 who were initially randonised to blood or 
urine testing, 81 patients were receiving treatment with bovine 
insulin, 58 with porcine and 8 with biosynthetic human insulin 
at entry to the study. 21 patients remained on porcine insulin 
and 20 on bovine insulin because glycaemic control was judged to 
the satisfactory on their regime at that time. The remaining 106 
patients were randonised to either beef or human insulin the day 
following admission to the study. 56 individuals (previously on 
beef (33), porcine (22) or human (1) insulin) were randonised to 
beef insulin whilst the remaining 50 (previously on beef (29), 
porcine (14) or human (7) insulin) were randonised to 
biosynthetic human insulin. I thereafter compared the effects of 
different insulin species on progress during the 1st year of the 
study. Of 76 subjects on beef insulin, 36 were randomised to 
blood testing, whilst 40 carried out urine testing, and overall 
61 completed the study. 24 patients treated with human insulin 
carried out blood testing and 26 urine testing, and 46 completed 
the 1st year. Of those 21 treated with porcine insulin 8 and 13 
were randomised to blood and urine testing respectively, and 17 
completed the study.
RESULTS:
GLYCAEMIC CONTROL: Glycaemic control assessed by all variables 
improved appreciably during the initial phase of the study in
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comparison to data at trial entry in patients on bovine or human 
insulin. Glycaemic control tended to be better at trial entry in 
the group treated by porcine insulin, so that changes with time 
in the porcine insulin treated group were less marked. No 
significant differences in glycaemic control were recorded 
between the groups at any time point, when assessed by HhAx 
(Table 81), nor by fructosamine or direct measures of glycaemia 
(data not shown), although Hh^ levels were a little higher in 
the bovine insulin treated group and lower in the porcine 
group,particularly after three months. GSA levels were a little 
more variable, although they tended to be high in the bovine 
insulin group, and this difference was significant (p<0.05) after 
3 months (Table 81).
LIPIDS AND LIPOPROTEINS: Lipid and lipoprotein levels improved 
overall in the bovine and human insulin treated groups in 
particular, in comparison to baseline levels. Overall there was 
no difference between any of the lipid and lipoprotein parameters 
at any time point between the bovine, porcine or biosynthetic 
human insulin treated groups (Table 82, Figure 45). HDL 
cholesterol levels fell after trial entry and remained lower in 
the porcine insulin treated group during the study (p<0.05, 
Figure 45).
INSULIN ANTIBODIES j_ A degree of cross-reactivity was observed 
between human and bovine insulin antibodies and corresponding 
types of insulin treatment. Both human and bovine insulin 
antibody titres rose during the year in the group who received 
bovine insulin (p<0.01), whilst in the group treated with human
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insulin, a fall was observed in the insulin antibody titres to
bovine (p<0.05) and to a lesser extent, to human insulin. As
expected, the human and bovine antibody titres remained unchanged 
in the group treated continuously with porcine insulin. (Table 
83). Consequently insulin antibody titres to both human and
bovine insulin were significantly elevated after 6 weeks, 6
months and 1 year in the patients treated with the more antigenic 
bovine insulin (p<0.01 to 0.001) (Table 83).
COMPLICATIONS Despite greater insulin antibody titres and 
suggestively poorer glycaemic control, the prevalence of 
microvascular, macrovascular and neuropathic canplications was 
similar irrespective of the type of insulin species both an entry 
to the trial, and after 1 year.
1:6 DISCUSSION
In trying to separate difference features of IDDM, the 
data presented in this chapter show that both metabolic control 
and complications in IDDM may be modified by specific influences 
particular for one individual or group of individuals. In 
section 1:1 I was able to demonstrate that one complication of 
IDEM (autoncmic neuropathy) may have a bearing on the progress of 
another (nephropathy). In chapter 4, section 1:2, I described 
that diabetic microvascular and macrovascular disease may be 
linked with an increased prevalence of large vessel disease 
accompanying early diabetic nephropathy. Whilst factors 
initiating the development of complications may remain unclear, a
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Table 81
GLYCAEMIC CONTROL ASSESSED BY HhAi (%) AND GSA j%) ACCORDING TO
TYPE OF INSULIN SPECIES
TYPE OF INSULIN SPECIES 
BOVINE BIOSYNTHETIC PORCINE
HUMAN
No. of patients 
At trial entry 76 50 21
following
randomisation
After 1 year 61 46 17
HhA! (%) 
Trial entry 9.4 (0.2)*** 9.4 (0.2)*** 8.9 (0.6)
Randomisation to 
blood or urine 8.2 (0.1) 8.1 (0.2) 8.2 (0.6)
testing 
3 months 8.2 (0.2) 7.7 (0.2) 7.8 (0.4)
6 months 8.3 (0.2) 8.2 (0.2) 7.7 (0.4)
9 months 8.3 (0.2) 8.1 (0.3) 8.2 (0.5)
1 year 8.4 (0.2) 8.0 (0.2) 8.1 (0.4)
GSA (%) 
Trial entry 10.4 (0.5)*** 10.9 (0.6)*** 7.6 (0.8)***
Randomisation to 
blood or urine 8.2 (0.4) 8.3 (0.5) 7.3 (1.0)
testing 
3 months 9.8 (0.5)* 7.9 (0.5) 7.7 (0.8)
6 months 8.8 (0.5) 8.3 (0.6) 9.0 (1.1)
9 months 9.1 (0.5) 8.9 (0.6) 8.0 (0.8)
1 year 8.7 (0.5) 8.2 (0.5) 8.2 (1.0)
Figures are mean (SEM)
* p<0.05 between groups 
***p< 0.001 within groups
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Table 82
CHANGES IN SERUM TRIGLYCERIDES, HDL CHOLESTEROL SUBFRACTIONS AND 
APOLIPOPRQTEIN B DURING THE HOME BLOOD GLUCOSE MONITORING STUDY 
IN PATIENTS TREATED WITH BOVINE, PORCINE OR HUMAN INSULIN
TYPE
BOVINE
OF INSULIN SPECIES 
BIOSYNTHETIC HUMAN PORCINE
TRIGLYCERIDES
(mmol/1)
Trial entry *1.29 1.39 0.98
(0.57-8.15) (0.39-3.84) (0.57-23.29)
Randomisation to
blood or urine 1.09 1.29 0.98
testing (0.34-4.70) (0.24-9.38) (0.59-19.39)
6 months 1.24 1.09 1.03
(0.29-6.44) (0.19-4.94) (0.29-58.90)
1 year 1.19 1.11 1.09
(0.29-8.90) (0.44-5.89) (0.59-11.89)
hdl2 CHOLESTEROL
(mmol/1)
Trial entry 0.70 (0.04) 0.75 (0.04) 0.76 (0.07)
Randomisation to
blood or urine 0.73 (0.04) 0.78 (0.06) 0.74 (0.10)
testing
6 months 0.71 (0.04) 0.72 (0.05) 0.75 (0.08)
1 year 0.67 (0.04) 0.75 (0.05) 0.75 (0.08)
hdl3 CHOLESTEROL
(mmol/1)
Trial entry ** 0.70 (0.03) * 0.72 (0.03) 0.74 (0.07)
Randomisation to
blood or urine 0.63 (0.03) 0.66 (0.04) 0.66 (0.09)
testing
6 months 0.69 (0.02) 0.66 (0.03) 0.63 (0.06)
1 year 0.75 (0.03) 0.76 (0.04) 0.67 (0.06)
APOLIPOPRQTEIN B
(mg/dl)
Trial entry 101 (3) 102 (4) 98 (5)
Randomisation to
blood or urine 99 (3) 102 (3) 98 (6)
testing
6 months 100 (3) 107 (4) 101 (5)
1 year 105 (3) 99 (3) 103 (7)
Figures are median (range, mean (SEM)
* p< 0.05 ** p< 0.01 within groups
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TOTAL CHOLESTEROL
6.0-
5.5-
5 .0 -
4.5-
mmol/L
4.0-
3 .5 -
3 .0-
2 .5 -
2.0-
1.5- 
1.0-
LDL CHOLESTEROL
HDL CHOLESTEROL 
*
O Bovine
•  Porcine 
□  Human
*  p <  0.05 Within Group
Trial Randomisation 6 Months 
Entry to Blood or 
Urine Testing
1 Year
FIG. 45 Total plasma, HDL and LDL cholesterol levels during the home 
blood glucose monitoring study according to the type of insulin 
species.
Figures represent Mean ± SEM
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Table 83
HUMAN AND BOVINE INSULIN ANTIBODY TITRES DURING THE YEAR IN 
PATIENTS TREATED WITH BOVINE, PORCINE OR BIOSYNTHETIC HUMAN
INSULIN
TYPE OF INSULIN SPECIES 
BOVINE BIOSYNTHETIC HUMAN PORCINE
BOVINE INSULIN 
ANTIBODY TITRE 
(BINDING UNITS)
Trial entry *** 17.8 *17.0 13.8
(3.1-224.0) (3.6-224.0) (4.9-64.0)
Point of
randomisation to
blood or urine 25.0 12.5 14.1
testing (6.0-292.0)*** (3.9-220.0) (4.9-51.0)
6 months 23.0 12.5 14.8
(6.4-196.0)*** (3.6-216.0) (4.1-52.0)
1 year 22.5 11.5 14.6
(3.1-200.0)** (3.1-116.0) (6.2-46.0)
HUMAN INSULIN 
ANTIBODY TITRE 
(BINDING UNITS)
Trial entry ***15.5 17.2 13.5
(2.7-206.0) (2.5-256.0) (3.0-62.0)
Point of
randomisation to
blood or urine 25.0 13.5 16.3
testing (4.2-232.0)** (2.5-228.0) (2.6-51.0)
6 months 21.5 14.3 11.3
(4.9-96.0)** (2.5-268.0) (3.9-52.0)
1 year 20.3 13.1 15.0
(2.8-116.0)* (2.5-132.0) (7.4-43.0)
Figures are median (range)
Differences within groups * p<0.05 *** p<0.001
Differences between groups * p<0.05 ** p<0.01 *** p<0.001
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'cascade of canplications1 may operate once particular features 
(i.e. autoncmic neuropathy, hypertension, nephropathy) have 
become established.
The finding of an increased AER in association with 
autoncmic neuropathy, particularly at night (section 1:1), was 
novel. However it provides one further potential explanation, 
along with metabolic control and hypertension, why only 50% of 
patients with IDEM develop nephropathy (360). The likeliest 
mechanism for this phenomenon would be via the effects of the 
autoncmic nervous system on renal haemodynamics. Renal 
hyperfiltration is associated with increased AER (650), and may 
be the consequence of the reduced splanchnic vascular resistance 
demonstrated in autonomic neuropathy (660). The hyperfiltration 
hypothesis (623) for the development of diabetic nephropathy may 
therefore be subject to modification by altered sympathetic 
vascular tone. Sympathetic renal tubular denervation may provide 
a further explanation for enhanced urinary protein as well as 
urinary sodium excretion. The observation that renal handling of 
protein and sodium was more disturbed in diabetic autoncmic 
neuropathy partly reflects the importance of posture in renal 
function. Renal blood flow normally increases in healthy 
subjects whilst supine (740); therefore pre-existing derangements 
of renal haemodynamics in diabetic nephropathy might be subject 
to further modification at night, as has been observed previously 
in non-diabetic autoncmic neuropathy (363). This may in turn 
explain the increased nocturia, natriuresis and AER.
Autoncmic neuropathy has also been associated with 
reduced plasma renin activity (FRA) in diabetes (741,742),
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although associated juxtaglomerular sclerosis is more likely to 
be implicated in the cause (742) than autoncmic neuropathy, as 
infusions of noradrenaline had little effect of PRA in such 
patients (742). Finally, vasopressin levels may sometime fail to 
repond to postural stimuli in autoncmic neuropathy, contributing 
to natriuresis and early polyuria on waking (741). Whatever the 
precise pathophysiology, these abnormalities together will 
certainly contribute to the exaggerated early morning orthostatic 
hypotension of diabetic autoncmic neuropathy (742).
In sections 1:2-1:4, I examined the metabolic and 
clinical consequences of persistent C-peptide (i.e. endogenous 
insulin) secretion.
The overall comparison frcm the cross-sectional and the 
longitudinal studies was that residual p cell function does 
beneficially influence glycaemic control in IDEM. However it is 
clear that this effect is of relatively minor importance, since 
cross-sectional comparisons often failed to show significant 
differences in glycaemic control, and it was often GSA levels 
rather than the less sensitive glycaemic index or H h ^ , that were 
different amongst patients with residual C-peptide secretion. In 
chapter 5, I found that GSA was a more sensitive index of 
glycaemic instability than HbAx, and it would appear that the 
measurement of this more sensitive index may be necessary for 
future investigations of the role of C-peptide and other 
potential determinants of glycaemic control. It was also clear 
frcm the longitudinal study that the influence of a residual C- 
peptide reserve on glycaemic control is not an 'all or none' 
phenomenon. Whilst HhAx levels only appeared lower in the high
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C-peptide group, a graded reduction in GSA levels was apparent in 
the negative, low and high C-peptide responder groups at 
virtually all time points.
In contrast to the effect on glycaemic control, 
persistant C-peptide secretion seems to bring little influence to 
bear on lipid and lipoprotein levels in IDEM. In the cross- 
sectional study, I found that serum triglycerides and differences 
in gender were the most important determinants of HDL cholesterol 
in IDDM, whilst C-peptide exerted a minor effect on HDL2 
cholesterol, and no significant predictions of HDL3 cholesterol 
were found. No difference in any lipid or lipoprotein 
estimations were found between the negative low or high C-peptide 
groups. These findings are in contrast to the only other large 
study to examine the role of C-peptide on lipoproteins in IDDM 
(293), where an independent inverse relationship between HDL and 
HDL2 cholesterol and C-peptide was observed. However that study 
by Laakso et al (293) concentrated on middle-aged insulin treated 
diabetics, and the group with the higher C-peptide levels were 
markedly hypertriglyceridaemic, and were characterised by poorer 
glycaemic control, obesity and a higher daily insulin dose, in 
contrast to the C-peptide responders in my investigation. 
Despite the use of multivariate analysis to correct for these 
compounding factors, the high C-peptide group studied by Laakso 
et al (293), were in effect a group of non-insulin dependent 
diabetics treated with insulin. On that assessment their lower 
HDL and HDL2 cholesterol levels would have been anticipated on 
the basis of numerous reports (262,743-748), and would not 
necessarily be the consequence of higher C-peptide levels. I
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also found no relationship between Hh^ and HDL levels in IDEM, 
and my overriding impression is that HDL levels in IDEM are 
modified predominantly by the ambient hypertriglyceridaemia, 
alcohol and tobacco consumption, and exercise, rather than by 
residual C-peptide secretion or glycaemic control, unless there 
is profound insulin deficiency, when HDL levels will fall. The 
cause of the relatively high HDL cholesterol levels in IDEM 
remains unclear, and apparently unrelated to an alteration in the 
portal supply of insulin to the liver. Furthermore residual C- 
peptide secretion bore no influence on lipid and lipoprotein 
levels during the prospective phase of the study, so as with 
glycaemic control, it would appear that other factors which 
influence lipids and lipoproteins in IDDM (e.g. diet, insulin 
supply, apoprotein polymorphism and renal disease) are more 
relevant than residual p-cell function. Despite relatively minor 
changes in glycaemic control and no alteration in lipids and 
lipoproteins, a consistently reduced daily insulin dosage was 
achieved in the high C-peptide group during the longitudinal 
analysis of all 147 patients. In addition to helping minimise 
weight gain, the effect of reduced peripheral hyperinsulinaemia 
on the vasculature may be a futher potential advantage. It 
should be noted in the study of longer standing IDDM (1:4), that 
the daily insulin dosage was no different between those patients 
with and without C-peptide secretion, so that any differences in 
peripheral hyperinsulinaemia would if anything be reversed, with 
higher levels in those with circulating C-peptide. In this study 
I also found that glycaemic control tended to be better in 
patients with C-peptide secretion, particularly when assessed by
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GSA. With regard to the prevalence and evolution of 
complications, I found that the prevalence of proliferative 
retinopathy was greater, and that of background retinopathy less, 
in those without detectable circulating C-peptide at inception to 
the study, in support of the study by Sjoberg et al (557). 
However the incidence of retinopathy development was such that 
the prevalence of background and proliferative retinopathy was 
virtually identical in the two groups after 1 year. This would 
suggest that time (i.e. duration of disease) is a more important 
factor for the progression of retinopathy than persistant C- 
peptide secretion and metabolic control. This fact also helps 
make the point that whilst persistant circulating C-peptide may 
lead to marginal improvements in glycaemic control, this effect 
is not sufficient to have any impact on the natural history of 
diabetic microvascular disease, particularly since renal function 
was also virtually identical after 1 year in both groups. I also 
found that residual p cell function had no bearing on the 
prevalence or incidence of diabetic neuropathy. This is in 
keeping with the observations of Sjoberg et al (554) and again 
suggests that a threshold effect for improvement in neuropathy is 
not attained simply by the minor effect of residual C-peptide on 
glycaemic control.
The number of patients with ischaemic heart disease and/or 
hypertension remained comparable in long standing IDDM with and 
without circulating C-peptide, but an increased prevalence of 
peripheral vascular disease was a feature of the group with C- 
peptide secretion, an observation also shown recently by Ronnemaa 
et al (749). Ronnemaa et al (749) studied mainly non-insulin
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dependent diabetic patients treated with insulin and found the 
highest prevalence of large vessel disease amongst wcmen, who 
formed a minority of the patients in my study. Despite these 
differences, one noteworthy point is that the daily insulin dose 
was similar in both studies in patients with and without C- 
peptide secretion, so relative hyperinsulinaemia and/or insulin 
resistance was probably a feature of those patients with 
detectable C-peptide. Although it remains uncertain whether 
hyperinsulinaemia per se or insulin resistance is more important, 
there is circumstantial evidence from clinical (16, 750, 751) 
and in vitro (752) studies that insulin may be important for the 
development of atherosclerosis in insulin-resistant states.
The prevalence of peripheral vascular disease was only 
significantly greater at entry to the study, but it should be 
pointed out that were it not for the withdrawal of 1 subject from 
the study following limb amputation, the prevalence of peripheral 
vascular disease after 1 year in the C-peptide responsive group 
would have remained greater.
Like most (555, 643, 753-755), although not all (756, 757) 
previous reports, I found no relationship between insulin 
antibodies and either the presence or absence of persistant C- 
peptide secretion or the loss of B-cell function over 2 years. 
In addition I could not confirm previous observations of an 
association between high insulin antibody titres and 
microvascular complications (372, 373, 617), and found that
insulin antibodies had no inpact on lipid and lipoprotein levels 
during the study, although glycaemic control was suggestively 
poorer in the group treated with bovine insulin, who had the
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highest antibody titres. It would appear in practice, that 
insulin antibodies make little difference to either metabolic 
control or the development of complications.
Finally the observation of attenuation of the C-peptide 
response with time merits discussion. 8 patients lost the 
capacity to produce C-peptide after 1 year, often accompanied by 
poor metabolic control in relation to those in whan C-peptide 
secretion persisted. The majority of these (6 of the 8) had lew 
C-peptide levels (<0.060 pmol/ml) at entry to the study, but it 
was of interest to record that glycaemic control was particulaly 
poor in the remaining 2 individuals with higher C-peptide levels 
initially (0.100 and 0.360 pmol/ml). Therefore it would appear 
that whilst strict metabolic control itself may not necessarily 
lead to recovery of B-cell function in the long term (551, 758), 
gradual destruction of the B-cell reserve is a feature of IDDM, 
and the process may be accelerated by poor glycaemic control, 
presumably due to'exhaustion1 of the Beta cells.
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CHAPTER 7
PSYSaCSOCIAL ASPECTS
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All participants in the heme blood glucose monitoring study 
were given the opportunity to complete questionnaires designed to 
give an index of several psychosocial parameters. The M.H.L.C. 
(Multi Health Locus of Control) questionnaire was administered to 
give an assessment of patient' s beliefs about health and in 
particular an idea of the relative importance of the individual, 
chance or the health care professional in its determination. 
The Zung rating gave an idea of depressive symptoms, the Efestein 
Fenz questionnaire assessed the degree of anxiety and gave 
separate ratings for feelings of insecurity, muscle tension or 
the physical component due to autoncmic arousal. The Leyton 
inventory assessed the prevalence of obsessional symptoms and 
traits, which were assessed separately. Finally, IQ was assessed 
by the Mill Hill questionnaire which gave scores for vocabulary 
(synonym score) and abilities in solving problems of pattern 
recognition (standard progressive matrices). The questionnaires 
were administered on separate occasions during the initial period 
of the study whilst intensification of management was underway. 
Patients completed them without assistance from medical or 
nursing staff, and independent of members of their family or 
advice from other patients.
The intention of this part of the study was :
1) to assess the prevalence of psychopathology in our study group
2) to determine the relationship between the various aspects of 
the psyche and metabolic control
3) To investigate whether the presence of or concern for the 
development of complications or specific beliefs about diabetes 
affected psychometric evaluation
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4) to see whether performance in the heme blood glucose 
monitoring study was related to psychological status.
1:1 PREVALENCE OF PSYCHOPATHOLOGY
Complete psychometric data was available on 130 (83 men and 
47 women) of the 147 subjects who were randomised after the 
initial 6 week period of intensified management. Abnormal 
scores on psychological tests indicative of psychopathology were 
based on normal data collected in the Department of Psychology at 
Hope Hospital by Dr. Chris Mains or frcm a previous report in the 
case of the Leyton Inventory (759), and were greater than the 
upper 95% confidence limits of the diabetic patient population in 
the current study.
Zung Depression Inventory
A maximum possible score of 60 was attainable with the Zung 
rating and values greater than 26.9 for women and 23.0 for men 
were compatible with a clinical diagnosis of depression. 19 
(14.6%) of the 130 patients were classified as having an abnormal 
Zung rating, of whom there were 9 (19.1%) women and 10 (12.0%) 
men, with a significantly greater prevalence (p<0.01) amongst 
women.
Leyton Obsession Rating
68 questions were asked, with a maximum possible symptom 
score of 46 and a maximum trait score of 22. Based on data from 
patients with obsessional neurosis, houseproud housewives and 
their spouses, and 'normal men and women' (759), abnormal symptom 
scores of >22.4 for women and >17.8 for men were established,
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with abnormal trait scores of >11.4 and >10.9 respectively. 
Abnormal Leyton symptom scores were recorded in 34 (41.0%) of men 
but in only 10 (21.3%) of women (p<0.01), whilst the prevalence 
of abnormal trait scores was similar in men (24 (28.9%) cases) 
and women (16 (34.0%)).
Epstein Fenz Anxiety Eatings
The questionnaire consists of 45 questions and a maximum 
rating of 5 is theoretically possible for each of the 3 fifteen 
question components (Autoncmic Arousal, Muscle Tension and 
Feelings of Insecurity). Abnormal autoncmic arousal scores of 
greater than 2.85 for women or 2.40 for men were recorded in 10 
(12.0%) men and 4 (8.6%) women, whilst the score was abnormally 
low (less than the lower 95% confidence limit for all patients) 
in 2 men and 2 women. A similar prevalence of high muscle 
tension scores was recorded in 9 (10.8%) men (score >2.10) and in 
6 (12.8%) women (score >2.26). The most surprising feature was 
that very low Feelings of Insecurity ratings were recorded in 18 
(38.3%) women and 47 (56.6%) men (p<0.05), whilst abnormally high 
levels (3.36 for men and women) were apparent in 5 (10.6%) women 
but not in any men.
Associations between Psychometric Tests and Demographic Factors 
There was no difference between males and females for IQ, 
MHLC, Zung or Leyton Scores, nor for the Autoncmic Arousal and 
Muscle Tension components of the Epstein Fenz questionnaires. 
However the Epstein Fenz Feelings of Insecurity Score was 
significantly lower (p<0.05) in men. Employment status had no 
bearing on IQ, Leyton, Epstein Fenz Autoncmic Arousal and Muscle 
Tension Scores, or most of the MHLC ratings, but higher Zung
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Depression Ratings (p=0.001), Epstein Fenz Feelings of
Insecurity Scores (p<0.001) and MHLC self-help scores (p<0.001) 
were recorded in those patients who were unemployed. Differences 
in social class had no bearing on Epstein Fenz, Leyton or MHLC 
ratings, although the IQ symptom (p<0.05) and standard 
progressive matrics (p<0.01) scores were lowest, and Zung 
Depression Ratings highest (p<0.05) in Social Class groups IV and 
V. The duration of diabetes did not correlate with any 
psychometric score although patient age was positively correlated 
with Zung and Leyton Scores. In general terms mean Zung
depression and Epstein Fenz autoncmic arousal and muscle tension 
ratings were no different to previous studies of healthy 
controls. The Leyton symptom score in particular was higher than 
previously recorded in healthy controls, whilst the feeling of 
insecurity score was lower than anticipated. The Zung depression 
scores were significantly correlated with the Leyton symptom
score (r=0.40, p<0.001) and the Leyton trait score (r=0.24, 
p<0.01). In addition Zung scores correlated closely with Epstein 
Fenz autoncmic arousal (r=0.42, p<0.001), muscle tension (r=0.48, 
p<0.001) and feelings of insecurity (r=0.62, p<0.001) scores.
The Leyton Synptcm scores correlated closely with the Epstein
Fenz autoncmic arousal (r=0.39, p<0.001), muscle tension (r=0.41, 
p<0.001) and feelings of insecurity (r=0.55, p<0.001) ratings, 
whilst Leyton trait score correlated with Epstein Fenz autoncmic 
arousal (r=0.24, p<0.01), muscle tension (r=0.19, p<0.05) and 
feelings of insecurity (r=0.35, p<0.001) to a lesser degree. 
MHLC scores correlated with one other with the exception of the 
self-help component. The powerful others ccrrponent correlated
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with the Zung and the Leyton symptcm and trait scores (all 
p<0.001), and the Epstein Fenz feelings of insecurity score 
(r=0.22, p<0.01). The MHLC chance score correlated with the 
Epstein Fenz Autoncmic Arousal rating (r=0.26, p=0.02). Of a 
maximum score of 36 for each of the MHLC sections, the highest 
score was recorded for the internal/external scale (27.5 (0.4)), 
followed thereafter by powerful others (23.1(0.6) and chance 
(17.0(0.6)), and then a particularly notable low self help score 
(11.8(0.2)). The number of men and wcmen with abnormal 
psychological scores for more than 1 parameter are shown in 
Tables 83 and 84. In general, men and women with abnormal Zung 
depression or Epstein Fenz anxiety ratings had abnormal Leyton 
symptcm and trait scores in roughly 50% of cases. On the other 
hand abnormal Zung and Epstein Fenz scores were recorded together 
in 3-4 females but only in 1 male (Tables 84, 85).
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TABLE 84
Number of male patients with abnormal psychological scores in 
more than 1 test (Total number =83).
Test
Total
Number with 
Abnormal 
Score
Epstein Fenz Eatings 
Leyton Leyton Autoncmic Muscle Feelings of
Zung Symptcm Trait Arousal Tension Insecurity
10 34 24 10
Zung
Leyton
Symptcm
Leyton Trait
Epstein Fenz
Autoncmic
Arousal
Epstein Fenz
Muscle
Tension
Epstein Fenz 
Feelings of 
Insecurity
17
17
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TABLE 85
Number of Female patients with abnormal psychological scores in more than 1 
test (Total number = 47)
Test
Total
Number with 
Abnormal 
Score
Epstein Fenz Ratings 
Leyton Leyton Autoncmic Muscle Feelings of
Zung Symptom Trait Arousal Tension Insecurity
10 16 4 6 '5
Zung
Leyton
System
Leyton Trait
Epstein Fenz
Autoncmic
Arousal
Epstein Fenz
Muscle
Tension
Epstein Fenz 
Feelings of 
Insecurity
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1.2 PSYCHCM5TRIC EVALUATION: RELATION TO GLYCAEMIC CONTROL
Levels of mean blood glucose, GSA, HbAx, and frequency and 
knowledge of hypoglycaemic symptoms did not correlate 
significantly with any psychometric score for the total group. 
When data on males and females were pooled and psychometric 
scores compared in the 66 and 64 subjects with respectively 
lower and higher HhAx, values than an arbitrary level of 9.1%, a 
significantly greater proportion with high levels had abnormal 
Leyton symptcm scores (p<0.03), whilst abnormal Zung depression 
scores were suggestively more common (p=0.08) in this group. 4 
of the 14 subjects who claimed to experience daily hypoglycaemic 
episodes perhaps unsurprisingly had abnormally high Epstein Fenz 
autoncmic arousal scores, in comparison to 16 of the remaining 
116, who allegedly experienced less frequent hypoglycaemia 
(p=0.01). However mean Zung, Leyton and Epstein Fenz scores were 
not significantly different amongst patients with lower or higher 
HhAi levels, or those with daily or less frequent hypoglycaemia.
1.3. PSYCHOMETRIC EVALUATION: RELATION TO COMPLICATIONS
Impotence: The presence of impotence was unrelated to MHLC, 
Leyton or Epstein Fenz scores, but was significantly correlated 
with the Zung depression rating (r=0.28, p<0.01). Furthermore, 
more male subjects with impotence had abnormal Zung scores than 
those without (8 v 2, p<0.01). Social class distribution and 
employment status were no different amongst men with and without 
impotence.
Retinopathy j_ The presence of proliferative retinopathy was 
unrelated to any psychometric evaluation apart frcm higher 
Epstein Fenz autoncmic arousal scores (p<0.05).
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Ischaemic Heart Disease j_ The presence of IHD was unrelated 
to any psychological trait other than the Zung Depression 
score, when scores were significantly greater (17.3(2.3) v 
13.0(0.7) (mean (SEM), p=0.02). However more patients with 
abnormal Leyton symptcm and trait scores had ischaemic heart 
disease than those without high scores (p<0.05) and IHD was also 
more ccmmon in those subjects who were unemployed (p<0.05).
Peripheral Vascular Disease: Patients with peripheral
vascular disease had a higher Zung depression rating that those 
without (16.1(2.4) V 13.1(0.7), p<0.05), but no other association 
with psychological parameters was recorded, other than abnormal 
Epstein Fenz muscle tension scores, which were recorded more 
frequently in patients with peripheral vascular disease (p=0.02), 
who were more commonly unemployed (p<0.01).
Peripheral Neuropathy: Neuropathic symptoms were more
conspicuously associated with depression and anxiety than signs 
of neuropathy or with other complications. There were more 
patients with low neuropathy scores (24) than with neuropathic 
symptoms (13). As well as a significant association between the 
Zung depression rating and the extent of neuropathic symptoms 
(r=0.26, p<0.001), patients with sensory neuropathic synptcms had 
a higher Zung rating than those without (19.7(2.6) V 12.8(0.6), 
p<0.01). Furthermore abnormal Zung ratings were more commonly 
observed in those with sensory neuropathy symptoms (p<0.05). A 
low clinical neuropathy score (in more extensive neuropathy) was 
inversely related to the Zung score (r=-0.27, p=0.005), but low 
neuropathy scores (<11) were not significantly more prevalent 
amongst patients with abnormal Zung scores. Neuropathic
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symptcms were also associated with the Epstein Fenz autoncmic 
arousal (r=0.26, p<0.001) and muscle tension (r=0.38, p<0.001) 
scores. The autoncmic arousal score was greater in patients with 
symptcms of neuropathy(2.19(0.13) V 1.85(0.04), p=0.01), and were 
frequently abnormal in these patients (p=0.001). Likewise the 
muscle tension score was greater in patients with symptcms 
(1.99(0.16) V 1.46(0.04), p<0.005), in whcm it was more
frequently abnormally high (p<0.001). Interestingly the 
neuropathy score was not related to Epstein Fenz anxiety ratings. 
There was no relationship between clinical features of neuropathy 
and the Epstein Fenz feelings of insecurity score, or the MHLC or 
Leyton scores.
1:4. ROLE OF PSYCHE DURING HOME BLOOD GLUCOSE MONITORING PROJECT 
Patient Compliance and Psychological Status: Patients were asked
at entry to the study whether or not they always carried a source 
of carbohydrate and/or diabetic identification with them, in 
keeping with the suggestion by Lockington et al (527), that this 
assessment gave a reasonable indication of patient compliance 
with their self-care programme.
70% of patients regularly carried both diabetic 
identification and a source of carbohydrate, whilst only 4% 
carried neither. The Zung depression, Leyton obsession and 
Epstein Fenz anxiety ratings were no different amongst those 
subjects who did or did not carry carbohydrate or diabetic 
identification.
Following randomisation to blood or urine glucose testing, 
compliance in the study was assessed frcm the number of completed
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filter card blood spots suitable for analysis over the ensuing 
twelve month period. The number of blood spots per patient 
ranged fron 29 to the maximum of 120. Regardless of gender, 
patients who submitted 70 or less spots (20% of cases) did not 
differ frcm the remaining 80% with regard to their initial 
psychological status when assessed by Zung, Leyton, Epstein Fenz 
or MHLC ratings. Furthermore those who submitted 70 or less 
blood spots (deemed non-ccmpliers) were no different frcm the 
remaining group with regard to social class, employment status, 
or glycaemic control when assessed by three monthly glycosylated 
blood protein measurements.
Relation of psyche to contact patterns during the heme blood 
glucose monitoring study: Following randomisation, those 19
patients with abnormal Zung depression ratings made significantly 
more contacts with their GP (0.67(0.29) V 0.25(0.08) contacts per 
patient (mean (SEM) ), p=0.01) and myself (0.44(0.24) V
0.13(0.05) contacts per patient, p<0.02) over the first three 
months. Although the group with higher Zung ratings also spent 
significantly more days off work during the year (36.6(23.8) V 
7.1(1.6) days per patient, p<0.05), this probably reflected the 
higher prevalence of complications.
Abnormal Leyton symptcm scores were not associated with more 
frequent contacts, but those 9 subjects with an abnormal Leyton 
trait score contacted the diabetic liaison sister more frequently 
over the first three months (0.24(0.11) V 0.11(0.08) contacts per 
patient per month, p<0.02), but not thereafter, although the 
total number of hospital contacts made during the year was also
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greater in these patients (2.1(0.4) V 1.3(0.3) contacts per 
patient per month, p<0.05).
Only 4 patients had high Epstein Fenz autoncmic arousal 
ratings, but they made appreciably more contact with the diabetic 
liaison sister during the first three months (0.42(0.19) V 
0.12 (0.07) contacts per patient per month, p=0.0004). Abnormal 
Epstein Fenz muscle tension ratings had no bearing on the pattern 
of hospital contacts, whilst those with notably low Epstein Fenz 
feelings of insecurity ratings made significantly fewer contacts 
with the diabetic liaison sister during the first three months (0 
V 0.26(0.12) contacts per patient per month, p<0.005).
Psychological traits were not associated with other patterns 
of contact with health professionals, and most notably had no 
association with contact patterns beyond the first three month 
period after randomisation.
Changes in Psyche during the heme blood glucose monitoring study: 
39 of the 124 subjects who completed the first year of the study 
filled in psychological questionnaires at the one year follow up 
visit. A notable correlation between the various psychometric 
measures was observed after one year and importantly there were 
no significant correlations between changes in measures of 
glycaemia and changes in psychological status. Overall, mean 
scores for the Zung, Leyton and Epstein Fenz questionnaires did 
not differ significantly after one year. The most apparent 
change was in the MHLC self-help score which rose frcm 12.0(0.4) 
to 18.4(0.7), p<0.001.
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1:5. DISCUSSION
The extent of psychopathology amongst the diabetic 
population studied was not distinct frcm previous studies and no 
greater than the general population with the notable exception of 
high Leyton obsessional ratings. More important is of course to 
consider the implications of the adverse psychological status for 
the management of such individuals. As in the non-diabetic 
population, I found that the prevalence of high Zung depression 
scores was higher in wcmen, although an unexpected excess of 
abnormal Leyton obsessional symptom scores was recorded in men.
The enforced disciplines of self-management of IDDM might be 
expected to lead to a degree of rigidity in behaviour, reflected 
in the high Leyton obsession ratings, and the preponderance of 
men in the population I studied may in part explain the result. 
Furthermore a considerable difference in upper limits of male and 
female Leyton symptcm scores was less apparent for the Leyton 
trait scores where the prevalence of abnormal scores was similar 
in men and wcmen. It would therefore seem that IDDM leads to 
behavioural changes which reverse the tendency for wcmen to 
display obsessive symptcms more often than men.
One interesting finding was that, as in the study of Bradley 
et al (523), I found that the diabetic patients rated the 
internal/external and powerful others components of the locus of 
health control highly. In addition a notably low score for the 
Epstein Fenz feelings of insecurity rating was apparent. Despite 
this a low self-help locus of health control was recorded.
This might suggest that whilst diabetic patients may perceive 
both positive and negative health outcomes as primarily
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attributable to their medical practitioners as well as 
themselves, so that consequently they were not necessarily 
insecure, there would appear to be a poor insight into their own 
ability to beneficially modify patterns of health. It could be 
argued whether this state of relative security despite a lack of 
initiative for self-help may in fact be the major obstacle facing 
health professionals trying to improve diabetic management.
Whilst there does not seem to be an excess of psychiatric 
illness in IDDM, I found that the burden of psychopathology was 
heaviest in particular groups of patients, namely those who were 
unemployed, of lower social class, or the victims of diabetic 
complications (v.i). It is not possible in the present project 
to conclude whether unemployment is the cause of the higher 
depression and feelings of insecurity ratings, but it was of 
interest to record higher MHLC self help ratings in those who 
were unemployed, suggesting that despite more mood disturbance, 
independent behaviour may be the one beneficial acccnpaniment of 
unemployment. Perhaps suprisingly, I only found Zung depression 
ratings were higher in the lower social class groupings. 
Although all forms of neurotic illness are generally recognised 
more frequently in lower social classes, the unintentional bias 
towards selection of most patients frcm the lower social 
classes may have led to an excess of anxiety in the current 
study.
A clear relationship was recorded between patterns of 
depression and anxiety ratings, and between obsession and anxiety 
scores. Consequently patients with abnormal Zung depression or 
Epstein Fenz anxiety ratings often also had high Leyton obsession
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scores. Notwithstanding the fact that patients with features 
compatible with both anxiety and depression were observed less 
consistently, there would appear to be a group of individuals in 
whcm several neurotic traits are evident, and in whcm presumably 
psychological dysfunction is more extensive and difficult to 
treat.
Unlike the report frcm Cassileth et al (540), I did not 
record more anxiety or depression in patients with a short 
duration of diabetes, although older patients had higher Zung 
depression and Leyton obsession scores. The latter finding may 
simply reflect the luxury of a more ordered existence that 
growing older provides. One possible explanation for the higher 
depression ratings in my study may be the presence of more 
complications in the older patient, which had a major bearing on 
the psyche (v.i.). The effect of complications may have 
'swamped' any apprehension, anxiety or depression that 
accompanies the diagnosis of diabetes, and in the event 
relatively few patients in the present study were newly 
diagnosed. Furthermore it is not stated how many of the diabetic 
patients of Cassileth et al (540) had complications. It is of 
interest to note that none of the other chronic diseases that 
Cassileth et al studied, with possible exception of cancer, 
usually lead to a physical loss. Loss of vision, limbs (and 
perhaps potency) were those fears most often voiced by my 
patients (in Chapter 3), and it was those patients with 
retinopathy, lower limb neuropathy, and impotence who often had 
the highest depression and anxiety ratings.
One notable feature was the lack of a consistent association
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between metabolic control and psychological factors in patients I 
studied. More recent reports in IDEM have suggested that anxiety 
and depression ratings may be higher in poorly controlled 
subjects (541, 760). Whether hyperglycaemia itself affects mood 
or disturbed mood affects behaviour and compliance indirectly 
leading to hyperglycaemia was uncertain. The reason for the 
discrepancy between the findings are unclear, although patient 
selection differed with regard to the type of diabetes and/or 
the presence of complications. Furthermore I was able to 
demonstrate that the less compliant patients did have poorer 
glycaemic control during the study, so it is feasible that whilst 
these subjects need not necessarily be anxious or depressed, it 
is their behaviour which led to the poor glycaemic control in the 
reports by Mazze et al (541) and Robinson et al (760). My 
observation that high anxiety ratings were recorded more 
frequently in patients with frequent hypoglycaemia confirms the 
findings of Sanders et al (539), and in practice the relationship 
between mood and recurrent hypoglycaemia is perhaps more relevant 
than that with hyperglycaemia, where compliance is the real 
issue. Finally the limitations of questionnaires in evaluating 
mood and stress should be acknowledged. The type of acute 
anxiety and stress that may lead to hyperglycaemia (533, 543) may 
not always be reflected by a high Epstein Fenz rating.
I found that the presence of complications, particularly 
neuropathy and retinopathy, was the most consistent predictor of 
psychological disturbance. It is now becoming clearer that the 
specific complications where the loss of vision or limbs is 
perceived as a threat by the patient are most clearly associated
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with altered mood and increased anxiety, and my observations are 
in keeping with several other previous reports (537, 538, 546, 
547, 760). The association between coronary heart disease and a 
higher depression rating in diabetics confirms previous findings 
in non-diabetics (544).
Finally, the higher depression rating in impotent men 
supports recent work (547) and it is perhaps not suprising that 
'loss of manhood1 is another 'potent' mood depressing stimulus.
In summary it would appear that psychological disturbances 
are not particularly common in IDDM, with the exception of 
obessional traits, which may be encouraged by the process of 
diabetic self-management. Glycaemic control is not strongly 
associated with psychological status in general, other than in 
maladapted non-ccmpliant individuals. The most striking 
observation is that diabetic patients with complications carry a 
heavy psychological load, particularly if there is evidence of 
serious retinopathy, neuropathy or impotence. The co-existence 
of neuropathy and depression in particular may be of practical 
importance since psychological disturbances can often compound 
neurological disease and indeed atypical dysaesthesiae is a not 
infrequent manifestation of depression. Therefore the 
relationship between complications and mood change is a complex 
one, and not necessarily cause and effect. At any rate there 
would appear to be evidence to support the need to enquire about 
psychological disturbance in those subjects with established 
complications.
Initial psychological status had little bearing on 
performance during the heme blood glucose monitoring study. In
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particular, those patients with high anxiety, depression, or 
obsession ratings did not comply with the study requirements any 
differently from the remaining group, nor did they experience 
poorer glycaemic control. However those patients with higher 
Zung, Leyton and Epstein Fenz ratings did make more demands on 
health care professionals, but only during the first three months 
of the study following randomisation. It would therefore appear 
that this type of intensified management programme might lead to 
increased patient contact in the short term with subjects who 
have neurotic tendencies, although this phenomenon will dissipate 
with time. In view of the relatively small numbers, it is not 
possible to state whether contact with a particular health care 
professional (e.g. general practitioner as opposed to diabetic 
sister) was of any relevance.
Mazze et al (541), previously suggested that improved 
diabetic management led to improved depression and anxiety 
ratings, which I could not confirm after one year in the current 
series of investigations. Comparison of the two studies is 
rather difficult since it would appear that none of the selected 
population studied by Mazze et al initially had anxiety or 
depression ratings high enough to represent psychopathology, so 
it is debatable whether improved glycaemic control directly 
improved mood. Whilst my data would suggest that programmes of 
intensified diabetic self-management do not necessarily modify 
anxiety, depression or obsessional tendencies, I was able to 
demonstrate a benefit in patients1 perceptions of their health. 
A definite improved MHLC self-help rating would suggest that 
diabetic patients' attitudes to illness are more positive
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following such a prograinme and it could be hoped that there might 
be longer term pay-offs as a consequence of a more independent 
approach to diabetic management.
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CHAPTER 8
(ENERAL DISCUSSION AND CONCLUSIONS
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The work presented in this thesis throws sane light on the 
broad areas of enquiry that were raised in the introduction.
1^ WHAT FACTORS DETERMINE METABOLIC CONTROL?
The first major point to make is that measures of lipid and 
carbohydrate metabolism in IDEM often give quite distinct 
information regarding metabolic control, and it is therefore best 
to discuss these two broad areas separately.
Glycaemic control was assessed by established methods in 
addition to monthly filter card blood glucose profiles and GSA 
using affinity chromatography, with methods that I helped to 
develop as part of the work for the thesis. In addition the 
clinical performance of the 1 fructosamine1 assay was subjected to 
careful scrutiny.
When I examined those factors that iirproved glycaemic 
control, I was initially able to analyse the effects of intensive 
management, and thereafter to assess how important heme blood 
glucose monitoring was, and whether glycaemic control was 
modified by residual endogenous insulin secretion, insulin 
species and antibody titre and psychosocial and educational 
factors.
The most marked improvement in glycaemic control was 
apparent following the initial 6 week period of intensified 
management when insulin regimes were modified, patients 
instructed in diabetic self-management and in blood glucose 
monitoring, and fortnightly contact and continued education 
carried out. Improvements in glycaemic control and educational 
scores were maintained for 1 year.
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It is therefore possible to conclude that the initial 
intensive programme can be applied successfully to large numbers 
of sub-optimally controlled insulin-dependent diabetics who 
attend the regular diabetic clinic and whose initial short t e m  
improvements can be maintained to a greater or lesser extent for 
a period of at least 1 year.
The question as to whether it was alteration of the insulin 
regimen, regular access to medical staff, blood glucose 
monitoring, or the educational programme that contributed most 
to the improvement cannot be measured from my study, and it is 
perhaps unnecessary to attempt to answer it, since the isolation 
of one particular approach, apart fran being difficult in 
practice, would not be appropriate for good diabetic management. 
However the easy access policy that was maintained throughout the 
study may have enabled the group as a whole to maintain their 
improved glycaemic control, as may have the fact that the 
inproved educational ratings were retained after 1 year in the 
study.
Before discussing how important other factors were in 
determining glycaemic control, it is worth considering the 
different measures of glycaemic control that were made in the 
various studies.
Firstly, it is important to evaluate the methodological 
limitations and performance of the various assays. The filter 
paper blood glucose assay was developed to provide a validated 
record of direct glycaemic measures for carparison with the 
glycosylated blood proteins, in addition to a quality control 
check on patient-generated domestic blood glucose recordings.
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The continuous flow auto-analyser system was found to be 
accurate, sensitive and reproducible, in agreement with previous 
reports (492-499). The main practical consideration was 
optimisation of storage conditions. I found that refrigeration 
of the filter cards without preservative was sufficient to ensure 
blood glucose stability for up to 28 days, supporting the 
findings of Seiter et al (492) but contesting those of Burrin et 
al (495) who found that blood glucose levels fell by as much as 
30% after 5 days refrigeration without preservative. I also 
found that application of boric acid as a preservative led to 
initial artefactual rises in blood glucose. The reason for this 
is unclear, but in view of the protective effect of 
refrigeration, the expense of impregnation of filter cards with 
preservative, and the failure of others to find that boric acid 
was an effective preservative (492, 493), I continued to use 
filter cards without preservative for use by patients during the 
study.
Although it is impossible to be certain that all patients 
always refrigerated their filter cads as requested, it is notable 
that only small falls in filter card blood glucose levels were 
apparent when stored at rocm temperature for 48 hours, and 
previous studies suggested that samples were reasonably stable 
for up to 1 week under these storage conditions (462, 492, 496). 
On balance the method produced patient generated results suitable 
for analysis. Using this approach I was able to confirm as in 
previous laboratory based studies (476, 477), that the Reflolux 
blood glucose meter consistently over-read blood glucose 
recordings in patients' hands, particularly in the low normal to
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hypoglycaemic range. This latter finding is of particular 
importance when one notes how frequently asymptomatic biochemical 
hypoglycaemia was observed during the study.
The GSA affinity chromatography assay was developed in two 
stages and ultimately yielded a method that was simple, sensitive 
and precise. In the initial experiments I was able to confirm 
previous reports (163, 173) that overloading the columns with 
protein (in serum) leads to artificially low yields of 
glycosylated protein. I was also able to confirm that dye binding 
techniques are unsuitable to measure the small amounts of albumin 
that are necessary to prevent column overloading (163, 176). The 
modified method employed immunoturbidimetry which was much more 
reliable in this respect, and also ensured that recovery of 
albumin frcm the column was complete. The between batch 
precision of the GSA assay was 4-7%, which compared favourably 
with 1-3% for the fructosamine and 3-6% for the HbAx assays. 
Several previous reports on GSA (120, 168, 171, 172, 177, 178) 
used brcmocresol green to measure albumin in the glycosylated and 
non-glycosylated fractions, which limit conclusions being drawn 
from them.
In evaluating the fructosamine kit I found that whilst the 
method was certainly economical in time and cost, values in 
hypertriglyceridaemic diabetic patients seemed inappropriately 
lower throughout the study. Whilst the exact mechanism of the 
'fructosamine1 reaction remains uncertain, it is difficult to 
explain this phenomenon fully, particularly as non-diabetic 
hypertriglyceridaemic sera may apparently produce high 
fructosamine values (761). One explanation may be that
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superoxide generation frcm glycosylated protein bonds m y  be 
relevant to the mechanism of NBT reduction in the fructosamine 
reaction (213), and it has recently been shown that all lipaemic 
sera has the capacity to generate free radicals (762). It would 
appear reasonable to speculate that non-diabetic lipaemic sera 
might accelerate NBT reduction early in the time course of the 
reaction leading to higher fructosamine values, whilst in 
diabetic patients the effect would be to reduce the amount of 
substrate (NBT) available for reduction by glycosylated serum 
proteins, leading to relatively low fructosamine values.
Secondly, the results in Chapter 5 make it clear that 
different measures of glycaemia give information that is 
complementary, and not always comparable. The most important 
findings were that GSA and fructosamine respond more than HhAx to 
improved glycaemic control, and that fructosamine and GSA do not 
necessarily always provide the same information about glycaemic 
control in IDEM. These observations reflect the inherent 
instability of IDEM, and suggest that at least 2 different 
glycosylated blood proteins should be measured to enable an 
assessment of both short-term and longer-term integrated 
glycaemia. In a report by Ziel and Davidson (178) it was 
suggested that GSA and HhAi gave broadly interchangeable 
information about glycaemic control in stable IDEM. I have shown 
that this is clearly not the case and that seriously discordant 
information is produced on up to 19% of occasions in patients 
studied over the course of 1 year. The methodological 
difficulties in the measurement of GSA were not addressed by Ziel 
and Davidson (178), which might explain the discrepancy, and to
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date, no other studies have evaluated the utility of the 
different glycaemic measures in clinical practice. With regard 
to the comparison of the GSA and fructosamine assays, I found 
that GSA was more sensitive in reflecting shorter term 
improvements in glycaemic control, as well as correlating better 
with the M value, an index of glycaemic instability. The serious 
discordance between GSA and fructosamine recorded on 6-15% of 
occasions during the year should make it clear that the 
reduction of NBT in the fructosamine reaction cannot be the only 
source of the colorimetric change. Regardless of the
methodological considerations, GSA and fructosamine levels do not 
always parallel one another in IDEM. Although the economic 
argument should not necessarily prevail, it is Important to
acknowledge that the automated fructosamine assay can be costed
in terms of pence, whilst the combined affinity
chrcmatography/immunoturbidimetric GSA assay costs about fl per 
sample. On balance it would appear that HhAx and either 
fructosamine or GSA should be routinely measured in the 
management of IDEM and in future studies of the determinants of 
glycaemic control and its relationship to vascular complications, 
in order to give an adequate impression of the short and long­
term glycaemia. At present the majority of diabetic clinics and 
ongoing prospective clinical studies investigating the links 
between glycaemic control and complications are not using more 
than one glycaemic measure. It might be argued that since the 
evolution of vascular complications is a lengthy process, the 
assessment of longer term glycaemic control by serial 
measurements of HhAi alone would suffice. I would contest
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this assertion for several reasons. Firstly, since a particular 
HhAx level may reflect a range of mean blood glucose levels 
differing by as much as 5mmol/l (140), one could not assume the 
same degree of glycaemic control for a group of patients with 
similar Hh^ levels. Secondly, failure to remove the labile 
fraction of Hh^ prior to its measurement is still cannon 
practice in hospital laboratories because the procedure is time 
consuming, and the HhAj results may be at least 1.5% higher if 
there is acute hyperglycaemia at the time of blood sampling 
which would then misleadingly represent longer term integrated 
glycaemic control. Finally it is unclear how accurately Hh^ 
reflects glycaemic instability, particularly hypoglycaemia, in 
IDEM.
The use of several measures of glycaemia providing 
complementary information also proved to be important when 
evaluating factors which might determine blood glucose control. 
Following the intensive period of management, those patients with 
detectable C-peptide levels had better glycaemic control when 
assessed by Hh^ and GSA, with a suggestion that even low levels 
of C-peptide conferred the potential for glycaemic control, 
although of a relative subtle nature, evident only by differences 
in GSA levels. It was interesting to record that the differences 
in fructoasmine levels in the different C-peptide groups 
following the period of intensive management were much more 
variable, again suggesting that the fructosamine assay probably 
measures something in addition to GSA.
The findings that persistent C-peptide secretion did confer 
the potential for subtle improvements in glycaemic control sits
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favourably with the other published work on the subject (551, 
554-447) where smaller numbers, and different methods of patient 
selection and assessment of glycaemic control may have 
contributed to the lack of a clear consensus.
However other factors had less inpact on glycaemic control. 
The continued use of hone blood glucose monitoring beyond the 
initial period of intensified management was associated with 
inproved glycaemic control in comparison to those who reverted to 
urine glucose monitoring. The most important feature of this
improvement was that it was not overwhelming or apparent for all
glycaemic measures at all time points. Direct measures of 
glycaemia frcm filter card profiles were most consistently 
improved, whilst significantly higher GSA levels at 3 months, 
HhAx at 6 months and fructosamine at 9 months were observed in 
the blood testing group. When put into the context of the
previous report by Worth et al (77), it is fair to conclude that
long-term blood glucose monitoring does lead to improved 
glycaemic control but that assessment of HhAx levels alone are 
not sensitive enough to detect this and monthly 24h blood glucose 
profiles may show the benefit most clearly. I would acknowledge 
that my study design only allowed me to examine whether continued 
blood glucose monitoring led to maintained improvements in 
glycaemic control since the majority had attained good glycaemic 
control following the initial 6 week period. Nonetheless, other 
benefits of blood glucose monitoring were apparent apart frcm the 
differences in glycaemic control; notably more retention of 
educational skills, an increase in the MHLC self-help rating, and 
less absenteeism frcm work (v.i.). This would suggest that heme
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blood glucose monitoring not only has a definite role as an 
educational tool but that it may modify individual1 s perceptions 
about how they can manage their own condition. This was achieved 
without any excess of reported hypoglycaemia, although the 
increased number of hospital contacts in the blood glucose 
monitoring group suggests that a back up service is essential, 
but this degree of reliance on the hospital may be a price worth 
paying. A similar benefit frcm such an approach has also been 
previously reported by Berger and colleagues in Dusseldorf (724, 
725, 730), and it is noteworthy in both the Salford and
Dusseldorf studies that the opportunity for active self­
management led to more frequent use of soluble insulin and a 
sustained increase in body weight irrespective of the means of 
glucose monitoring.
The effect of different insulin species and antigenicity on 
glycaemic control was less apparent, but it appeared suggestively 
poorer in patients treated with bovine insulin when GSA was used 
to assess glycaemic control. Presumably this reflects the effect 
of the higher insulin antibody titre which was the consequence of 
using a more antigenic insulin. In addition the faster onset of 
insulin action described with biosynthetic human insulin (381) 
may be relevant. It is fair to conclude that even if bovine 
insulin leads to a smoother peripheral insulinaemic profile 
(374, 375), it does not improve metabolic control.
Finally, I found that psychological factors apparently had 
very little inpact on glycaemic control. The relationship 
between the psyche and glycaemic control is complex. Although 
previous reports have suggested that glycaemic control was
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related to anxiety and depression (541, 542), it is not clear how 
this relationship operates other than by an indirect effect of 
mood on compliance and thereby glycaemic control. These reports 
were on selected young diabetics free of complications and my own 
observations that only frequent hypoglycaemia was a feature of 
patients with abnormal anxiety ratings suggest that glycaemic 
control may be related to the psyche in a small number of cases.
In contrast to glycaemic control, I found that the 
disordered lipid metabolism of IDEM was not simply the 
consequence of adverse diabetic management or impaired metabolic 
control. In keeping with previous reports (50-54), I found that 
intensified therapy led to significant reductions in serum levels 
of triglycerides and total and LDL cholesterol in the short-term. 
Moreover I was able to demonstrate that these improvements were 
maintained for the group as a whole for at least 1 year. The 
reason for such changes are likely to be in the main the 
consequence of inproved insulin delivery and better matching of 
the insulin dose to the dietary lipid load. It is uncertain 
whether additional dietary modification had any significant role. 
However, previous reports have shown that low fat diets are 
poorly tolerated by insulin dependent diabetic patients at heme, 
particularly in the long run (319, 324) and a notable increase in 
EMI was observed in the patients I studied, so I think that 
modified dietary fat intake is not the major explanation for the 
sustained reduction in total lipids.
I found that HDL3 cholesterol levels fell after the initial 
period of inproved control, and remained low, whilst HDL2 levels 
remained stable, and total HDL cholesterol levels did not alter
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appreciably. Other (47, 51, 52) studies have found that the 
improved glycaemic control is associated with a rise in HDL 
cholesterol, but have not specified in which of the HDL 
fractions this took place. One reason for the discrepant 
findings may be that the degree of insulin deficiency and 
hyperglycaemia in the previous reports was more severe than in my 
studies. Consequently HDL levels were initially much lower than 
I found, and therefore more amenable to correction with insulin 
repletion.
It is in fact quite reasonable to anticipate that HDL3 
cholesterol levels might have fallen with improved glycaemic 
control. Glycosylation of the apoproteins of HDL has been shewn 
to lead to enhanced HDL synthesis as well as an increased 
catabolic rate (181). As HDL3 is the precursor of HDL2 
following its conversion frcm nascent HDL, the effect of reducing 
hyperglycaemia on glycosylated HDL would be expected to be a 
reduced HDL3 synthesis.
The effects of improved glycaemic control on apolipoprotein 
B levels are also unclear. Previous reports have suggested that 
they rise (47, 54), although in both prevailing glycaemic control 
was particularly poor at the inception of the study. Whilst I 
found that apo B levels did not alter significantly in the group 
as a whole, a dramatic reduction was apparent in the sub-group 
with combined hyperlipidaemia, who importantly had particularly 
poor control. Scrutiny of other changes in patients sub-divided 
according to their initial lipid status was of seme interest. 
Patients with either hypercholesterolaemia or 
hypertriglyceridaemia in particular seemed more amenable to
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correction to nomolipidaemia than the canbined hyperlipidaemic 
group. Nonetheless, the improved metabolic state led to definite 
reductions in all cholesterol fractions in the combined 
hyperlipidaemic group, including HDL2 cholesterol, suggesting 
that a generalised reduction in lipoprotein synthesis took place.
Therefore it would appear that limited improvements in lipid 
metabolism accompany better glycaemic control, particularly in 
those subjects who have type Ila or IV hyperlipidaemia using the 
Fredrickson classification.
The stable insulin dependent diabetic would still appear to 
have subtle conformational changes in lipoproteins. An enhanced 
cholesterol: triglyceride ratio in VLDL has been reported in well 
controlled IDDM (259) and the presence of IDL has been suggested 
(269) although not confirmed. I was able to demonstrate that the 
density of LDL in IDDM may be altered due to a saturation of the 
molecule with cholesterol relative to apoB, and Schonfeld et al 
have made similar observations (54, 56). All these findings 
suggest the remnant-triglyceride rich 'LDL-like1 particles may 
accumulate in IDDM regardless of glycaemic control. Despite such 
changes, I was able to demonstrate that the Friedwald formula is 
still appropriate to calculate DDL cholesterol in IDEM, which may 
imply that the build up of IDL (LDLX) in IDEM will ccrrpensate for 
any saturation of VLDL with cholesterol.
In addition to these changes in VLDL and LDL, I found that 
alterations in HDL are also an integral part of IDDM. Like most 
other reports (287, 288, 292-296), I found that HDL cholesterol 
levels in stable IDDM tend to be higher, and that this mainly 
reflects the build up of HDL3 cholesterol (299, 300). I did not
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find any significant relationship between HDL and either Hh^ or 
C-peptide. A lack of association between HbAi and HDL is the 
conclusion of the majority of previous reports (262, 283, 290, 
292, 293, 295, 296), whilst higher C-peptide levels had
previously been suggested to be independently associated with 
reduced HDL and HDL2 cholesterol levels (293). Patient selection 
may be crucial in this regard. As stated previously low HDL 
levels may correlate with high HhAx if glycaemic control is 
particularly poor, and a close inverse relationship between HDL 
and serum triglycerides may have been iitportant in explaining the 
aforementioned link with C-peptide, since many patients in the 
report by Laakso et al (293) with higher C-peptide levels were 
obese, hypertriglyceridaemic type II diabetics who would of 
course have been expected to have low HDL cholesterol levels.
These abnormalities of lipoprotein structure may be in part 
under genetic control. I found a much higher than expected 
prevalence of ApoE2 hcmozygosity and noted that as in health, 
the E2 allele is associated with higher triglyceride and lcwer 
cholesterol levels than the E4 allele. This difference in lipid 
levels reflects altered apoE receptor affinity for the different 
apoprotein E phenotypes, and would provide a further mechanism by 
which triglyceride-rich lipoproteins could accumulate in IDDM 
patients who were €2 hanozygotes. Although C-peptide secretion 
seemed to be unrelated overall to total, LDL or HDL lipid levels, 
a portal insulin supply may encourage uptake of IDL in IDDM 
associated with Apo E2 hcmozygosity, since hypertriglyceridaemia 
was present in only 2 of the 8 subjects whcm I found to be E2 
hanozygotes.
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The influence of renal dysfunction on lipoprotein metabolism 
in IDDM was more evident. I was able to confirm previous reports 
(329-331) that mild proteinuria is accompanied by a build-up of 
atherogenic lipids and lipoproteins and a reduction of HDL and 
HDL2 cholesterol in the absence of nephrotic syndrome, but also 
found that minor renal dysfunction made a significant 
contribution to lipid levels in IDDM. Urinary loss of HDL3 may 
be important in explaining the reduction in HDL cholesterol, 
particularly if an increased hepatic synthetic rate of nascent 
HDL could be demonstrated, and the explanation for the increased 
total and LDL cholesterol levels may also reflect the hepatic 
response to proteinuria. Whatever the cause, it is evident that 
lipid metabolism may be significantly altered by early diabetic 
nephropathy. I was not able to demonstrate a role for tobacco, 
alcohol consumption or exercise in lipid metabolism in IDDM, 
although these factors are undoubtedly important. However I did 
find that wanen have higher HDL levels than men with IDDM, 
supporting the findings of Walden et al (343), although they 
pointed out that the difference between IDDM and healthy controls 
was attenuated in wcmen compared to men. Finally I found that 
body mass index has a bearing on lipid levels in IDDM, a feature 
previously reported by Nikkila and Hbrmila (292).
In conclusion, it would appear that lipid metabolism in IDDM 
is more ccmplex than carbohydrate metabolism, and that there 
appear to be intrinsic abnormalities which may be modified not 
only by inappropriate diabetic care, but also by changes in renal 
function and body mass.
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2. WHAT ARE THE DETERMINANTS AND ACCOMPANIMENTS OF DIABETIC
COMPLICATIONS?
Macrovascular Disease: The aetiology and clinical course of 
coronary and peripheral vascular disease are often presumed to be 
the same, although this is not necessarily the case, particularly 
in diabetes. Despite this, I was able to demonstrate that both 
types of large vessel disease were associated with an increase in 
systolic and diastolic blood pressure levels, and it was notable 
that almost all patients with clinical evidence of
atherosclerosis in the current study had diabetic renal disease, 
since epidemiological evidence clearly shows the vast excess of 
mortality fran atherosclerosis in IDEM to reside in this 
particular sub-population (560). Borch-Johnsen et al (560), has 
suggested that the presence of proteinuria operates independently 
of the traditional risk factors for vascular disease 
(hypertension, hyperlipidaemia, and smoking), despite the
evidence frcm the present work and many other sources (7-9, 329, 
331, 584, 606, 611, 628) that these risk factors are particularly 
associated with diabetic nephropathy. Regardless of the exact 
mechanism, it is clear that the development of nephropathy leads 
to a change in the natural history of diabetic large vessel
disease. In this regard, the influence of proteinuria in IDEM 
on lipid metabolism is of special interest. I found that 
hyperlipidaemia was uncommon amongst subjects with stable
metabolic control and no nephropathy, although conformational 
changes of LDL and HDL appeared intrinsic to IDEM. These 
findings provide the basis for further research to investigate 
the mechanism and consequences of such changes, but do not in
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themselves suggest that insulin-dependent diabetics are 
especially vulnerable to premature atherosclerosis by virtue of 
their lipid profile.
However, like Eckel et al (329), and Vannini et al (331), I 
found that proteinuria without renal failure was associated not 
only with the build up of serum cholesterol and triglyceride 
levels, but also with a reduction in HDL2 cholesterol. In 
addition proteinuria may have led to further conformational 
changes in lipoproteins, so that overall the patient with 
diabetic nephropathy could be classified as at risk for 
macrovascular disease on the basis of associated hypertension and 
hyperlipidaemia. I was unable to examine the relevance of 
hyperglycaemia and genetic factors to large vessel disease, but 
the recorded excess of apoE2 hcmozygosity raises the possibility 
of an inherited predisposition to hypertriglyceridaemia and 
diabetes, and there is support for the suggestion that 
glycosylation may modify both lipoprotein metabolism and arterial 
function (597, 600).
Finally, I found an increased prevalence of peripheral 
vascular disease in subjects with long standing IDDM and residual 
C-peptide secretion. This may be no more than circumstantial, 
but is ccmpatable with the concept (16, 749) that peripheral 
hyperinsulinaemia may facilitate atherogenesis.
Irrespective of the pathophysiology, I found that 
macrovascular disease was accompanied by unemployment and adverse 
psychological ratings, particularly the Zung depression scale, 
and perhaps also certain facets of anxiety and obsessional 
behaviour. Although depression is often the consequence of
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myocardial infarction (544), this aspect of diabetic care may 
have been neglected in the past and certainly merits further 
investigation. It was particularly interesting to record a low 
level of concern regarding vulnerability to heart disease in 
IDEM, confirming the findings of Bradley et al (523). This 
possibly reflects a lack of awareness of the importance of 
atherosclerosis to IDDM which perhaps should be incorporated into 
further educational strategies, particularly as the epidemic of 
coronary heart disease in the non-diabetic population has been 
found to be amenable to correction (763, 764). The question of 
the long-term effects of lipid lowering agents in diabetes 
mellitus needs to be urgently addressed.
Retinopathy; I did not specifically attempt to corroborate 
previous suggestions that glycaemic control, blood pressure, and 
smoking were important determinants of retinopathy (7-9, 40, 584, 
604, 605, 611), but did find that proliferative retinopathy was 
initially more common in long standing cases of IDEM if residual 
C-peptide secretion was absent. This difference was no longer 
apparent after one or two years of observation, so that even if 
one accepts that loss of endogenous insulin reserve leads to 
poorer glycaemic control and consequently more severe 
retinopathy, it would appear that the increasing duration of 
diabetes overwhelmed any such disadvantage, a point made on 
previous occasions (7-9, 40, 604, 605).
The independent association between retinopathy and various 
markers of nephropathy is well known (7, 584, 604, 608), and I 
was able to demonstrate proliferative retinopathy more frequently
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in IDEM accompanied by nephropathy. Whether or not this reflects 
underlying disturbances of coagulation and/or enhanced vascular 
permeability ccmmonon to both complications would require further 
studies, but I could not provide support for the suggestion (605, 
617) that insulin antibodies were implicated in either.
The higher Epstein Fenz anxiety ratings amongst those with 
serious retinopathy might have been anticipated since both 
Bradley et al (523) and I found that fear of visual loss 
understandably generated great concern amongst patients with 
IDDM, and Wulsin et al (546) suggested that visual impairment 
and/or laser photocoagulation lead to considerable stress, 
although they pointed out the lack of research in this area. 
Meanwhile there is a good argument for further education designed 
to convey to patients the optimistic outlook for retinopathy 
whilst reinforcing those aspects of self-management that might 
minimise deterioration of the retinopathy.
Nephropathy: An association between early diabetic nephropathy 
and hypertension was observed in this thesis and appears 
virtually indisputable (8, 9, 584, 626, 628), although the
'chicken v egg' argument remains. I did not find glycaemic 
control in relation to residual C-peptide secretion had a major 
bearing on the presence or progression of renal function, but 
other reports have testified to a role for hyperglycaemia and 
glycosylation in albumin excretion and renal tissue damage, at 
least during the phase of incipient nephropathy (15, 357,
630, 640, 651).
I have previously discussed the effect of diabetic 
nephropathy on lipid metabolism in IDDM. Potentially detrimental
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effects of smoking (8, 584, 605, 611) and insulin antibodies 
(584) on diabetic renal disease were not apparent frcm my cross- 
sectional or longitudinal observations. However I was able to 
show that autoncmic dysfunction could modify both sodium and 
albumin excretion in IDEM. I was only able to speculate as to 
the mechanism behind such observations, but a more recent study 
frcm Lilja et al (765) supports the concept that autoncmic 
neuropathy might modify the natural history of diabetic renal 
disease, and it may be more than coincidental that renal failure 
was the ccmmonest reported cause of death in the study by Ewing 
et al (684) on the outccme in patients with autoncmic neuropathy. 
Furthermore a close association between nephropathy and 
autoncmic neuropathy has considerable implications for the 
management of systemic hypertension in patients with enhanced 
natriuresis and postural hypotension.
As with patients with large vessel disease, the lack of 
association between psychopathology and nephropathy may reflect a 
lack of awareness and concern about the implications of renal 
disease.
Neuropathy: I did not observe any significant alterations in
symptcms or signs of peripheral or autoncmic neuropathy following 
improvements in metabolic control, although poor glycaemic 
control has been linked with neuropathy in several other studies 
(37-40, 640, 651), but this may reflect failure to cross the 
glycaemic threshold suggested by Young et al (40) which would 
have ameliorated the situation.
The most important acccmpaniment of both symptcms and signs
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of peripheral neuropathy was more frequent abnormal anxiety and 
depression ratings. This does not necessarily imply that the 
relationship was one-way, but it appears reasonable to suggest 
that the high level of concern regarding amputation (Chapter 3) 
may have had seme bearing on the psychological response to 
neuropathy.
Impotence: I did not specifically examine the role of ageing, 
glycaemia, ethanol intake, blood pressure and neuropathy in the 
present study, as others have previously testified to the 
independent inpact of these factors on diabetic impotence (714, 
715), but I was able to demonstrate higher depression ratings in 
impotent men, supporting the findings of Cavan et al (547).
Hypoglycaemia: In keeping with ’ reports frcm Dusseldorf f
intensified conventional therapy aided by hcrne blood gluose 
monitoring, was not accompanied by an excess of hypoglycaemia, 
although I did record that frequent hypoglycaemia was associated 
with a higher anxiety rating in the individual, as has been 
previously reported in the relatives of insulin dependent 
diabetics (544).
The work covered in this thesis covered several broad areas 
and understandably I have not reported every finding in detail.
I found that a programme of intensified diabetic management 
with regular access to the hospital could improve and maintain 
metabolic control, educational skills, and attitudes to diabetes, 
apparently without adverse effect other than a temporary increase 
in the number of contacts with health professionals. The
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time course of the study was really too short to evaluate the 
inpact of such a programme on the development and progression of 
complications, although this issue is to be addressed in the much 
larger DCCT study currently underway in the United States (766). 
It would appear frcm the current work that the DCCT and similar 
studies must address the effect of residual endogenous insulin 
secretion on metabolic control and also utilise different 
measures of glycaemic control to resolve fully the controversy 
regarding the role of glycaemia in the development of 
complications.
My studies on lipid metabolism show that 'metabolic control1 
in IDDM plays a relatively small part in determining levels of 
lipids and lipoproteins. Genetic and renal factors made a 
definite impact and hyperlipidaemia was shown to be a significant 
feature of IDDM. This work should provide the basis for further 
research designed in the first instance to demonstrate 
conclusively a build up of IDL in IDDM and to reveal the complete 
range of conformational abnormalities of lipoproteins, and the 
mechanism for dyslipoproteinaemia in early diabetic renal 
disease. Furthermore the evaluation of the relevance of fasting 
lipid estimations to diabetic vascular disease may be 
inappropriate since triglyceride-rich particles may be of vital 
importance, and they are obviously subject to modification by 
dietary intake.
The natural history of diabetic nephropathy and its relation 
to hypertension has still to be clarified, but the current work 
suggests that disturbed autoncmic tone may be of seme importance, 
and further studies of the effects of the autoncmic nervous
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system on renal haemodynamics and tubular function are 
undoubtedly required.
Finally, the impact of diabetic complications on the psyche 
has been underestimated. Those complications were loss of a 
faculty (vision, mobility, potency or consciousness) or of a job, 
which appear to lead to definite adverse changes in psychological 
status. Future programmes of diabetic care should recognise this 
and provide appropriate education and access to psychological 
counselling. Collaborative research in this area between 
diabetologists and psychologists would now appear to be a 
priority.
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rapy
i l i n  -  le ng th  o f  t rea tm ent (years)
F i r s trent I n s u l in  dose: -
a.m.
P#ra.
p.m.
oucoinl
)
\ Before
j  ' t i g h te n in g  up ' 
)
a. in. 
p.m. 
p.m.
A f t e r
' t i g h t e n in g  up'
.1 'exchanges'
re  .‘ Break fa s t  a.m. Jnack Lund: p.m. Lnack Tea/evening meal Supper
r :B re a k fa s t  a.m. Snack Lunch p.m. S n ick  ,Tea/evening meal Supper
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i t i e n t ’ s Assessment o f  Own C o n tro l and Knowledge o f  D iabetes 
p a t i e n t s  Goals
Why do you th in k  i t  is  im portan t to  a ttend  a d ia b e t ic  c l i n i c ?
Give me your own d e f i n i t i o n  o f d iabetes
Provided you fo e ]  w e l l ,  hcvr im portan t do you be lieve  i t  i s  to have as normal an 
average blood glucose le v e l  as poss ib le?
Very / Qui t  e/IJo t a t  a11
a b c
M edica tion
Where is  . in je c t io n  given? ARMS L.EGS BUTTOCKS A BDPME;
Do you ro ta te  s i te s ?  . . . . .
Any lumps o r  p i t t im r  a t  s i te s ?  ................ ................
Who g i v ]Q yon r  in je c  t io n ?   • • . ...........................
Does anyone e lse  in  your fa m i ly  know how to  g ive  you r  in je c t io n s ?
Where do you keep your in s u l in ?  • ..............
What type o f  equipment do you use? Glass . „ ............ How do you care f o r  i t ? . . . . . . .
D is p o s a b le   ...........
Do you have any d i f f i c u l t y  drawing up the c o r re c t  amount o f  i n s u l i n  o r  g i v in g  the 
in je c t io n ?  ............ • < . .» • . .» •• • ...............  •
Show me e x a c t ly  how you draw tip arid g ive  your i n j e c t i o n .
Exerc ise : Type o f  a c t i v i t y
Hom ing:.............................................. ................ ................. ..
A fte rnoon :  . . . • • •
Evening:.............................................. ................ ...................
What are you r  usua l hours o f  sleep? . . • • • • • • • »
How does your schedule vary from day to  day?
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Diet H in tp ry
Are you fo l lo w in g  a c e r ta in  number o f c a l o r i e s ?  . . . . . . . . . . . . . . . . . . . . . . ..................
How many ? . . . . . ....................• •
Have you had diet, in s t r u c t io n  in  the past? . . . . . . . . . ....................................................................
Do you eat th ree  meals a d a y ? .............. . . . . .
Do you eat between m e a ls ? ....................
Who pre p i res your m e a Is ? ..............
How o f te n  do you eat out? 0#
Where do you eat out? . . o . o o . o . . 0 0 . < . . . . . . ......................................................... .....................
What times o f  day do you eat? . . . . . . c o . o * .  • ....................................................................
. I f  •: -.eluded in  you r  rneal p lan , i s  i t  p r a c t ic a l  to  eat n tse.'-t * -ig, a f  tcrriooa and oven; 
snack? I f  n o t ,  why not?
Why do you eat?
Good n u t r i t i o n   ................................. F ru s t ra t io n   ......................................
Hunger  .................. .............................................  D e p re s s io n ..........................................................
To please o thers   ............. . ............. Boredom ..................................................... ..
S o c ia l  o b l ig a t io n   ........... ..
Do you eat : M i lk  . . . . .< > . .o o  Fresh f r u i t  . . . . • • • » • •  Vegetables ...................................
Fggs . . . . . . . o . o  M eat/F ish  ..White/Wholemeal B r e a d . . . . . . . . . . . .
How w e l l  do you th in k  your d iabe tes  has been c o n t ro l le d  d u r in g  the  past year? ( c i r c l t
E x c e l le n t ,  good, f a i r ,  t e r r i b l e
Urine te s t in g
Do you check your u r in e  fo r  sugar? . . . . . . . . . . o . . .
t/hat method do you use? C l i n i s t i x  • • • • • • « • •  • <>•• •
D ia s t ix
Glinitest  .......
How o f te n  do you to s t?   ..........   *
Do you te s t  before o r  a f t e r  meals?
Do you ompty your b ladder f i r s t ,  vo id  a f t e r  1 ‘J — 30 mine, l a t e r  and t e s t  the second 
specimen? • <,<>•.•••«.................. •  *
Show me ( o r  t e l l  me) how you check you r  u r in e    ....................................
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Do you check for acetone or ketones?  ...............V/hen ? ................
Show me (o r  t o l l  ure ) how you check fo r  th is   ........... ................................................ . *<
Do you record your lo o t r e s u l t s ? ........... • • • • •
Mont common re s u lt?  0, 4-, 1 , 12,-'
Hood Sugar R egu la tion
(a) Low b lood sugar ( hypog 1 yeaoa ia )
Dame o symptoms ol iow blood sugur • • • • • • • • • • • • o * * * *  • * • • • » • « • • • • • » • • • • * • • « • • • • • • • •
Have you ever had symptoms o f low b lood sugar?
ilow o fte n  do you take hypos? ( d a i ly ,  weekly, m onth ly, le a s  o fte n )  ( C ir c le )
What time o f day? M orning A fte rn oon  live n in g  N ig h t ( C ir c le )
What symptoms d id  you have?
W h a t a c t io n  d 3. d v o u a ke r » o * o o « e* * o * oo * * * * * * « * * o * o«o* o * * * * oo * o * oo * * * * * * * * * * * * « * * *
Why do you th in k  these re a c tio n s  occurred? • „• * ••<> •©«>•••• • ......... ......................
Can you t o l l  when you are going hypo in  time to  take a c t io n  -  a lw ays, u s u a lly ,  nex
( c i r c le )
Do you always ca rry  some form o f  sugar on you fo r  emergencies?  ......................   •
Wli-l t  ty  |^e?
Do you always have some form  o f  d ia b e t ic  id e n t i f ic a t io n  w ith  you? • • • • • • • • • • • • • • • «
V/hat is  glucagon?  ......... .............................. * , ....................................... .............
b) H igh blood sugar ^Qryrerg.lyc^ycjnia^
What is  k e to a c id o s is ?  , , . *  „ „*  ..........................» . * • • • • • • • * • • • • • • • • • • • • • • • • • • • • • • • «
Have you even been in  ke to a c id o s is?
Name 5 symptoms o f ke toac idos is?  . 1 * . * . * • • •
Do you ever show ketones in  you r u rin e ?   ..........   • » • • • • • • • * .  « • • • • * . . « • ................. ..
When was the la s t  tim e they appeared in  your u r in e ?
V/hat do you do i f  you become i l l ? *  • • • • • • * »   ......... ................................................ ..
What symptoms o f  h igh  blood sugar have you had?  ................ .....................................................
Why do you th in k  you had a k e to a c id o t ic  episode? • • • • • • * • • « • • « • • • • • • • • • • • • • » • • • • • •
What a c tio n  d id  you take?  ............................................
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Do you fe e l th a t you have accepted the f ac t  th a t you have d ia b e te s ? ........................ ..
In  what ways? ............................................................ ............................................................ ..
Do you fe e l depressed, h o s t i le ,  fe a r fu l  o r aiw;ry about having d ia b e te s ? (c ir c le )
Do you have any s p e c ia l concerns about d ia b e t ic  c o m p lica tio n s? ..................................... • ••♦
Have you had a s i . ^ i i i i c a n t  lo ss , or change in  your l i f e  o r  fa m ily  l i f e  in  the  past 
one to  two years?
Death .................     Hove     R e t ire m e n t ............ ..
D ivorce .................. S epara tion   Loss o f  Job
Change o f jo b  . . . . . .  O ther • • • • • • • • • • ........... .....................
!:.ad a se riou s  . il ln e s s  o r in ju r y  in  past 1 -  2 years 
Do you know anyone e lse  who has d iabetes?
How many days o f work o r  schoo l have you missed in  the past ye a r due to  d iabe tes?
006000000 '
Reasons  ...........  • • • • . . ,
Have you been hospi tn lin e d  f o r  you r d ia b e te s ?  .
When? .....................................................................................
Circumstances? . ......................................................................
Do you examine you r fe e t each day? .........................
How? ......................................................................................................... .
Why do you th in k  fo o t care is  im p o rta n t f o r  d ia b e tic s ?
a c tive  Measurements -  be fore  't ig h te n in g  up *
i.) ?A hour u r in e  glucose  ........................................  n /m o l 24h (d a te ) ........................... ..
Snot u r in e  A lb u s t ix  mg/lOO ml (date.). ## ## # # # #. . . . . . . .
C -a
24 hour u rin e  a lb u m in . . . . . . . ........................ m?J (d a y ) . . , , .m g/ 'n i g h t ) .
24 hour u r in e  m ic roa l hundnurea (s tu ra g e ) .  . .  . * XQ lJA i;.............  .....................
Serum urea 99 ..m M o l/L  U rine  C re a tin in e  . . . . . . .m M ol/24hr
Serura c re a t in in e  » > • » • • • » • • • « . • « • » • • • •  .m K o l/ C re a tin in e  c le a r ................... mL/min.
Fast.: n& serum ch b o re s te ro l • • • • » • » » • • • • » . * • • .
f a s t  inf.; serum T r ig ly c e r id e .................. ..
C p e p ti ie  le v e ls  p o s tp ra n d ia l ( s e n t ) . ♦ * . . . . .
L ip o n ro te in a  HDL  ............................................. )
AP0B........  mg/DL \
D D L..........................................................)
!ii)L;> ....................................................... )
HDL3 ........................................................ ...
Home blood glucose profile (mHol/l,)
Hreakfu; i t Lunch Tea /D inner L
0 1 2h 0 1 2h 0 1 ?h
I n i t i a l
End o f ’ t ig h t ­
en ing  up ’ ’ ’
-  lib A^c -  basal 
“  (J. o . A. -  basal
. A liq u o ts  o f u r in e  (2 x *3 ml) 
in  deep fre e sc .
(b e fo re  ’ t ig h te n in g  u p 1)
"c (be fo re  ' t ig h te n in g  u p ' ) 
g lucose meter t r i a l  box on 5 day ward, to  be ke j
o c ia l C ircum stances:-
ecupation  ....................................................................................................... S o c ia l "C lass"
a r i t a l  s t a t e ........... . ................... ...........................
h i ld rc n  (ages)  „ . 0. o . . . o .......... 0. o « . . . . . . .
t t i t u d e  to d iabe tes  o f p a rtn e r  ....................
i. t i  tude to  d iabe tes  o f paren ts ................. .................................................................... ..
ticking: C ig a re tte s  (number per day) . . . . .
Pipe (ounces o f tobacco per week) ••••••«••• ,None 0
) M iId  1
lc o h o l: Type  „ o . . oo Amount . . . • « • • • «  .<> • o ••  o . . .  .(M oderate 2
(Excess ive  3
rugs :  ................ ............................... ..
\"l M edical H is to ry  ., 
Mu:r re le v a n t d e ta i ls
.a b e tic  S is te r ’ s E duca tiona l Assessment: (E x c e lle n t Good F a ir  Poor T e r r ib l
G eneral In s u lin  
I n je c t io  n/i)o sa ge
Hypos Use o f 
Glucagon
D ie t E x e rc is e I l l n
up ’
up ’
.cim iaues: In s u lin  In je c t io n U rine  te s t in g  
( d ia s t ix )
B lood g lucose  m o n ito r in g
’ t ig h te n in g  u p ’
’ t ig h te n in g  up*
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D o c to r’ s assessment o f probable b lood flu/^ar c o n tro l in  f^ast y ear
E xce llen  t  
1
l . ln ic a l d ta to
ird to v a s c u la r
Cardiac
P eri phc ra l 
V ascu la r
AN3
s o ira to rv
i r o l o g ic a l
-e r i  phcra l 
Jenrooathy
>t r o ke 
) th e r
is u a l
Good
o
i*ai r  
'5
Poor
4
Terrible
Symptoms
(O-none, 1~m ild, 
2-!nod. , i-s e v e re )
Angina 
Dyn i.'.-iooi
Leg -sk in  ischaemic 
C la u d ic n tio n  
Hypotons ion 
Oedema
E re c t i lo 
impo tonee
Ref ract  ive 
problems 
poor c o n tro l?
O ther
Physj ca 1 S ir.ns 
l e r j  phcra l V ascu la r 
Femoral 
F o p li te a l 
root Tib,
Jors. fed.
SBP/ DBP
©
• B r u it
Q
A No SCORE
Cough
Pa.racs thes.iae
BP ly in g  
s tand ing  
?. handgrip
>.* HI v a r i a t i o n  wi t h  deep b re a th in g  
4., HR sta.adinf; 
b. HR v a ls a lv a
TOTAL
Cher t :
C o n d itio n  o f Feet
R L
P 1 2 3
- — 4- ++ + -H
Ankle Jerks
a
V hrn.Tense 
Fine Touch 
F in P r ic k
A c u ity  (s n e lla n a )
w ith  g lasses
C a ta rac t 
(0 - 4)
Fundoscopy 
(0  -  4 each)
Mi c roa ne u ry  sin s
Haema
Exudates
Hew V esse ls
Ret .  p ro li fe ra n a
Op th a lra o lo g ic a l 
assessment (d a te )
Op tha lrno lo g i ca 1 
trea tm en t (d a te )
1 ha p i 1 la  r  y Reac t  i  on:
©
24 HOUR URINE vJn] ,L?v.M' I ON
DAY T.iF.E : From ........................ Uni. i i  ......................... Volume
NIGHT TIME: F ro m ........................ U n t i l    Volume
TOi'A.L 24 HOUR VOLUME Volume
ml  -v 24 Hour u r in e  flucoue
2 x r3 m l m icron 1 bumi n u ria
Renidual volume  ----- -> 24 hour c re a t in in e  c learance
CXR
EGG
( - M )
( - ‘3ml)
( - cjm l)
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enal P o ly u r ia  
Nooturia 
Dyuu r i.a 
T n fuo i: i orin
Me te r Lab.
Corel 1 a t i o r  Ju ra r
lUinnI ThreshoLd'1 U rine Blood
;y c ho logy (separate pro f  i !•:; shoot)
eck J j in t  
T r ia l  Onset :
as oat Lent undorataud t he natuit? o f the t r i a l ,  and th a t there  is  an equal chance th a t
... w i l l  be a llo c a te d  to  glucose meter o r c o n tro l ^rouns fo r  one year? Y33/H0
ce c o - t r o l  Juis Jpeen irnp.’ o’/'n l as rinch as pract i c a b l e , wi t h short - te rm  use o f  a l l  mean a 
al Ltvble .  the p a t ie n t in  r eady t o bo i.nc la ded in  t ’.e t r i a l .
rrdc Have you -  Couple ted t r i a l  document?
-  Completed W duoa tion /re -educa tion?
-  ?4h u r in e  Glucose -  c o lle c te d  sample -  deepfreeze on I'M?
-  UbiVIc -  sent sample to  lab?
-  Chocked Baseline 1 0 -p o in t p r o f i le  -  and optim ised trea tm en t?
-  Chocked Blood g lucose) .
,1, < in ,  ^ tecun ique r-  Chocked ! urine gl ucose)
l e n t1a Concent
. 6o . . . . . . . .................    o • .agree to  take p a rt in  the S a lfo rd  blood, g lucose m onito:
a l ,  the nature o f which bar. b<on exp la ined  to me oy h r .......................
'■> i  g n e d   .................
W i tn ess  ................ ..
•> t a n d i n g •' ro b 1 c m a
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ONE XEAR GLUCOSE METER TRJ./lL FOLLOW-UP . DOCUMENT
krnaK9  .......... *.   Fir a t Names
IPX No * / d&te of Birth »<>.••••••• e»o*«e**
)at:e of Completion of Form • • ••••««
Sex
nsulin dosage
Case Number
Trial Number ... Grouj
Weight*• .<>. • •.......   Kg.
?otal contacts with hospital/clinic in 1 year 
?otal visits to hospital/clinic in 1 year:- 
Fotal days of work in 1 year:- 
Bu9 to diabetes:- 
Due to other causes:-
lypo attacks:- monthly rate over last 3 months * co ...... .« *o.eo
LINGER PRICK PROFILES:-
/jonth
1
Own
Kean BS/MUS
Results
f b s/f u s. M Value
Lai 
Mean BS
) Resul
■1 — 1 (I’ll +MV3M «■
FBS
j/ts
M Value
Paired , 
Number
\nal;
Cji-
at;Suitable
2 V
3 ‘
4
\
5
•
6
7
i
8
. -9
10
11
----------
12
i l l
TWO YEAR GLUCOSE METER TRIAL FOLLOW-UP DOCUMENT
| r»
irnarne  ...................   First Names.............. j...........Sex *
FI
’I No./date of Birth........... . Case Number ..•••••••
Lte of Completion of F o r m ........................  Trial Number •••••••• Group
Veight ..........   Kg.
s u lin  Dosage .............................. .
>tal contacts with hospital/clinic in 1 year:-  ............ .
>tal visits to hospital/clinic in 1 year:-
>tal days offwork in 1 year:-.................. ...........
Due to diabetes:-
Due to other causes:- ...... .
rpo attacks:- monthly rate over last 3 months   ..... .............
[NGSR PRICK PROFILES: -
Dnth Own Results Lab Results . Paired Analysis
1
Mean BS/KUS fbs/fus K Value Kean B3 FBS M Value Numbe r Correl
/
Suitable ation
2
3 <
4
5
6
7
8
*
9
10
11
12 *
33T1
i
-2-
!4h Urine Glucose
[h&1c    Glycosylated Albumen
'pot urine albustix......    (mg/lOOml)
!4 hour urine proteinuria TOTAL
CONGN
Correlation Blood Sugar ...Meter
....Labi
!4 hour urine microalbuminuria DAY
NIGHT
TOTAL
ierum Urea >mmol/L Urine creatinine
Jerum creatinine .....   .^ Iraol/L Urine creatinine
ireatinine clearance ........mmol/min.
V
,mmol/L
TOTAL
(mmol/24 hr
'asting serum triglyceride
lasting serum cholesterol
jDL
[DL
[DL, mmol/L
[DL-
j
lPOB m,g/DL.
J
JPeptide .....o. pmmol/mL
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-3-
total ’exchanges1
Breakfast a.m. Snack Lunch p.m. Sr.ack Tea/Evening meal Supper
ring: cigarettes per day Stopped smoking (Yes/lTo) ..........
pipe tobacco Jounces’per week • ••••
)hol: type......................   amount............. (none 0, mild 1,
moderate 2, excess. 3)
cs:
»ar Educational assessment by staff (Excellent 1, Good 2, Fair 3, Poor 4, Terrible 5)
General Insulin Hypos Use of Diet Exercise Illness
In.iection/Dosage Glucagon
Techniques: Insulin Injection Urine Testing or Blood glucose monitoring
(diastixT
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Joctor^s assessment of probably blood sugar control in past year
Excellent Good Fair Poor Terrible
1 2 3 4 5
Linical State Symptoms Physical Signs *Bruit
(0 - none, 1 - mild,
2 - mod., 3 - severe Peripheral Vasculai 
Femoral
R L
)vascular Popliteal •
Cardiac Angina
Dyspnoea
Post Tib. 
Dors. Ped.
)heral
;cular
Leg-skin ischaemic 
Claudication 
Hypotension 
Oedema
SBP/ DBP
BP lying
1.standing
2.handgrip
ANS SCORE
3.HR variation with deep brthing
T.HR standing
ANS Erectile
Impotence
5.HR valsalva
TOTAL:
*atory Cough Chest
Logical Condition of Feet (2) 0
Lpheral
ropathy
)ke
?r
Paraesthesiae
Weakness
R
0 1
Ankle Oerks 
Vbrn. Sense 
Fine Touch 
Pin Prick
2
++
L
3+++
jal Refractive 
problems 
poor control?
Other
Acuity (snellans)
with glasses 
Cataract 
(0 - 4)
Fundoscopy 
(0 - 4 each)
Haems
Exudates
New Vessels
R L
4
i l Polyuria
Polydypsia
Nocturia
Dysuria
Infections
! 7
Ret. proliferans
Opthalmological . 
Assessment (date)
Opthalmological 
Treatment (date)
Pupillary Reaction:
>40
-  5 -
24 HOUR URINE COLLECTION:
DAY TIME: From  ......... Until............. Volume ...
NIGHT TIME: From   Until......  Volume ...
TOTAL 24 HOUR VOLUME Volume ...
5 ml------ L:-----^24 hour urine glucose
2 x 5  ml------- ^microalbuminuria
Residual volume 24 hour creatinine clearance
CXR
ECG
(- 5 ml) 
(- 5 ml)
(- 5 ml)
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METER GROUP - 1 YEAR QUESTIONNAIRE
) Do you feel that blood testing is more accurate than urine testing? IBS / NO
) Do you feel tliat blood testing is more helpful than urine testing? YSS / NO
) Do you wish to continue blood testing? YES / NO
If NO we will return you to urine testing * filter papers.
If YES *
) Would you be prepared to pay for the purchase of a meter if (a) sticle could be
provided by the 
hospital
(b) sticks were not 
provided by the 
hospital
NOT
) Would you be prepared to enter the 2nd year of the study with a further equal
chance of entering one of two groups
either using the meter (Group 1) or BP1 sticks alone (Group 2) in conjunction
with filter papers to check which is most accurate for a 6 month peridd in each 
group.
r / G C n
.8.84.
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1^ 0 ' I
im rrm Krnow n fo r  q u e s tio n s : below is  a i . is r  o f  th e  ways you H.tuirr have
FELT on tlEHAVEl). IT,EASE TELL ME HOW OFTEN YOU HAVE FELT THIS WAY DURING 
THE PAST WEEK.
f
Rarely or 
none of the 
time (loss 
than 1 day)
Some or a 
little of 
the time 
(1-2 days)
Occasional ]y 
or a moderate 
amount of time 
(3-4 days)
Most of 
the time
(5-7 daya)
I feel down-hearted and 
sad 0 2 3
Morning .in when I feel 
the best 0 2 3
I have crying spells or 
feel like it 0 2 3
J have trouble getting 
to sleep at night 0 2 3
I feel that nobody cares 0 2 3
1 eat as much as I used 
to (1 2 3
I still enjoy sex 0 2 3
I notice that 1 am 
losing weight 0 2 3
I have trouble with 
constipation 0 2 3
My heart beats Printer 
than usue L 0 2 3
I get tired for no 
reason 0 2 3
My mind in nr*, clear an 
i t used to be 0 2 3
I tend to woke up too 
early 0 2 3
1 find it racy to do 
the things I used to 0 nr„ 3
I am restless and can *b 
keep still 0 o€. 3
1 feel hopeful about 
the future 0 2 3
1 a m  more .irritable 
than usual 0 2 3
.1 find it easy to make 
decisions 0 2 3
1 feel quite guilty 0 2 3
I feel that I am useful 
and needed 0 2 3
My life is pretty full 0 2 3
I feel that others 
would be better off if 
1 were dead 0 . 2 3
1 still enjoy the 
things I used to 0 2 3
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*elow are ft u w Sx t  of statements about health and illness. Each item is a 
rtatement frith Which you may agree or disagree. Underneath the statement la a 
*nele which goes from ’Strongly Disagree* to ’Strongly Agree’ Would you 
rend the etat«M*nt. Then decide What you feel about it, Deoide whether you 
*gree or difttsgree with it. Decide how etrongly you feel about it one way or 
the other. Then put a circle round one of the alternatives underneath it.
fere in m enomple of ft question and an mower:
M  feel healthier in the summer than I do in the winter*11
Strongly Moderately Slightly ^lightly\ Moderately Strongly
Disagree: ..Disagree: Disagree: VjAgreet^x Agree: Agree:
Flease answer eaoh statement carefully. But do not spend too much time on 
any one item. Try to answer each statement separately. When choosing your 
answer do not be influenced by your earlier choices. Answer in the way that 
explains how you feel about the statements.
Thank you
1. If I get pick, it ie my own behaviour which determines how soon 
I will get well again.
Strongly
Disagree:
Moderately
Disagree:
Slightly Slightly 
Disagree: Agree: -
Moderately Strongly 
Agree: Agree:
2. Wo atatter frtiat I do, if I era going to get sick, I will get siok.
Strongly Moderately Slightly 81ightly Moderately Strongly
Dioagree: Disagree: Disagree: Agree: Agree: Agree:
3. Saving regular contact with my dootor is the best way for me 
to avoid illness.
Strongly
Disagree:
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
Moderately
Agree:
4. Most things that effect my health happen to me by accident.
Strongly
Disagree:
Moderately
Disegree:
Slightly
Disagree:
Slightly
Agree:
Moderately
Agree:
Strongly
Agree:
Strongly
Agree:
5. Whenever I don't feel well, I should consult a medically trained 
professional.
Strongly
Disagree:
Moderately
Disagree:
ilightly
Disagree: 
6. I era in control of my health.
Strongly 
Dioagree:
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
Slightly
Agree:
Moderately
Agree:
Moderately
Agree:
Strongly
Agree:
Strongly
Agree:
My family has a lot to do with my becoming sick or staying healthy.
Strongly
Disagree:
Moderately
Disagree:
Slightly
Disagree:
8. When I get sick I am to blame.
Strongly
Disagree:
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
Slightly
Agree:
Moderately Strongly
Agree:
Moderately
Agree:
Agree:
Strongly
Agree:
9. Duck ploys a big part in determining how soon I will recover from 
an ilinoss.
.Strongly
Disagree
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
10. Health professionals control my health.
S trongly 
Disagree:
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
Moderately
Agree:
Moderately
Agree:
Strongly
Agree:
Strongly
Agree:
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1. My good health is largely a matter of good fortune.
trongly
Isagree:
Moderately
Disagree:
Slightly
Disagree:
Slightly
Agree:
Moderately
Agree:
2. The main thing which affects my health is what I myself do.
trongly Moderately Slightly Slightly Moderately
Usagret: Disagree: Disagree: Agree: Agree:
3. If I take care of myself, I can avoid illness.
Wrongly Moderately Slightly Slightly Moderately
disagree: Disagree: Disagree: Agree: Agree:
Strongly
Agree:
Strongly
Agree:
Strongly
Agree:
4. When I recover from an illness, it's usually because other people 
(for example, doctors, nurses, family, friends) have been taking 
good oare of me.
J trongly Moderately 'lightly Slightly
Agree:liragree: Disagree: Disagree:
15* Wo matter what I do, I'm likely to get sick.
Strongly Moderately Slightly Slightly
Disagree: Disagree: Disagree: Agree:
16. If it's meant to be, I will stay healthy.
Strongly Moderately Slightly Slightly
Disagree: Disagree: Disagree: Agree:
Moderately
Agree:
Moderately
Agree:
Moderately
Agree:
17. If I take the right actions, I can a toy healthy
Strongly Moderately Slightly Slightly Moderately
Disagree: Disagree: Disagree: Agree: Agree:
Strongly
Agree:
Strongly
Agree:
Strongly
Agree:
Strongly
Agree:
IB. Regarding my health, I can only do what my doctor tells me to do.
Strongly Moderately Slightly Slightly Moderately Strongly
Disagree: Pisagree: Disagree: Agree: Agree: Agree:
.19* Generally I don't bdherabout trying to protect my health.
Strongly Moderately Slightly
Disagree: Disagree: Diaagree:
20. I really try to avoid illness
Strongly Moderately Slightly
Disagree: Disagree: Disagree:
21. I work at keeping healthy and fit.
'-■'-v.. Jloderately Slightly
Dioegree:
Slightly
Agree:
Slightly
Agree:
Slightly
Agree:
Moderately
Agree:
Moderately
Agree:
Moderately
Agree:
Strongly
Agree:
Strongly
Agree:
Strongly
Agree:
(Form E-F 1 3 72)
sun©. . . . . . . . . . . . . . . ... . . . .. . . . . . . . . . . . . . . . . . . . . . .
5©  ....................... Sex  .........Date  ...... .
Detractions: The following are some statements on feelings!
*ydrcams, attitudes, and behaviour. Head each statement and 
»cide how ofton it applies to you;
Ircle *1* if the statement nover applies to you;
*5* if experience it almost all of the time; 
ia *2', *3* and **♦' for inbetween ratings.
Nover c 1 
Rarely c 2 
Sometimes e 3 
Fairly often » 4 
Nearly always ss 5
few itmes may be difficult to answer by checking frequencies, 
or these, you may indicate how true or false the item is for you by 
sing 'I' for "Definitely False", '3' for "Questionable", *5* f°r 
Definitely True", and '2' and *V for inbetween ratings.
i
\
e honest, but do not spend too much time over any one statement. 
b  a rule, first impressions are as accurate an any. 
re there any questions?
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2
i
Nover » 1 
Rarely = 2 
Somotimea =» 3 
Fairly often « ** 
Nearly always = 5
• I am an easy going person 1 2  3'**
•• I have sensations of burning, tingling, or crawling 1 2  3**
in certain parts of my body
• I feel chilly at temperatures that-are comfortable to 1 2  3**
others
M y feelings are easily hurt 1 2  3**
. I am either too hot or too cold and cannot get 1 2  3**
comfortable at a constant temperature setting
I have trouble getting my breath for no special reason 1 2 3**
M y mouth feels dry 1 2  3**
I have feeli.r.g3 of panic for no special reason 1 2 3 **
• I have pounding headaches in which I can feel a- 1 2  3**
definite beat
D. I am a relaxed person 1 2 3 r
1. I cleftch my teeth v/hen anxious 1 2  3**
2. I am troubled by discomfort in tho pit of rny stomach 1 2  3**
3. 1 v/orry about little things 1 2  3**
**. I have a hard time swallowing 1 2  3**
5- I become upset when I have to wait •> 1 2  3**
6. My skin becomes painfully sensitive 1 2  3**
7- I notice my heart pounding 1 2  3**
8. I take things hard 1 2  3**
9 I grind rny teeth in my sleep 1 2  3**
0; I am bothored with blushing ' 1 2  3**
1 I cun troubled by tension interfering v/ith my speech 1 2  3**
2 My finger tips or other extremities become cold 1 2  3**
3. I bocomirirritable about little things 1 2  3**
2
3
3
3
5
3
5
5
3
3
5
5
3
3
5
3
5
3
3
3
3
3
5
5
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324. I have pressure headaches in which my head feels as 1 2  3 *1 3
if it were in a vice, or as if thero were a tight 
hand around it
25* When embarrassed, I break out in a sweat which annoys 
mo greatly
26. I take tilings in my stride
2.7* I have trouble with my hand shaking while I write
28. I would rather win than lose in a game
29. X am troubled with diarrhoea
30* I have pains in the back of my neck
31. I suddenly feel hot fill over, without apparent cause
32. I am troubled with backaches 
33- X am a nervous person
34. In the absence of physical action my heart beats 
rapidly
33- My hand shakes when I try to do come tiling 
36. I have stomach trouble
37* I go to sleep without thoughts bothering me
38. My head feeds tender to the point that it hurts 
when .1 comb my hair or put cn a licit
39• My sleep is fitful and disturbed
40. The muscles of rny neck ache as if they v/ere tied in knots
41. I feel that I am about to go to pieces
42. I am easily frightened
43. I have frightening dreams
44. I have trouble with muscles twitching and jumping
45. I am bothered by dizziness
Have you completed all itoms'
1 2 3 4 3
1 2 3 4 3
1 2 3 3
1 2 3 5
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
1 2 3 3
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(diHcicnl winding !<>r (lie Male Vcision is pivcn ;i( (lie end of Hie Appendix)
'< heck’ indicates that this wotd should he wiiltcn on the back of the catd: the opeiator denis with these three 
raids accniding to the 'inslmctions lor tisets*. (*+) indicates that a maik is put on (lie hack of the card to 
show that it goes lluough to the lesislancc ami inlet let encc stapes.
SVMt’IOM ours t ions 
j'lioupbts
1. Aic you often imvaidly compelled to do certain 
things even though your tcason tells you it is not 
nccessaiy? (Check)
2. Do unpleasant or frightening thoughts or woids 
:vei keep going over and over in your mind ? (Check)
3. Do you ever have persistent imaginings that your 
•hildien or hushaud might he having an accident or 
that something might have happened to them 7 (+f)
I. Have you ever heen liouhled hy ccilain thoughts 
:u ideas of hatmiug youtself or persons in your 
amily thoughts which come and go without any 
>at(icular tcason 7 (**)
[ ’becking
>. Do you often have to check things several limes? 
». Do you ever have to check gas or water taps or 
iglil switches after you have altcady Ini tied them 
ill ? (♦♦)
Do you ever have to go hack and check doois, 
nphoatds or windows to make sutc (hat they ate 
rally shut ? (**)
)irf iim l cmifmnintifimi 
. Do you hate diit and ditty things?
. Do you ever feel that if something has heen used,
touched or knocked by someone else it is in some 
way spoiled for yon ? (**)
10. Do you dislike brushing against people or being 
touched in any way? (**)
11. Do you feel that even a slight contact with bodily 
sectetions (such as sweat, saliva, urine, etc.) is 
unpleasant or dangerous, or liable to contaminate 
your clothes or belongings? (**)
12. Do you worry if yon go tluough a day without 
having your bowels open ?
Donp n  ous objects
13. Ate you ever wot tied by the thoughts of pins, 
needles, or hits of hair that might have been left 
lying a bout 7 (**)
M. Do you worry about household things that might 
chip or splinter if they were (o be knocked or 
biokcn?!**)
15. Does the sight of knives, hammers, hatchets, or 
other possibly dangerous things in your home ever 
upset yon or make you feel nervous ?(**)
I'crsonol cleanliness and tidiness
1(5. Do you tend to worry a bit about personal
cleanliness or tidiness?
17. Arc you fussy about keeping your hands clean? 
(")
62 John Cooper
MR. Do yon ever wash and iioo clothes when (hey 
me nol obviously iliity in onlcr to keep (hem cxtia 
clean and bosh ? !44)
19. Do you (akc erne flint (lie dollies yon aic 
wealing me always clean and ncal, whalcver you arc 
doing? (**)
20. Do yon like (o put your personal belongings in 
sc( places or pallcrns? (44)
21. Do you lake gical caie in hanging and folding 
your clothes a( niglit ? !44)
Household eleonliness and tidiness
*22. Arc you very strict about keeping (lie house
always very clean and lidy? !44)
2.1. Do you dislike having a room untidy or not 
quite clean Tor even a short time?!44)
24. Do you sometimes get angry that children spoil 
your nice clean and lidy rooms?
25. Do you like furniture or ornaments (o be in 
exactly the same place always? (**)
26. Do your easy chairs have cushions which you 
like to keep exactly in position ?
27. If you notice any bits or specks on the floor or 
furniture do you have to remove them at once before 
you me due to clean round?!44)
28. Do you ever clean or dust the rooms that haven't 
had lime to get ditty, just to make sine that they aie 
leally clean? (**)
29. Do you ever have to dust, sweep, or wash things 
over again scvcial times just to make smc they are 
leally clean? (**)
Order and routine
30. Do you have to keep to stiicl timetables or 
routines for doing ordinary things? (44)
31. Do you have to keep a certain order lor undres­
sing and dressing, or washing and bathing?!44)
*32. Do you get a hit upset iT you cannot do your 
housework at set times or in a certain order? ( * * )
Repetition
33. Do you ever have to do things over again a 
certain number of times befoie they seem quite 
right ?(**)
31. Do you ever have to count things scvcial times 
or go through numbers in your mind ? (44)
*35. Do you ever get behind with (he housework 
because you have to do something over again several 
times? (**)
Over-const icnfiousnrss and hu h o j satisfaction
36. Aie you a pci son who often has a guilty con­
science over quite oidinary things?
37. Arc you the soil of pci son who has to pay n 
great deal of attention to details?!44)
38. Are you ever over-conscientious or very strict 
with yourself ?
39. Do you ever waste lime by doing a thing more 
thoroughly than is ically necessary just to see it is 
leally finished ? (44)
40. flven when you have done something carefully, 
do you often feel that it is somehow not quite right 
incomplete?!44)
41. Do you feel unsettled or guilty if you haven’t 
been able to do something exactly as you would 
like?!44)
42. Do you always fail to explain things properly, in 
spile of having planned beforehand exactly what to 
say?
Indecision
43. Do you have dillicully in making up your 
mind?!44)
44. .Doyou have to turn things over and over in your 
mind for a long time before being able to decide 
about what to do?!44)
45. Do you ask yotusclf questions or have doubts 
about a lot of things you do? !44)
46. Are there any particular things that you try to 
keep away fiom or that you avoid doing, because 
you know that you would he upset by them? !44) 
(Check)
III All r)i ms I IONS 
Hoarding
47. Do you find it difficult to throw things aivay?!44)
48. Do you keep rather a lot of empty boxes, paper 
hags, old newspapcis, or empty tins in case they 
come in useful one day? (44)
449. Does your stock of soap, detergents, or clean­
ing mrtlciiuls ever gel large because you find yourself 
buying moie than you actually rise?
C 'leanUness
50. Do you regard cleanliness as a virtue in itself?
Meanness
51. Do you gel more pleasure from saving money 
than from spending it?
52. Are you more careful with money than most 
people you know?
53. Do you keep regular accounts of the money you 
spend every day?
Irritab le  and morose
54. Do you usually look on the gloomy side of 
things?
55. Do people oltcn get on your nerves and make you 
feel irritable?
56. When you feel critical of someone, do you 
usually say what you are thinking?
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'7 . Do \(mi pel angry "i i11iI;t(r(1 if people don't do 
tilings carefully oi coiircllv7
the it!it y
5R. Ho )oo liy fo avoid changes in yom house or 
work or in flic way \ou do things?
5’k Do you liy lo nvoitl dumping yom niiml once 
uni listve made :i decision about something7 
fid. Aie you :i prison uliu likes fo slick lo principles 
nnd decisions whale\rt fhe opposition oi dilliculfir.s? 
61. Do you pride yom self on thinking tilings over 
very cnielnlly helmc making decisions 7
Health
67. Dn ynn think Ili:if icgttlat dnily bowel inoveinenls 
sue inipni Innl lor yom health?
63. Do you ollen pel scared fh:d you iniphf he 
devclopinp some soil of sciions illness oi esmccr 7
Ihy.nhnity
fil. Aie you veiy systematic siud mefliodicsd in your 
dsiily life ?
6*>. Do you like lo pel liiinps done cxsiclly lipid, 
down lo the similes! detail 7
(ifi. Do you lliink il is iinpmlsud lo follow Miles and 
regulations exactly 7
*67. Do you like lo lisivc scl limes or oideis for 
doinp yom household jobs?
I ’unefnnlity
6R. Aie you cvci Isile hecsuise you jusl csm’l seem lo 
gel (hiough eveiylhinp in lime?(**)
69. If  you have lo calch a liain or keep an impoilanl 
appoinlmenl, do you have lo plan mil how lo do il 
hcloichand in gieal delail 7 (**)
( I I ANMI S I N WtMMMNf!  I Oi l  MAI I" v r U S I O N  
IR. Ilecomes: Do you e.vei ask lo have clothes 
washed or cleaned lhal aie uol 
obviously diily in otdei hr keep llicm 
exit a dean and ficsh? (**)
72. becomes: Aie you sliicl ahoul (lie house always 
being kepi veiy clean and lidy?
28. Ilecomes: Do you ollen do any dusting or 
cleaning al home wilhoul heing asked 
lodoso7(ff)
77). Ilecomes: Do you evei have lo clean or wash 
filings ovci ag.aiu scvcial limes jusl lo 
make smc lliey aie ically clean? (**)
j- .Substitute‘woik’Tor’housework’.
•19. Omil
67. Ilecomes: Do you like lo have scl limes or 
orders for doinp your woik?
01 IIS IIOIJ.S OMIIIPI)
I lie following questions wcic in (he fust veision used, 
hul ueie omilled nflei approximately 100 suhjecls 
had heen seen. Ilolh high and low scmeis answcicd 
‘yes’ (o these questions to the same extent. (I he 
uumhets aie those in the otipinal veision.)
.1. I )o you ever get times, umnhcis, or woids tunning 
Ihiough your mind that you can’t get lid of for a 
while?
9. If you have lo add up columns of lipmcs or sums 
of money, do you have to do it more Ilian twice heftne 
you can accept il as collect 7 (**)
7.7. Do you fail to keep your own tilings neat and 
tidy, even though you tiy ?
77. Do you have a mom in which childien aie not 
allowrd alone for Icar of distmhing or dii tying- 
things?
35. Do you make lists of tilings you have to do 7 
<11. Do you ever have to slop a moment lo woik 
things out in your mind hefoic being able to go on 
and do something else? (Check)
53. Is Ihcic anything that you avoid doing because 
you know' that even if you liy you won’t feel satisfied 
(hat you’ve done il piopcily?(**)
55. Do you accumulate a lot or old things just in 
case they might come in useful one day 7 (**)
57. When you go shopping do you (end to buy more 
of a tiling than you actually need 7 ((’heck)
5R. Do you ever find yom.self buying moic tinned or 
packaged goods than you really iteed 7 
60. Arc you a veiy lidy pci son 7
66. Do you gel fed up with people who aie always 
blight andchccifill7
67. Do you think that in general it is foolish to be 
optimistic?
81. Do you do tilings or keep appointments exactly 
on time?
83. Do you ever gel to stations or appointments too 
caily and have to wail rather than risk being late 7 (**)
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STANDARD PROGRESSIVE MATRICES
it begun_______________________________  Test ended.
A B C D E
J
2
-------------- —
1
2
1 1 1
2 2 2
3 3 3 3 3
4 4 4 4 4
5 _5
G
7
5 5 — 5
6
—
6 6
coj 
P-7 7 7
8 8 8 8 8
9 9
to
11
9 9 9
10 10 10 10
11 11 11 11
12 12 12 12 12
Time Total Grade
Notes
Tested by.
G.P. 77 120.000
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SET B
In each group of six words below underline the word which means the same as the 
word in heavy type above the group, as it has been done in the first example:
Begun
1 MALARIA
basement fever
theatre fruit
ocean tune
2 FASCINATED
ill-treated modelled
poisoned charmed
frightened copied
3 LIBERTY
freedom worry
rich serviette
forest cheerful
4 ANONYMOUS
applicable magnificent
nameless fictitious
insulting untrue
5 STUBBORN
steady obstinate
hopeful hollow
orderly slack
6 PROSPER
imagine propose
trespass beseech
punish succeed
7 PRECISE 
natural stupid
faulty grand
exact small
8 RESEMBLANCE
likeness fondness
assemble repose
attendance memory
9 SCHOONER
building man
scholar singer
plant ship
10 ELEVATE
revolve move
raise work
waver disperse
11 COURTEOUS
dreadful proud
polite short
curtsey truthful
12 RUSE
limb paste
colour hum
trick rude
13 LAVISH
unaccountable selfish 
romantic extravagant
lawful praise
14 IMMERSE
frequent hug
dip reverse
rise show
15 CONCILIATE
congregate pacify
reverse radiate
compress strengthen
16 ENVISAGE
enfeeble activate
surround estrange
contemplate regress
17 AMULEI
charm jacket
flirtation crest
cameo savoury
18 GARRULOUS
talkative daring
massive ugly
ridiculous fast
19 LIBERTINE
missionary rescuer
farrago canard
regicide profligate
20 BOMBASTIC
democratic pompous
bickering cautious
destructive anxious
21 LEVITY
parsimony velleity
salutary frivolity
alacrity tariff
22 WHIM
complain noise
fancy tonic
wind rush
23 RECUMBENT
fugitive cumbersome
unwieldy repelling
penitent reclining
24 QUERULOUS
astringent fearful
petulant curious
inquiring spurious
25 TEMERITY
impermanence rashness
nervousness stability
punctuality submissive!!
26 FECUND
esculent optative
profound prolific
sublime salic
27 ABNEGATE
contradict decry
renounce execute
belie assemble
28 TRADUCE
challenge attenuate
suspend establish
misrepresent conclude
29 VAGARY
vagabond caprice
obscurity vulgarity
evasion fallacy
30 SPECIOUS
fallacious coeval
palatial typical
nutritious flexible
31 SEDULOUS
rebellious dilatory
complaisant diligent
seductive credulous
32 NUGATORY
inimitable adamant
sublime contrary
numismatic trifling
33 ADUMBRATE
foreshadow' protect
detect eradicate
elaborate approach
34 MINATORY
implacable diminutive
belittling quiescent
depository threatening
Ended
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SET A
Wrilc clown in a few words tlic meaning of each of the following words as il has 
been done for the first word. Begun
1. Brag .............
7. Rage .............
5. Squabble ......
•!. Conned .......
5. Provide .......
0. Mingle .........
7. Stance .........
R. Verify ..........
T  Formidable .
10. Thrive .........
11. Shrivel ........
12. Docile ..........
15. Surmount ...
14. Snllry ..........
15. Criterion ....
Id. l atent .........
17. Dwindle ......
I T  Construe .... 
IT  Efface .........
20. Trumpery  ...
21. Virile ..........
22. Pei pel rate ..
25. Glower ........
21. Sensual .......
75. Obdurate ...
2(i. Palliate .......
27. -Adulate ......
2N. Felicitous ... 
2T Ambit .........
50. Recondite ...
51. Cachinnation 
57. Exiguous ....
55. Putative ......
54. Manumit ....
Ended
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APPENDIX II
2^ SYNOPSIS OF STATISTICAL TERMINOLOGY AND METHODS 
PARAMETRIC STATISTICS- Tests using parametric statistics presume 
that observations made in individuals are independent (i.e. 
selection of any one case from the population for inclusion in 
the sample should not bias the chances of other cases for 
inclusion, and must be drawn frcm normally distributed 
populations). Populations should have the same variance, and 
variables should have been measured in an interval scale so that 
the means of the populations are linear combinations (i.e. the 
effects are additive).
NON-PARAMETRIC STATISTICS - Tests using non-parametric statistics 
do not specify conditions about the parameters of the population 
from which the sample was drawn. Although it is assumed that the 
variables under study are independent and demonstrate continuity, 
these criteria are less important that for parametric testing. 
Non-parametric statistics are relevant for analysis using small 
sample sizes, observations from several different populations, 
and data which is simply ranked (i.e. 
nil/background/proliferative retinopathy), or classificatory.
THE KOIMDGQROV-SMIRNOV ONE-SAMPLE TEST
This is a test of goodness of fit of data. It measures the 
degree of agreement between the distribution of a set of sample 
values (observed scores) and normal distribution for that 
variable. The test involves specifying the cumulative frequency 
distribution which would occur under the theoretical distribution 
and comparing it with the observed cumulative frequency
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distribution. The point at which the theoretical and observed 
distributions show greatest divergence is determined. Reference 
to the sampling distribution determines whether the divergence is 
likely on the basis of chance. On the basis of this test, data 
is classified as normally distributed or otherwise and 
consequently parametric or non-parametric statistics are 
employed.
NON-PARAMETRIC TESTS
1. THE McNEMAR TEST - This test is designed to compare the 
significance of changes between 2 groups over a period of time. 
Subjects effectively serve as their own controls and 'nominal 
measurements' are used to assess the 'before to after change'.
2^ WILCOXON 'MATCHED PAIRS' SIGNED RANKS TEST - The test 
utilizes information about the relative magnitude and direction 
of the differences within pairs, and gives more weight to a pair 
which shows a large difference between the 2 conditions than to a 
pair which shows a small difference. This test was used when 
measurements were in an ordinal scale both within and between 
pairs, and analysed repeated measurements over periods of time. 
Both the McNemar and the Wilcoxon Signed Ranks Test are 
applicable to studies involving 2 related groups. The following 3 
tests are suited for use in a study design involving 2 
independent groups.
3^ FISHER EXACT PROBABILITY TEST - The test allows analysis of 
either ncminal or ordinal discrete data when the two independent 
samples are small in size. It is used when the scores frcm two
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independent randan samples all fall into one or the other of two 
mutually exclusive classes (i.e. scored as one of two possible 
scores). Scores are represented as 'frequencies’ in a 2 x 2 
contingency table. This test was employed to examine prevalences 
of ccmplications in 2 independent samples (e.g. retinopathy in 
diabetics with or without proteinuria).
4^ TIE X2 (CHI-SQUARED) TEST FOR TWO INDEPENDENT SAMPLES.
The test determines the significance of differences in 
frequencies between two groups, where the measurement involved 
may be as weak as nominal scaling. The hypothesis under test is 
that two groups differ with respect to seme categorical 
characteristics and therefore with respect to the relative 
frequency with which group members fall in several categories. 
The test can be extended to measure the prevalence in more that 
two groups if corrected by Yates' continuity test (as in 
assessment of the observed prevalence of the Apolipoprotein E 
phenotypes in comparison to that expected according to Hardy- 
Weinberg equilibrium). The chi-squared test can best be used in 
such situations if fewer than 20% of the cells have an expected 
frequency of less than 5 and if no cell has an expected frequency 
of less than one, otherwise adjacent categories must be combined 
to increase the expected frequencies. For example, in the 
analysis of 81 healthy and 81 insulin-dependent diabetic men, the 
Chi-squared test was employed to assess any difference in the 
prevalence of hyperlipidaemia between the 2 groups.
5. THE MANN-WHITNEY U TEST - This tests for the equality of 
means or variables between 2 independent groups, and is a
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sensitive useful alternative to 't testing’ for parametric data 
when data is likely to be 1distribution free’, or when the actual 
measurement was weaker than the interval scaling. It was used 
for all but very small sample sizes, and is more resistant to 
distortion by 'rogue' values than the t test, and therefore more 
useful when dealing with clinical data.
(L THE KRUSKAL-WALLIS 1-WAY ANALYSIS OF VARIANCE - This was 
used when comparing more than 2 groups of data with continuous 
variables and ordinal measurement of these variables. It 
assesses whether 3 or more groups where sample values differ are 
genuinely different population differences or whether they 
represent merely chance variations such as are to be expected 
among several randan samples frcm the same population.
7^ SPEARMAN RANK CORRELATION COEFFICIENT - The correlation 
coefficient gives a measure of the degree of association between 
variables where both are measured on an ordinal scale. Values 
are replaced by rankings and the test is more robust than the 
Pearson correlation coefficient against non-normalised data 
distribution (V.I.) The statistic attained 'rho' is represented 
as rs.
KENDAL RANK CORRELATION COEFFICIENT - This statistic is 
designated tau (r), and measures correlation with the same sort 
of data for which rs is used if ordinal measurement of both X and 
Y variables has been achieved, r can be generalised to a partial 
correlation coefficient unlike rs, when there is a possibility 
that the correlation is due to the association between each of 
the two variables and a third variable.
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PARAMETRIC STATISTICS
1^ PAIRED AND UNPAIRED STUDENT'S 't' TEST
These tests cctnpare the mean values between 2 populations 
and compare the difference in amount of scatter if data is 
normally distributed in both populations. Unpaired t testing is 
used more often in reponse to intervention with for example 
education and heme blood glucose monitoring. Therefore it would 
be appropriate to utilise paired testing to compare the outcome 
of the initial intensive management during the run-in period, 
whilst unpaired t testing would be more appropriate in assessing 
difference between blood and urine testing in the two groups.
Il PEARSON'S CORRELATION COEFFICIENT
If data is categorical the Pearson's product movement 
correlation coefficient can be employed where the significance 
pertaining to this would be the P value of the corresponding t 
test. Whilst the measurement is therefore less reliable, it can 
still be quoted as an index of non-independence of sex and 
height. The Pearson correlation coefficient for continuous data 
requires parametric measurements in at least an equal interval 
scale. In small samples the Spearman's test would be more 
appropriate.
STEPWISE MULTIPLE REGRESSION (MULTIVARIATE) ANALYSIS - In this 
procedure a variable is expressed as a weighted sum of 
'predictor' variables, to assess independent associations between 
variables. The stepwise procedure starts by taking the predictor 
variable which correlates best with the test variable, and then 
adding others successively, until addition of further variables
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does not improve the prediction of the test variable. If the 
predictor variables are themselves correlated, the method 
automatically chooses the correct weights, so that the 
contribution of each predictor to the test variable is found. If 
a particular variable 'wants' to cone into the equation in 
preference to another, then the former must be more closely 
related to the test variable, even after correction for the 
latter.
